Conditions: Prostate Cancer Metastatic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 255
Healthy volunteers: no

Brief summary:
Primary Objective:

To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan lesions or death due to any cause) with chemotherapy (cabazitaxel plus prednisone, Arm A) versus Androgen Receptor (AR)-targeted therapy (enzalutamide or abiraterone acetate plus prednisone, Arm B) in mCRPC participants who have been treated with docetaxel and who had disease progression while receiving AR-targeted therapy within 12 months of AR treatment initiation (less than or equal to \[\<=\]12 months, either before or after docetaxel).

Secondary Objective:

* To compare efficacy for:
* Prostate-specific antigen (PSA) response rate and time to PSA progression (TTPP).
* Progression-free survival (PFS).
* Overall survival (OS).
* Tumor response rate and duration of tumor response.
* Pain response and time to pain progression.
* Symptomatic skeletal event (SSE) rate and time to occurrence of any SSE.
* Health status and Health-related Quality of Life (HRQOL).
* To evaluate the correlation of a signature of resistance to AR-targeted agents with clinical outcome via the analysis of circulating tumor cell (CTC) phenotypes as well as expression and localization of proteins including AR isoforms in CTCs.
* To evaluate safety in the 2 treatment arms.

Detailed description:
The duration of the study per participant was approximately 2 years. Each participant was treated until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment, and each participant was followed after completion of study treatment until death, study cut-off date, or withdrawal of participant consent.

Arms:
arm 1: Participants received Cabazitaxel 25 mg/m\^2 intravenous (IV) infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic granulocyte-colony stimulating factor (G-CSF) as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks). arm 2: Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).

Interventions: intervention 1: cabazitaxel XRP6258 intervention 2: enzalutamide intervention 3: abiraterone acetate intervention 4: prednisone
Intervention descriptions: intervention 1: Pharmaceutical form: solution Route of administration: intravenous intervention 2: Pharmaceutical form: capsule Route of administration: oral intervention 3: Pharmaceutical form: tablet Route of administration: oral intervention 4: Pharmaceutical form: tablet Route of administration: oral

Protocol document:
Prot_000.pdf: 
AMENDED CLINICAL TRIAL PROTOCOL 05 
COMPOUND: Jevtana®/cabazitaxel/XRP6258 
A randomized, open label, multicenter study of Cabazitaxel versus an Androgen 
Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients 
previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent 
(CARD) 
STUDY NUMBER: LPS14201 
STUDY NAME: CARD 
VERSION DATE / STATUS: 01-March-2019 
CLINICAL STUDY DIRECTOR: 
Version number: 1 
EudraCT and/or IND number: 
2014-004676-29 
UTN number: 
U1111-1166-5329 
Date: 01-Mar-2019 
Total number of page: 
119 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity 
According to template: QSD-003152 VERSION N°2.0 (28-JUN-2013) 
Page 1 
NCT02485691


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
NAMES AND ADDRESSES OF 
 
COORDINATING 
INVESTIGATOR 
 
Name: 
Address
: 
 
 
Tel: 
Fax: 
E-mail: 
 
 
. 
 
MONITORING TEAM’S 
REPRESENTATIVE 
Name: 
Address
: 
 
Tel: 
Fax: 
E-mail: 
 
SPONSOR 
Company: 
Address: 
Sanofi aventis Groupe (SAG) 
54, rue La Boétie 
75008 Paris France 
 
 
 
OTHER EMERGENCY 
TELEPHONE NUMBERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group- strictly confidential 
Page 2 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
DOCUMENT HISTORY 
 
Document 
Country- 
specificity if 
applicable 
Date, version 
 
Amended protocol 05 
All 
01-Mar-2019, version 1 (electronic 6.0) 
 
Amended protocol 04 
All 
08-Nov-2018, version 1 (electronic 5.0) 
 
Amended protocol 03 
All 
11-May-2018, version 1 (electronic 1.0) 
 
Amended protocol 02 
FR 
31-Mar-2016, version 1 (electronic 4.0) 
 
Amended protocol 01 
All 
29-Oct-2015, version 1 (electronic 3.0) 
Original Protocol 
 
14-Apr-2015, version 2 (electronic 2.0) 
 
 
PROTOCOL AMENDMENT SUMMARY OF CHANGES 
 
Amended protocol 05 (01-Mar-2019) 
 
This amended protocol (amendment 05) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union. 
 
 
OVERALL RATIONALE FOR THE AMENDMENT 
 
Based on approved label for both study comparators (ZYTIGA 500 mg, Xtandi 40mg) and 
Cabazitaxel IB edition 16 Amendment 2 which could significantly impacts the safety of female 
partner and/or future child of participants of the study, this amendment introduces mainly update 
of exclusion criteria in relation with pregnancy, lactation, and reproductive potential for IMPs, 
with changes in exclusion criteria E09. 
 
 
Protocol amendment summary of changes table 
 
Section # and Name 
Description of change 
Brief rationale 
 
Clinical Trial Summary and 
section 7 of the protocol: 
study population, exclusion 
criteria E09. 
 
Patients with reproductive potential who do not agree, in 
conjunction with their partner, to use accepted and effective 
method of contraception during the study treatment period 
and up to 6 months after the last administered dose. The 
definition of “effective method of contraception” described 
hereafter: oral contraceptives, combined hormonal 
intravaginal, transdermal, intra uterine device or condoms will 
be based on respective study treatment labelling and 
country-specific regulatory requirements, and are 
documented in the Informed Consent Form. 
 
Inclusion criteria E09 has been 
updated and harmonized for the 
three arms of treatment, based 
on the approved label (for 
Abiraterone and Enzalutamide) 
and Cabazitaxel IB 16 
Amendment 2. 
 
 
 
 
Property of the Sanofi Group- strictly confidential 
Page 3 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
CLINICAL TRIAL SUMMARY 
 
 
COMPOUND: 
Jevtana®/cabazitaxel/XRP6258 
STUDY No: LPS14201 
STUDY NAME: CARD 
TITLE 
A randomized, open label, multicenter study of Cabazitaxel versus an AR- 
targeted agent (abiraterone or enzalutamide) in mCRPC patients previously 
treated with Docetaxel and who rapidly failed a prior AR-targeted agent (CARD) 
INVESTIGATOR/TRIAL LOCATION 
Multicenter/multinational 
PHASE OF DEVELOPMENT 
Phase IV 
STUDY OBJECTIVE(S) 
Primary objective 
• 
To compare the radiographic Progression-Free Survival (rPFS) [Using 
Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for tumor 
lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for 
bone scan lesions (1)(2)] or death due to any cause] with 
chemotherapy (Cabazitaxel plus prednisone) (Arm A) versus AR 
targeted therapy ( enzalutamide or abiraterone acetate plus 
prednisone) (Arm B) in mCRPC patients who have been treated with 
docetaxel and who had disease progression while receiving AR 
targeted therapy within 12 months of AR treatment initiation 
(≤12 months)(either before or after docetaxel). 
Secondary objectives 
• 
To compare efficacy of cabazitaxel plus prednisone to enzalutamide 
or abiraterone acetate plus prednisone for: 
- 
PSA response rate. 
- 
Time to PSA progression (TTPP). 
- 
Progression-free survival. 
- 
Objective tumor response (RECIST1.1 criteria in patients with 
measurable disease). 
- 
Duration of tumor response. 
- 
Pain intensity palliation. 
- 
Time to pain progression. 
- 
Symptomatic Skeletal Events (SSEs) rate. 
- 
Time to occurrence of Symptomatic Skeletal Events (SSEs). 
- 
Overall survival (OS). 
• 
To compare Health-Related Quality Of Life (HRQOL) according to 
FACT-P questionnaire. 
• 
To compare Health status/utility (EQ-5D-5L). 
• 
To evaluate the correlation of a signature of resistance to AR targeted 
agents with clinical outcomes, via the analysis of Circulating Tumor 
Cells (CTCs) phenotypes as well as expression and localization of 
proteins including AR isoforms in CTCs. 
• 
To evaluate safety in the 2 treatment arms. 
Exploratory Objectives 
Biomarkers: 
• 
 
 
 
 
 
 
Property of the Sanofi Group- strictly confidential 
Page 4 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
STUDY DESIGN 
• 
Open-label randomized phase IV study. 
• 
All eligible Patients (after Abi or Enza →Doc. 
or Doc → Abi or Enza) are randomly assigned to either arm A or B in 
a 1:1 proportion by using an Interactive Voice/Web Response System 
(IVRS/IWRS). 
• 
Patients who rapidly failed a prior AR-targeted agent are defined as 
patients who have disease progression while receiving AR targeted 
therapy within 12 months of AR treatment initiation (≤12 months). 
• 
Each patient will be treated until radiographic disease progression, 
unacceptable toxicity, or patient’s refusal of further study treatment. 
• 
A Steering Committee will be responsible for supervising the progress 
of the trial. This committee will include Study Chairmen’s and 
Sponsor’s representatives. 
• 
A translational Steering Committee will be responsible for supervising 
the biomarkers part. This committee will include Study Chairmen’s 
and Sponsor’s representatives. 
• 
Randomization will be stratified by: Eastern Cooperative Oncology 
Group (ECOG) performance status (0-1 Vs. 2), time from AR targeted 
agent initiation to progression ([0; 6 months] Vs. [6; 12 months]), 
timing of AR targeted agent (before Vs. after docetaxel). 
For patients who received docetaxel re-challenge, the last 
sequence of treatment must be considered for “the timing of AR 
targeted agent (before Vs. after docetaxel)” stratification factor. 
 
STUDY POPULATION 
Main selection criteria 
Inclusion criteria 
I 01. 
Histologically confirmed prostate adenocarcinoma. 
I 02. 
Metastatic disease. 
I 03. 
Effective castration with serum testosterone levels 
<0.5 ng/mL(1.7 nmol/L). If the patient has been treated with LHRH 
agonists or antagonist (ie, without orchiectomy), then this therapy 
should be continued. 
I 04. 
Progressive disease by at least one of the following: 
a) 
Progression in measurable disease (RECIST 1.1 criteria). Patient 
with measurable disease must have at least one lesion that can 
be accurately measured in at least one dimension (longest 
diameter to be recorded). Each lesion must be at least 10 mm 
when measured by computed tomography (CT) [CT scan 
thickness no greater than 5 mm] or magnetic resonance imaging 
(MRI). Lymph nodes should be ≥ 15 mm in short axis. As defined 
by PCWG2, if lymph node metastasis is the only evidence of 
metastasis, it must be ≥ 20 mm in diameter when measured by 
spiral CT or MRI. Previously irradiated lesions, primary prostate 
lesion and bone lesions will be considered non-measurable 
disease (see Appendix A) and/or 
b) 
Appearance of 2 or more new bone lesions (PCWG2). They must 
be confirmed by other imaging modalities (CT; MRI) if ambiguous 
results and/or 
 
 
Property of the Sanofi Group- strictly confidential 
Page 5 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
c) 
Rising PSA defined (PCWG2) as at least two consecutive rises in 
PSA to be documented over a reference value (measure 1) taken 
at least one week apart. The first rising PSA (measure 2) should 
be taken at least 7 days after the reference value. A third 
confirmatory PSA measure is required (2nd beyond the reference 
level) to be greater than the second measure and it must be 
obtained at least 7 days after the 2nd measure. If this is not the 
case, a fourth PSA measure is required to be taken and be 
greater than the 2nd measure. The third (or the fourth) 
confirmatory PSA should be taken within 4 weeks prior to 
randomization (see Appendix B). 
 
I 05. 
Having received prior docetaxel for at least 3 cycles (before or after an 
AR targeted therapy). Docetaxel administration in combination with 
Androgen Deprivation Therapy (ADT) in metastatic hormone-sensitive 
disease is considered a prior exposure (3). Docetaxel re-challenge is 
allowed. 
I 06. 
Having progressive disease (PD) (according to I04) while receiving 
AR targeted therapy with abiraterone acetate or enzalutamide within 
12 months of AR treatment initiation (≤12 months), even if treatment 
duration is longer than 12 months. Patients treated with Abiraterone 
Acetate + ADT in metastatic hormone-sensitive setting are eligible in 
the study if they have progressed within 12 months with the AR- 
targeted agent. Patients having PSA progression only (as per PCWG 
2) within 12 months are eligible 
I 07. 
A PSA value of at least 2ng/mL is required at study entry. 
I 08. 
Prior AR targeted therapy (abiraterone acetate or enzalutamide) must 
be stopped at least 2 weeks before study treatment. 
I 09. 
Signed informed consent. 
Exclusion criteria 
Related to methodology: 
E 01. 
Prior chemotherapy other than docetaxel for prostate cancer except 
estramustine and except adjuvant/neoadjuvant treatment completed 
>3 years ago. 
E 02. 
 Less than 28 days elapsed from prior treatment with chemotherapy, 
immunotherapy radiotherapy or surgery to the time of randomization. 
E 03. 
Adverse events (AEs) (excluding alopecia and those listed in the 
specific exclusion criteria) from any prior anticancer therapy of 
Grade >1 (National Cancer Institute Common Terminology Criteria 
[NCI CTCAE] v4.0) at the time of randomization (see Appendix C). 
E 04. 
Less than 18 years (or country’s legal age of majority if the legal age is 
>18 years). 
E 05. 
Eastern Cooperative Oncology Group performance status (ECOG PS) 
>2 (ECOG 2 must be related to prostate cancer, not to other 
comorbidities) (see Appendix D). 
E 06.      Prior malignancy. Adequately treated basal cell or squamous cell skin 
or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well 
as any other cancer for which treatment has been completed ≥5 years 
ago and from which the patient has been disease-free for ≥5 years. 
E 07. 
Participation in another clinical trial and any concurrent treatment with 
any investigational drug within 30 days prior to randomization. 
 
 
 
Property of the Sanofi Group- strictly confidential 
Page 6 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
E 08. 
Acquired immunodeficiency syndrome (AIDS related illnesses) or 
known HIV disease requiring antiretroviral treatment. 
E 09. 
Patients with reproductive potential who do not agree, in conjunction 
with their partner, to use accepted and effective method of 
contraception during the study treatment period and up to 6 months 
after the last administered dose. The definition of “effective method of 
contraception” described hereafter: oral contraceptives, combined 
hormonal intravaginal, transdermal, intra uterine device or condoms 
will be based on respective study treatment labelling and country- 
specific regulatory requirements, and are documented in the Informed 
Consent Form. 
Related to study treatments: 
E 10. 
Known allergies, hypersensitivity or intolerance to prednisone or 
excipients of abiraterone acetate or enzalutamide or docetaxel or 
polysorbate 80. 
E 11. 
Known history of mineralocorticoid excess or deficiency. 
E 12. 
History of seizure, underlying brain injury with loss of consciousness, 
transient ischemic attack within the past 12 months, cerebral vascular 
accident, brain arteriovenous malformation, brain metastases or the 
use of concomitant medications that may lower the seizure threshold. 
E 13. 
Unable to swallow a whole tablet or capsule. 
E 14. 
Inadequate organ and bone marrow function as evidenced by: 
a) 
Hemoglobin <10.0 g/dL 
b) 
Absolute neutrophil count <1.5 x 109/L 
c) 
Platelet count <100 x 109/L 
d) 
AST/SGOT and/or ALT/SGPT >1.5 x ULN; 
e) 
Total bilirubin >1.0 x ULN 
f) 
Potassium <3.5 mmol/L 
g) 
Child-Pugh Class C 
E 15. 
Contraindications to the use of corticosteroid treatment. 
E 16. 
Symptomatic peripheral neuropathy Grade ≥2 (National Cancer 
Institute Common Terminology Criteria [NCI CTCAE] v.4.0). 
E 17. 
Uncontrolled severe illness or medical condition including uncontrolled 
diabetes mellitus, history of cardiovascular disease (uncontrolled 
hypertension, arterial thrombotic events in the past 6 months, 
congestive heart failure, severe or unstable angina pectoris, recent 
myocardial infraction within last 6 months or uncontrolled cardiac 
arrhythmia). 
E 18. 
Concomitant vaccination with yellow fever vaccine. 
Total expected number of patients 
N= 234 randomized patients (117 per arm) approximatively 
STUDY TREATMENT(s) 
CABAZITAXEL (XRP6258) 
Investigational medicinal product(s) 
(IMP) 
Formulation 
• 
Cabazitaxel is supplied as a sterile, non-pyrogenic, non-aqueous 
yellowish to brownish yellow concentrate for solution for infusion at 
60 mg/1.5 mL and packaged in a 15 mL clear type I glass vial closed 
with a rubber closure. The rubber closure is crimped to the vial with an 
aluminum cap covered with a light green plastic flip-off cap. 
• 
Single-dose vial, containing a total of 60 mg of cabazitaxel expressed 
as anhydrous and solvent-free basis, per 1.5 mL of solution. The fill 
volume has been established to include an overfill (ie 1.5 mL [nominal 
 
 
Property of the Sanofi Group- strictly confidential 
Page 7 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
volume] + 0.33 mL). This overfill was determined to ensure that a 
10 mg/mL concentration is obtained in the premix and that 60 mg 
dose can be extracted. 
Solvent: 
• 
The diluent used for the preparation of the premix is a sterile, 
non-pyrogenic solution containing a 13% w/w ethanol solution in water 
for injection. This solution is contained in a 15mL clear glass vial, 
stoppered with a rubber closure. The rubber closure is crimped to the 
vial with either an aluminum cap covered with a light grey plastic flip- 
off cap or a gold-color aluminum cap covered with a colorless plastic 
flip-off cap. 
• 
Each vial of solvent is overfilled to ensure that a 10 mg/mL 
concentration is obtained in the Premix and that 60 mg dose can be 
extracted. (ie, 4.5 mL (nominal volume) + 1.17 mL]. 
• 
Each vial of cabazitaxel must be diluted with the ENTIRE content of 
one solvent vial. The solution is a clear colorless liquid. 
ABIRATERONE ACETATE: 
• 
250 mg tablets, white to off-white, oval tablets debossed with AA250 
on one side. Abiraterone acetate 250 mg tablets are available in high- 
density polyethylene bottles of 120 tablets. 
OR 
• 
500 mg tablets, Film-coated tablet. Purple, oval-shaped, film-coated 
tablets debossed with “AA” on one side and “500” on the other side. 
Abiraterone acetate 500 mg tablets are available 
in:PVdC/PE/PVC/aluminum blister of 12 filmcoated tablets in a 
cardboard wallet. Each carton contains (60 filmcoated tablets) 
5 wallets, or PVdC/PE/PVC/aluminum blister of 14 filmcoated tablets 
in a cardboard wallet. Each carton contains (56 filmcoated tablets) 
4 wallets. 
ENZALUTAMIDE: 
• 
40 mg capsules, white to off-white oblong soft capsules 
(approximately 20 mm x 9 mm) imprinted with "ENZ" in black ink on 
one side. 
Commercially available formulations will be used for the comparators 
(abiraterone acetate and enzalutamide). 
Route(s) of administration 
Cabazitaxel will be administered by IV route. 
Abiraterone acetate and enzalutamide will be administered by oral route 
Dose regimen 
Arm A 
Cabazitaxel 25 mg/m² intravenously in 1 hour (D1) every 3 weeks, plus 
prednisone 10 mg orally given daily. A cycle is defined as a 3 week period 
Primary prophylactic G-CSF is required for all patients in Cabazitaxel arm. 
Arm B 
Abiraterone acetate: Patients who were previously treated with enzalutamide 
before study entry, will receive abiraterone acetate at the dose of 1000 mg 
(4 tablets 250 mg or 2 tablets 500 mg) orally (PO) continuously once daily from 
D1 to D21. It must be taken on an empty stomach. No food should be 
consumed for at least 2 hours before the dose is taken and for at least 1 hour 
after the dose is taken. The tablets should be swallowed whole with water, plus 
prednisone 5 mg orally twice daily. A cycle is defined as a 3 week period. 
OR 
 
 
Property of the Sanofi Group- strictly confidential 
Page 8 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
Enzalutamide: Patients who were previously treated with abiraterone acetate 
before study entry, will receive enzalutamide at the dose of 160 mg (4 capsules) 
PO continuously once daily from D1 to D21, with or without food, capsules 
should be swallowed whole. A cycle is defined as a 3 week period. 
Non Investigational medicinal 
product(s) (IMP) 
Prednisone or Prednisolone: 
Commercially available product will be used. 
Prednisone or Prednisolone will be administered by oral route. G-
CSF in patients in Cabazitaxel arm: 
Commercially available products will be used. The choice of the product is left to 
the investigator’s decision. 
For any G-CSF product, the package insert or summary of product 
characteristics for details on description, administration, and precautions for use 
will be used. 
ENDPOINT(S) 
Primary endpoint 
Radiographic Progression-Free Survival (rPFS) defined as the time from 
randomization to the occurrence of one of the following: 
• 
Radiological tumor progression using RECIST 1.1 
• 
Progression of bone lesions using PCWG2 criteria 
• 
Death due to any cause 
Secondary endpoints 
Efficacy 
• 
PSA response defined as a reduction from baseline PSA level of at 
least 50%, maintained for at least 3 weeks. 
• 
Time to PSA progression (TTPP) defined as the time interval 
between the date of randomization and the date of first documented 
PSA progression. PSA progression is defined as (2) : 
- 
If decline from baseline value: an increase of ≥25% (at least 
2 ng/mL) over the nadir value, confirmed by a second PSA value 
at least 3 weeks apart. 
- 
If no decline from baseline value: an increase of ≥25% (at 
least 2 ng/mL) over the baseline value after 12 weeks of 
treatment, confirmed by a second PSA value at least 3 weeks 
apart. 
Early increase in PSA within 12 weeks, when followed by subsequent decline, 
is ignored in determining this endpoint. 
• 
Progression-free survival defined as the time interval between the 
date of randomization and the date of the first documentation of any of 
the following events: 
- 
Radiological tumor progression by RECIST 1.1 and PCWG2, 
- 
Symptomatic progression, 
- 
Pain progression, 
- 
Or death due to any cause. 
• 
Objective tumor response in patients with measurable disease 
(RECIST 1.1). 
• 
Duration of tumor response. 
• 
Pain intensity palliation defined as a decrease by <30% from 
baseline in the BPI-SF pain intensity item scores observed at  
2 consecutive evaluations ≥3 weeks apart without increase in 
analgesic usage score. 
 
 
Property of the Sanofi Group- strictly confidential 
Page 9 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
• 
Time to pain progression defined as the time interval from 
randomization to the first date increase by ≥30% from baseline in the 
BPI SF pain intensity score observed at 2 consecutive evaluations 
≥3 weeks apart without decrease in analgesic usage score or an 
increase in analgesic usage score ≥30%. 
Early increase in BPI-SF and analgesic usage within 12 weeks, when followed 
by subsequent decline, is ignored in determining this endpoint. 
• 
SSE rate, occurrence of SSE (by clinical evaluation) is defined as (4): 
- 
The occurrence of a new symptomatic pathological fracture, or 
- 
The use of external beam radiation to relieve bone pain, or 
- 
The occurrence of spinal cord compression, or 
- 
Tumor-related orthopedic surgical intervention. 
• 
Time to occurrence of SSE defined as the time interval between the 
date of randomization and the date of the occurrence of the first event 
defining a SSE. 
• 
OS (defined as the time interval from the date of randomization to the 
date of death due to any cause). 
Health Related Quality of life: 
• 
HRQOL as assessed by FACT-P. 
Health status/utility: 
• 
EQ-5D-5L. 
Biomarkers: 
• 
Evaluation of the correlation of a signature of resistance to AR 
targeted agents with clinical outcomes, via the analysis of Circulating 
Tumor Cells (CTCs) phenotypes as well as expression and 
localization of proteins including AR isoforms in CTCs. 
Safety: 
• 
Treatment Emergent Adverse Events (TEAE): Type according to 
MedDRA (Medical Dictionary for Regulatory Activities), frequency, 
severity according to NCI CTCAE V4.0, seriousness, and relationship 
of study treatment will be assessed. Laboratory abnormalities will be 
assessed according to the NCI CTCAE v.4.0. 
Other endpoints 
Biomarkers: 
 
 
 
 
 
 
ASSESSMENT SCHEDULE 
• 
Screening will be performed within 4 weeks before randomization. 
• 
Clinical examinations (including height at baseline only, weight, ECOG 
PS, vital signs), laboratory tests (including complete blood counts and 
serum chemistry), concomitant medications and AEs (NCI CTCAE 
v.4.0) will be obtained prior to drug administration, at every cycle 
before treatment administration and up to 30 days after the last study 
treatment administration. 
• 
Electrocardiogram (ECG) will be obtained within 8 days prior to first 
drug administration and at the end of treatment visit only if clinically 
indicated or cardiac event during the treatment period. 
• 
ECOG PS will be collected until disease progression, start of another 
 
 
Property of the Sanofi Group- strictly confidential 
Page 10 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
anticancer therapy or study cut-off and subsequent anti-cancer 
treatments administered will be collected until death or study cut-off 
date (see Section 6.2), whichever comes first. 
• 
Serum testosterone will be measured at baseline. 
• 
PSA will be determined at baseline, every 3 weeks at each visit before 
study treatment administration, at the end of treatment visit and every 
12 weeks at each follow-up until the end of the first further anticancer 
therapy if any, or study cut-off whichever comes first. 
• 
Pain intensity evaluation will be obtained at baseline (within 3 days 
prior the first study treatment), every 3 weeks at each visit before 
study treatment administration, at the end of treatment visit and every 
12 weeks at each follow-up until disease progression, start of another 
cancer therapy or study cut-off whichever comes first. 
• 
Patient’s diary will be given to record the consumption of abiraterone 
acetate or enzalutamide and/or prednisone or prednisolone. 
• 
SSE assessment will be obtained at baseline, every 3 weeks at each 
visit before study treatment administration, at the end of treatment visit 
and every 12 weeks until occurrence of first SSE or study cut-off, 
whichever comes first. 
• 
HRQOL as assessed by FACT-P at baseline (within 3 days prior the 
first study treatment), at each visit before drug administration, at end 
of treatment visit and every 12 weeks during the follow-up period until 
disease progression, start of other anticancer treatment or study cut- 
off, whichever comes first. 
• 
Health status/utility (EQ-5D-5L) evaluation at baseline (within 3 days 
prior the first study treatment), at each visit before drug administration, 
at end of treatment visit and every 12 weeks during the follow-up 
period until disease progression, start of other anticancer treatment or 
study cut-off, whichever comes first. 
• 
Tumor radiological evaluation by CT or MRI of the whole body (chest, 
abdomen, and pelvis) and by bone scan for all patients at baseline, 
every 12 weeks (+/- 1 week) until radiological tumor progression is 
documented, start of another cancer therapy or study cut-off, 
whichever comes first, using the same method for each assessment. 
• 
3 blood samples for CTCs analysis will be collected in patients at 
screening, at D1 of Cycle 2 and at relapse or EOT. 
• 
 
. 
• 
 
 
• 
After study treatment discontinuation, patients will be followed every 
12 weeks until death, study cut-off date or withdrawal of 
patients' consent. Details of any further anticancer therapy will be 
collected. 
STATISTICAL CONSIDERATIONS 
Sample size determination: 
In post-docetaxel setting, the HR for rPFS is 0.66 [0.58-0.76] between 
abiraterone/prednisone and prednisone in COU-AA-301(5) and 0.40 [0.35-0.47] 
between enzalutamide and placebo in AFFIRM (6). 
In pre-docetaxel setting, the Hazard ratio (HR) for rPFS is 0.53 [0.45 to 0.62] 
between abiraterone/prednisone and prednisone in COU-AA-302 (7) and 
0.19 [0.15-0.23] between enzalutamide and placebo in PREVAIL (8). We thus 
consider that a HR of 0.67 should be considered as the smallest effect of clinical 
interest between cabazitaxel and an AR-targeted agent (abiraterone or 
 
 
Property of the Sanofi Group- strictly confidential 
Page 11 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
enzalutamide). 
The following table presents how such a HR translates for a variety of 
envisaged median rPFS in the abiraterone acetate or Enzalutamide group (9) 
(10). 
 
 
Hazard Ratio 
median rPFS (month) 
Abiraterone acetate or 
Enzalutamide group 
Cabazitaxel group 
0.67 
4 
6.0 
0.67 
5 
7.5 
0.67 
6 
9.0 
 
 
 
A total of 196 patients with event is needed to achieve 80% power to 
demonstrate rPFS superiority of Cabazitaxel over abiraterone 
acetate/prednisone or enzalutamide by 2 sided log rank test at 0.05 type I error 
rate. 
 
At the time of the cut-off date, when the primary analysis will be conducted, 
events will be censored in some patients either by end-of-study or by cut-off 
date. This phenomenon is estimated with 
; 10% of patients 
are estimated to achieve the end-of-study (as currently censored either by 
events or by last contact in on-going patients) by 7.5 months. 
 
The observed accrual rates, that have been lower than expected, have been 
considered for this new sample size calculation: 
 
Period 
Starting at time 
 
Accrual rate 
(Patients per month) 
1 
Mid-November 2015 = M0 
3 
2 
Mid-October 2016 = M11 
8 
3 
Mid-February 2017 = M15 
7 
4 
Mid-August 2017 = M25 
12 
5 
Mid-December 2017=M29 
12 
(up to end of June 2018) 
 
A total of 234 patients in 2 arms (117 patients per arm) are anticipated to be 
needed to reach the targeted number of patients with event. This new target 
should be achieved for an estimated constant accrual rate equal to 12 until the 
end of the recruitment expected in June 2018. 
Analysis population: 
• 
Intent-to-Treat (ITT) population: This population includes all 
randomized patients. It is the primary population for all efficacy 
parameters. All analyses using this population will be based on the 
treatment assigned by randomization. 
• 
Safety population: This population includes all patients who will take at 
least one dose of the study drug. This population is for safety 
analyses. All analyses using this population will be based on the 
treatment actually received. 
• 
Evaluable population: tumor response will be evaluated in patients 
 
 
 
Property of the Sanofi Group- strictly confidential 
Page 12 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
with measurable disease at baseline. PSA response will be evaluated 
in patients with PSA value >2 ng/mL at baseline. Pain response will be 
evaluated using BPI-SF and WHO's analgesic ladder. 
• 
Health related quality of life population: subset of the safety population 
composed of patients with an evaluable FACT-P questionnaire at 
baseline and at least one post baseline evaluable FACT-P. 
• 
Health status population: subset of the Safety population composed of 
patients with an evaluable EQ-5D-5L at baseline and with at least one 
post-baseline evaluable EQ-5D-5L. 
Primary analysis: 
Primary analysis will consist of rPFS comparison between abiraterone acetate 
or enzalutamide group and cabazitaxel group through a 2 sided 5% log-rank 
adjusted for the stratification factors ECOG performance status (0-1 Vs. 2), time 
from AR targeted agent initiation to progression (]0; 6 months] Vs. ]6; 12 
months]), timing of AR targeted agent (before Vs. after docetaxel) as specified 
at the time of randomization. This analysis will be performed on the ITT 
population. If radiological progression or death is not observed during the study, 
data on rPFS will be censored at the last valid tumor assessment date or at the 
cut-off date, whichever comes first. 
The estimates of the hazard ratio and corresponding 95% confidence interval 
will also be provided using a 2 sided 5% Cox model adjusted for the 
stratification factors. Medians survival times and 95% confidence intervals will 
also be provided by treatment arm. The survival curves will be estimated using 
Kaplan-Meier estimates. 
Analysis of secondary endpoints: 
Time To event data will be analyzed as the primary efficacy endpoint. PSA 
response will be compared between groups using chi-square tests under 
evaluable population. 
Safety endpoints will be summarized by the frequency and percent in patients 
and by toxicity grade will be summarized by the frequency in patients and by 
toxicity grade. 
DURATION OF STUDY PERIOD (per 
patient) 
Patients will be treated until radiographic progressive disease, unacceptable 
toxicity, patient’s refusal of further study treatment. All patients will be followed 
when on study treatment and after completion of study treatment during follow 
up period until death, the study cut-off date (see Section 6.2), or withdrawal of 
patients’ consent whichever comes first. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group- strictly confidential 
Page 13 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
1 
FLOW CHARTS 
 
 
1.1 
GRAPHICAL STUDY DESIGN 
 
 
 
 
 
 
 
 
 
 
117 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 patients 
Property of the Sanofi Group - strictly confidential 
Page 14 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
1.2 
STUDY FLOW CHART 
 
Evaluation 
Baseline 
R 
A 
N 
D 
O 
M 
I 
Z 
A 
T 
I 
O 
N 
r 
Treatment period 
First cycle within 7 days after randomization 
Post- treatment follow-up 
period 
Prior to randomization 
Every cycle 
End of treatment 
(30 days after last treatment) 
Every 12 weeks (+/-1 week) 
Informed Consent 
Before any study procedures 
Inclusion/Exclusion Criteria 
Within 8 days 
Patient demography 
Within 28 days 
Prior Medical/Surgical & Cancer Historya 
Within 28 days 
Clinical Examinationb 
Within 8 days 
X 
X 
X (ECOG and weight only) 
Laboratory Studies c* 
Within 8 days 
X 
(Hematology/Biochemistry weekly 
during 3 first cycles) 
X 
12 lead ECG d 
Within 8 days 
Xd 
Study drug Administration e 
X 
Adverse Events f 
X 
X 
X 
Prior/ Concomitant/ Post Medications g 
Within 28 days 
X 
X 
X(if indicated)g 
Other investigations 
As clinically indicated 
X 
X 
X 
Symptomatic Skeletal Eventh 
Within 8 days 
X 
X 
X 
Tumor Assessment i 
Within 28 days 
every 12  weeks (+/- 1 week) 
X 
X 
Serum Testosterone Measurement j 
Within 28 days 
PSA Measurement k** 
Within 8 daysk 
X 
X 
X 
Analgesic & Pain l 
Within 3 daysl 
X 
X 
X 
HRQOL and Health statusm 
Within 3 daysm 
X 
X 
X 
Patient’s diaryn 
X 
Circulating Tumor Cells (CTCs)o 
Within 8 days 
D1 of Cycle 2 
Xo 
 
 
Within 8 days 
Xp 
  
Within 8 days 
Survival statusq 
X 
Property of the Sanofi Group - strictly confidential 
Page 15 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
* To be repeated if performed more than 8 days before the 1st infusion. ** Must be performed prior to registration for eligibility assessment. 
a Prior Medical/Surgical & Cancer History Includes cancer diagnosis (primary tumor characteristics and metastatic sites), prior surgery for cancer, radiotherapy, systemic anticancer therapy, and concurrent illness. 
b Clinical Examination: Includes examination of major body systems [blood pressure, heart rate, height (at baseline only), body weight, ECOG PS]. During the follow-up period, ECOG PS, weight will be collected every 12 weeks 
(+/- 1 week) from end of study treatment until disease progression, start of other anticancer therapy or study cut-off, whichever comes first. 
c Laboratory Studies Includes, prior each cycle, hematology (White blood cell (WBC) with differential count, Absolute neutrophil count (ANC), hemoglobin, platelet count), blood biochemistry (sodium, potassium, calcium, 
phosphorus, blood urea nitrogen(BUN), magnesium, LDH, creatinine, total protein, albumin, Serum Glutamooxaloacétate Transférase (SGOT) (AST), Serum Glutamo-Pyruvate Transferase (SGPT) (ALT), alkaline phosphatase, 
total bilirubin, glucose). Only at baseline: serum Chromogranin A (CgA). In addition, hematology and biochemistry will be performed every week (D8 and D15) during the 3 first cycles and then within further cycles in case of fever 
or infection. Coagulation (prothrombin time at baseline, and then within further cycles if needed [expressed as international normalized ratio]). 
d 12-lead ECG to be performed at baseline, and end of treatment visit only if cardiac event during the treatment period. 
e Study drug Administration Arm A: Cabazitaxel 25 mg/m² will be administered on Days 1 of each 21-day cycle + prednisone 10 mg daily per os (in countries where prednisone is not commercially available prednisolone 10 mg 
daily per os may be used). Primary prophylactic G-CSF is required at each cycle for all patients in cabazitaxel arm. Cycle administration will start within 7 days of randomization, and then repeated every 3 weeks. Arm B: 
Abiraterone acetate 1000 mg (4 tablets 250 mg or 2 tablets 500 mg) orally once daily plus prednisone 5 mg orally twice daily, continuously or enzalutamide 160 mg (4 capsules) orally once daily continuously. 
f 
Adverse Events The period of safety observation starts from the time the patient gives informed consent. All AEs will be recorded until 30 days after the last administration of study drugs. During the follow-up period, only  
ongoing related or new related AEs will be recorded. Serious adverse events (SAEs) ongoing at the end of the study treatment will be followed during the follow-up period until resolution or stabilization regardless of relationship 
with study drugs. Adverse events will be recorded according to NCI-CTCAE version 4.0. 
g Prior/ Concomitant/ Post Medications Concomitant medications and treatments will be recorded from 28 days prior to the start of study drug, before every cycle during the study treatment period and up to 30 days after the final 
dose of study drug. Once the patient has withdrawn from study treatment, concomitant medication should only be recorded if used to treat new or unresolved study treatment related AEs. 
h Symptomatic Skeletal Event: The use of external beam radiation to relieve bone pain, or occurrence of a new symptomatic pathological fracture, or occurrence of spinal cord compression, or tumor-related orthopedic surgical 
intervention, until the occurrence of the first SSE or study cut-off date. 
i 
Tumor Assessment Chest, abdomen, and pelvic CT-scan or MRI and bone scan to be performed to assess disease status at baseline (bone scan performed within 6 weeks prior to randomization is allowed) then every 
12 weeks (+/- 1 week) until radiological tumor progression, whenever disease progression is suspected, using the same method for each assessment to follow all target and/ or non-target lesions present at baseline. In addition, 
bone scan will be repeated to confirm progression in case PD is diagnosed only on bone scan (6 weeks after initial documentation of progression); In case of doubtful lesions on bone scan, bone-centered X-ray or MRI scan 
should be performed to determine the nature of those lesions (metastatic or not). In post treatment follow up period, patients that have not radiographic progression or started another anticancer therapy, tumor assessment to be 
performed every 12 weeks (+/- 1 week). 
j 
Serum testosterone measurement, to be performed at baseline only. 
k PSA measurements to be performed at baseline (last PSA if progression is defined by rising PSA only should be done within 8 days prior randomization) and then repeated on pre dose of D1 of each cycle, approximately 
30 days after the last study treatment administration (end of treatment visit), every 12 weeks (+/- 1 week). during the follow-up period until the end of the first further anticancer therapy if any or the study cutoff date, whichever 
comes first. 
l 
Analgesic and pain diary (BPI-SF). The collection will be done at baseline (within 3 days prior to the first treatment administration), before each cycle, at the end of treatment and every 12 weeks (+/- 1 week). until disease 
progression, start of another anticancer therapy or study cut-off, whichever comes first. 
m HRQOL and Health status: FACT-P and EQ-5D-5L to be completed by the patient at the center, at baseline (within 3 days prior the first study treatment), before each cycle, at the end of treatment visit and every 12 weeks (+/- 1 
week). during the follow-up period until disease progression, start of another anticancer therapy or study cut-off, whichever comes first. 
n Patient’s diary to be used by all patients to record the consumption of abiraterone acetate or enzalutamide and/or prednisone or prednisolone. 
o   Circulating Tumor Cells (CTCs) - CTCs assays will be done by a central laboratory. 3 samples will be collected at screening (within 8 days during abiraterone acetate or enzalutamide washout), D1 of Cycle 2, and at relapse or 
EOT if any other reason of discontinuation. 
p 
 
q Survival status: During the follow-up period, patients who went off study treatment prior to documented radiographic disease progression will be evaluated for tumor progression every 12 weeks (+/- 1 week). from end of study 
treatment until radiographic disease progression, start of other anticancer therapy or study cut-off date, whichever comes first. Further anticancer therapy data will be collected until death or study cutoff date. 
r 
Randomization All eligible patients will be randomly assigned to one of the 2 treatment groups using an Interactive Voice Response System (IVRS/IWRS). Study treatment should be started within 7 calendar days from 
randomization. 
Property of the Sanofi Group - strictly confidential 
Page 16 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
2 
TABLE OF CONTENTS 
AMENDED CLINICAL TRIAL PROTOCOL 05 .............................................................................................. 1 
DOCUMENT HISTORY ................................................................................................................................... 3 
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................................................... 3 
OVERALL RATIONALE FOR THE AMENDMENT ........................................................................................ 3 
1 
FLOW CHARTS  ............................................................................................................................ 14 
1.1 
GRAPHICAL STUDY DESIGN  ...................................................................................................... 14 
1.2 
STUDY FLOW CHART  ................................................................................................................. 15 
2 
TABLE OF CONTENTS  ................................................................................................................ 17 
2.1 
LIST OF TABLES  .......................................................................................................................... 22 
3 
LIST OF ABBREVIATIONS  .......................................................................................................... 23 
4 
INTRODUCTION AND RATIONALE  ............................................................................................ 25 
4.1 
INVESTIGATIONAL MEDICINAL PRODUCT  ............................................................................... 25 
4.1.1 
Preclinical data  .............................................................................................................................. 25 
4.1.2 
Summary of clinical data  ............................................................................................................... 26 
4.1.2.1 
Phase 1  ......................................................................................................................................... 26 
4.1.2.2 
Phase 2  ......................................................................................................................................... 26 
4.1.2.3 
Phase 3  ......................................................................................................................................... 26 
4.2 
STUDY RATIONALE  ..................................................................................................................... 28 
5 
STUDY OBJECTIVES  .................................................................................................................. 30 
5.1 
PRIMARY  ...................................................................................................................................... 30 
5.2 
SECONDARY  ............................................................................................................................... 30 
5.3 
EXPLORATORY  ........................................................................................................................... 30 
6 
STUDY DESIGN  ........................................................................................................................... 31 
6.1 
DESCRIPTION OF THE PROTOCOL  .......................................................................................... 31 
6.2 
DURATION OF STUDY PARTICIPATION  .................................................................................... 31 
6.2.1 
Duration of study participation for each patient  ............................................................................. 31 
6.2.2 
Determination of end of clinical trial (all patients)  .......................................................................... 32 
Property of the Sanofi Group - strictly confidential 
Page 17 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
6.3 
INTERIM ANALYSIS  ..................................................................................................................... 32 
6.4 
STUDY COMMITTEES  ................................................................................................................. 32 
7 
SELECTION OF PATIENTS  ......................................................................................................... 33 
7.1 
INCLUSION CRITERIA  ................................................................................................................. 33 
7.2 
EXCLUSION CRITERIA  ................................................................................................................ 34 
7.2.1 
Exclusion criteria related to study methodology  ............................................................................ 34 
7.2.2 
Exclusion criteria related to study treatments  ................................................................................ 35 
8 
STUDY TREATMENTS  ................................................................................................................. 36 
8.1 
INVESTIGATIONAL MEDICINAL PRODUCT  ............................................................................... 37 
8.1.1 
Preparation and administration of cabazitaxel  .............................................................................. 37 
8.1.1.1 
Preparation of the premix solution under aseptic conditions  ......................................................... 37 
8.1.1.2 
Preparation of the infusion solution under aseptic conditions  ....................................................... 37 
8.1.1.3 
Infusion conditions  ......................................................................................................................... 38 
8.1.1.4 
Storage period of premix and infusion solution  ............................................................................. 38 
8.1.1.5 
Recommendation for safe handling  ............................................................................................... 38 
8.1.2 
Dosage and schedule  .................................................................................................................... 38 
8.1.2.1 
Study treatments  ........................................................................................................................... 39 
8.1.2.2 
Premedication  ............................................................................................................................... 39 
8.1.2.3 
Dose modification and dose delay  ................................................................................................ 39 
8.2 
OTHER IMP(S)  .............................................................................................................................. 45 
8.2.1 
Administration  ............................................................................................................................... 45 
8.2.2 
Dosage and schedule  .................................................................................................................... 45 
8.2.2.1 
Dose Reductions and Delay due to Toxicity related to Abiraterone Acetate  ................................. 45 
8.2.2.2 
Management of Toxicity related to Abiraterone Acetate ................................................................ 46 
8.2.2.3 
Drug interactions related to abiraterone acetate  ........................................................................... 48 
8.2.2.4 
Dose Reductions and Delay due to Toxicity related to enzalutamide  ........................................... 48 
8.2.2.5 
Drug interactions related to enzalutamide  ..................................................................................... 49 
8.3 
NON INVESTIGATIONAL MEDICINAL PRODUCT  ...................................................................... 49 
8.4 
BLINDING PROCEDURES  ........................................................................................................... 49 
8.4.1 
Methods of blinding  ....................................................................................................................... 49 
8.5 
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP  .............................................. 50 
8.5.1 
Patient number and treatment number  .......................................................................................... 50 
8.5.2 
Allocation of treatment(s)  .............................................................................................................. 50 
8.6 
PACKAGING AND LABELING  ...................................................................................................... 50 
8.7 
STORAGE CONDITIONS AND SHELF LIFE  ............................................................................... 50 
Property of the Sanofi Group - strictly confidential 
Page 18 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
8.8 
RESPONSIBILITIES  ..................................................................................................................... 51 
8.8.1 
Treatment accountability and compliance  ..................................................................................... 51 
8.8.2 
Return and/or destruction of treatments  ........................................................................................ 52 
8.9 
CONCOMITANT MEDICATION  .................................................................................................... 52 
9 
ASSESSMENT OF IMP  ................................................................................................................ 54 
9.1 
PRIMARY ENDPOINT  .................................................................................................................. 54 
9.2 
SECONDARY ENDPOINTS  .......................................................................................................... 54 
9.2.1 
PSA endpoints  ............................................................................................................................... 54 
9.2.1.1 
PSA response  ............................................................................................................................... 54 
9.2.1.2 
Time to PSA progression (TTPP)  .................................................................................................. 55 
9.2.2 
Progression free survival  ............................................................................................................... 55 
9.2.3 
Tumor endpoints  ........................................................................................................................... 55 
9.2.3.1 
Tumor response  ............................................................................................................................ 55 
9.2.3.2 
Duration of tumor response  ........................................................................................................... 56 
9.2.4 
Pain endpoints  ............................................................................................................................... 56 
9.2.4.1 
Pain response  ............................................................................................................................... 56 
9.2.4.2 
Time to pain progression  ............................................................................................................... 56 
9.2.5 
Symptomatic Skeletal Events  ........................................................................................................ 57 
9.2.5.1 
SSE rate  ........................................................................................................................................ 57 
9.2.5.2 
Time to occurrence of SSE  ........................................................................................................... 57 
9.2.6 
Overall Survival  ............................................................................................................................. 57 
9.2.7 
Health-Related Quality Of Life and Health status/utility  ................................................................ 57 
9.2.8 
Biomarkers  .................................................................................................................................... 58 
9.3 
SAFETY ENDPOINT  ..................................................................................................................... 58 
9.3.1 
Adverse events  .............................................................................................................................. 58 
9.3.2 
Laboratory safety variables  ........................................................................................................... 58 
9.3.3 
Vital signs  ...................................................................................................................................... 58 
9.3.4 
ECG variables  ............................................................................................................................... 58 
9.4 
OTHER ENDPOINTS  .................................................................................................................... 59 
9.5 
FUTURE USE OF SAMPLES  ....................................................................................................... 59 
10 
STUDY PROCEDURES  ................................................................................................................ 60 
10.1 
VISIT SCHEDULE  ......................................................................................................................... 60 
10.1.1 
Screening  ...................................................................................................................................... 60 
10.1.2 
Randomization  .............................................................................................................................. 62 
10.1.3 
During study treatment  .................................................................................................................. 62 
Property of the Sanofi Group - strictly confidential 
Page 19 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
10.1.4 
End of treatment  ............................................................................................................................ 63 
10.1.5 
Follow-up period  ............................................................................................................................ 64 
10.1.6 
Post study cut-off date  ................................................................................................................... 65 
10.2 
DEFINITION OF SOURCE DATA  ................................................................................................. 65 
10.3 
HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION  ....................................... 65 
10.3.1 
Permanent treatment discontinuation with IMP(s)  ......................................................................... 66 
10.3.2 
List of criteria for permanent treatment discontinuation  ................................................................. 66 
10.3.3 
Handling of patients after permanent treatment discontinuation  ................................................... 66 
10.3.4 
Procedure and consequence for patient withdrawal from study  .................................................... 67 
10.4 
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING  .......................... 67 
10.4.1 
Definitions of AEs  .......................................................................................................................... 67 
10.4.1.1 AE  .................................................................................................................................................. 67 
10.4.1.2 SAE  ............................................................................................................................................... 68 
10.4.1.3 Adverse event of special interest  .................................................................................................. 69 
10.4.2 
General guidelines for reporting AEs  ............................................................................................. 69 
10.4.3 
Instructions for reporting SAEs  ...................................................................................................... 70 
10.4.4 
Guidelines for reporting AEs of special interest  ............................................................................ 70 
10.5 
OBLIGATIONS OF THE SPONSOR  ............................................................................................. 71 
10.6 
SAFETY INSTRUCTIONS  ............................................................................................................ 71 
10.6.1 
Physical examination  ..................................................................................................................... 71 
10.6.2 
Laboratory variables  ...................................................................................................................... 71 
10.7 
ADVERSE EVENTS MONITORING  ............................................................................................. 72 
11 
STATISTICAL CONSIDERATIONS  ............................................................................................. 73 
11.1 
DETERMINATION OF SAMPLE SIZE  .......................................................................................... 73 
11.2 
DISPOSITION OF PATIENTS  ....................................................................................................... 74 
11.3 
ANALYSIS POPULATIONS  .......................................................................................................... 74 
11.3.1 
Efficacy populations  ...................................................................................................................... 74 
11.3.1.1 Intent–to-treat population  .............................................................................................................. 74 
11.3.1.2 Evaluable populations  ..................................................................................................................... 75 
11.3.1.2 Health-Related Quality Of Life and Health status populations  ........................................................ 75 
11.3.2 
Safety population  ........................................................................................................................... 75 
11.4 
STATISTICAL METHODS  ............................................................................................................. 76 
11.4.1 
Extent of study treatment exposure  ............................................................................................... 76 
11.4.2 
Analyses of efficacy endpoints  ...................................................................................................... 76 
Property of the Sanofi Group - strictly confidential 
Page 20 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
11.4.2.1 Analysis of primary efficacy endpoint(s)  ........................................................................................ 76 
11.4.2.2 Analyses of secondary efficacy endpoints  ..................................................................................... 76 
11.4.2.3 Multiplicity considerations  .............................................................................................................. 77 
11.4.3 
Analyses of safety data  ................................................................................................................. 77 
11.4.4 
Analyses of pharmacogenetic variables  ........................................................................................ 78 
11.4.5 
Analyses of HRQOL and of Health status  ..................................................................................... 78 
11.4.6 
Analyses of Biomarkers  ................................................................................................................. 79 
11.5 
INTERIM ANALYSIS  ..................................................................................................................... 79 
12 
ETHICAL AND REGULATORY CONSIDERATIONS  .................................................................. 80 
12.1 
ETHICAL AND REGULATORY STANDARDS  .............................................................................. 80 
12.2 
INFORMED CONSENT  ................................................................................................................. 80 
13 
STUDY MONITORING  .................................................................................................................. 82 
13.1 
RESPONSIBILITIES OF THE INVESTIGATOR(S)  ....................................................................... 82 
13.2 
RESPONSIBILITIES OF THE SPONSOR  .................................................................................... 82 
13.3 
SOURCE DOCUMENT REQUIREMENTS  ................................................................................... 83 
13.4 
USE AND COMPLETION OF CRFS AND ADDITIONAL REQUEST  ........................................... 83 
13.5 
USE OF COMPUTERIZED SYSTEMS  ......................................................................................... 83 
14 
ADDITIONAL REQUIREMENTS  .................................................................................................. 84 
14.1 
CURRICULUM VITAE  ................................................................................................................... 84 
14.2 
RECORD RETENTION IN STUDY SITES  .................................................................................... 84 
14.3 
CONFIDENTIALITY  ...................................................................................................................... 84 
14.4 
PROPERTY RIGHTS  .................................................................................................................... 85 
14.5 
DATA PROTECTION  .................................................................................................................... 85 
14.6 
INSURANCE COMPENSATION  ................................................................................................... 85 
14.7 
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES  ................................. 86 
14.8 
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE  ........................................................................................................................................... 86 
14.8.1 
By the Sponsor  .............................................................................................................................. 86 
14.8.2 
By the Investigator  ......................................................................................................................... 87 
14.9 
CLINICAL TRIAL RESULTS  ......................................................................................................... 87 
Property of the Sanofi Group - strictly confidential 
Page 21 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
14.10 
PUBLICATIONS AND COMMUNICATIONS  ................................................................................. 87 
15 
CLINICAL TRIAL PROTOCOL AMENDMENTS  .......................................................................... 88 
16 
BIBLIOGRAPHIC REFERENCES  ................................................................................................ 89 
17 
APPENDICES  ............................................................................................................................... 93 
APPENDIX A 
MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS             
(RECIST1.1)  .................................................................................................................................. 94 
APPENDIX B 
PSA ELIGIBILITY CHANGES AND PROGRESSION  ....................................................... 100 
APPENDIX C 
NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR 
ADVERSE EVENTS (9)  .............................................................................................................. 101 
APPENDIX D 
ECOG PERFORMANCE STATUS SCALE  ...................................................................... 102 
APPENDIX E 
BRIEF PAIN INVENTORY (SHORT FORM) ..................................................................... 103 
APPENDIX F 
WHO ANALGESIC LADDER FOR CANCER PAIN  .......................................................... 105 
APPENDIX G 
EVALUATION OF QUALITY OF LIFE BY FACT-P (VERSION 4 – 19 NOVEMBER 
2007) 106 
APPENDIX H 
EQ-5D-5L QUESTIONNAIRE  ........................................................................................... 109 
APPENDIX I 
CYP 3A4 INHIBITORS AND CYP 3A4 INDUCERS (UPDATED NOVEMBER 2011)  ........ 111 
 
 
 
 
 
2.1 
LIST OF TABLES 
 
Table 1 • Study treatments ............................................................................................................................ 36 
 
Table 2 • Cabazitaxel dose reduction levels .................................................................................................. 40 
Table 3 • Dose modifications for cabazitaxel*  ............................................................................................... 40 
Table 4 • Interventions in case of hypersensitivity reaction  .......................................................................... 42 
Table 5 • Abiraterone dose reduction level  ................................................................................................... 45 
Table 6 • Management of Hypokalemia  ........................................................................................................ 46 
Table 7 • Enzalutamide dose reduction levels  .............................................................................................. 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 22 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
3 
LIST OF ABBREVIATIONS 
 
 
 
ACTH: 
adrenocorticotropic hormone 
ADT: 
Androgen Deprivation Therapy 
AE: 
adverse event 
AESI: 
AE of special interest 
ALT: 
alanine aminotransferase 
ANC: 
absolute neutrophil count 
AR: 
androgen receptor 
ASCO: 
American Society of Clinical Oncology 
AST: 
aspartate aminotransferase 
AUC: 
area under the curve 
BPI-SF: 
Brief Pain Inventory-Short Form 
BUN: 
blood urea nitrogen 
CBC: 
complete blood count 
CBZ: 
cabazitaxel 
CR: 
complete responses 
CRF: 
case report form 
CRPC: 
castration-reistant prostate cancer 
CT: 
computer tomography 
CTCs: 
circulation tumor cells 
DLT: 
dose limiting toxicity 
DRF: 
Discrepancy Resolution Form 
ECG: 
electrocardiogram 
ECOG: 
Eastern Cooperative Oncology Group 
EMEA: 
European Medicines Agency 
FDA: 
Food and Drug Administration 
GCP: 
good clinical practice 
G-CSF: 
Granulocyte-Colony Stimulating Factors 
GI: 
gastrointestinal 
HLGT: 
high group level term 
HLT: 
high level term 
HR: 
hazard ratio 
HRPC: 
hormone refractory prostate cancer 
HRQOL: 
Health-Relatd Quality Of Life 
ICH: 
International Conference on Harmonisation 
IMP: 
investigational medicinal product 
INR: 
International Normalized Ratio 
IRB/IEC: 
Institutional Review Board/Independent Ethics Committee 
ITT: 
intent to treat 
IV: 
intra-venous 
IVRS/IWRS: 
Interactive Voice/Web Response System 
LDH: 
lactate deshydrogenase 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 23 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
mCRPC: 
metastatic Castration Resistant Prostate Cancer 
MedDRA: 
Medical Dictionary for Regulatory Activities 
MRI: 
magnetic resonance imaging 
MTD: 
maximum tolerated dose 
MTX: 
mitoxantrone 
NCI CTCAE: 
National Cancer Institute Common Terminology Criteria 
NIMP: 
non investigational medicinal product 
NSAIDs: 
Nonsteroidal Antiinflammatory Drugs 
OS: 
overall survival 
PCWG2: 
Prostate Cancer Working Group criteria 2 
PD: 
Progressive Disease, Progressive Disease 
PFS: 
progression free survival 
PI: 
package insert 
PO: 
orally 
PR: 
partial response 
PS: 
performance status 
PSA: 
Prostate-Specific Antigen 
PSA: 
Prostate-Specific antigen 
PT: 
preferred term 
rPFS: 
radiographic Progression-Free Survival 
SAE: 
serious adverse event 
SAP: 
statistical analysis plan 
SC: 
Steering Committee 
SGOT: 
Serum Glutamooxaloacétate Transférase 
SGPT: 
Serum Glutamo-Pyruvate Transferase 
SmPC: 
summary of product characteristics 
SOC: 
System Organ Class 
SSE: 
symptomatic skeletal event 
SUSAR: 
Suspected Unexpected Serious Adverse Reactions 
TEAE: 
Treatment Emergent Adverse Events 
TTPP: 
Time to PSA progression 
ULN: 
upper limit of normal 
WBC: 
white blood cell 
WHO: 
World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 24 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
4 
INTRODUCTION AND RATIONALE 
 
Prostate cancer is the most frequently diagnosed cancer in men, and represents the third cause of 
male cancer-related death, after lung and colorectal cancers, in Europe (11). 
 
Treatment of advanced prostate cancer is palliative. Androgen ablation remains the mainstay of 
treatment, producing a rapid decrease in bone pain, metastases, and prostate-specific antigen 
(PSA) levels. Nevertheless, in virtually all patients, the tumor becomes resistant to castration 
within a median of 18 months after castration (12). 
 
Until 2010, chemotherapy with docetaxel (75 mg/m² every 3 weeks) associated with daily 
prednisone was the unique treatment option having demonstrated a survival benefit in mCRPC, 
based  on results of two phase III trials (TAX 327 and SWOG 99-16) which included around 
2000 patients (13, 14, 15). Docetaxel every 3 weeks reduced by 24% the risk of death compared 
to the active comparator mitoxantrone plus prednisone (hazard ratio [HR] of death 
0.76 [95% CI 0.62-0.92]), with a concomitant improvement of pain and quality of life. 
 
Since 2010, the medical management of mCRPC has changed dramatically with five new agents 
(cabazitaxel, abiraterone, enzalutamide, radium 223, sipuleucel T) having demonstrated a survival 
benefit in mCRPC patients (16, 17, 18, 5, 6, 19). The challenge for physicians is now to integrate 
this broad armamentarium rationally in daily practice and appropriately tailor therapy to optimize 
treatment outcomes. 
 
 
4.1 
INVESTIGATIONAL MEDICINAL PRODUCT 
 
 
4.1.1 Preclinical data 
 
Cabazitaxel (also known as XRP6258, RPR116258A) is a semisynthetic compound derived from 
the 10•deacetyl Baccatin III, which is extracted from European yew needles. This new taxoid 
which promotes the tubulin assembly in vitro and stabilizes microtubules against cold-induced 
depolymerization as efficiently as docetaxel was selected for development based on a better 
antiproliferative activity on resistant cell lines than docetaxel. Using cell lines with acquired 
resistance to doxorubicin, vincristine, vinblastine, paclitaxel and docetaxel, the resistance factors 
ranged from 1.8 to 10 and 4.8 to 59, for cabazitaxel and for docetaxel, respectively.  Cabazitaxel 
exhibited a broad spectrum of in vivo antitumor activity, not only in docetaxel •sensitive tumor 
models, but also in tumors models in which docetaxel was either poorly active or not active. A 
trend for schedule-dependency was observed with maximum tolerated dosages 4.8-fold higher 
with an intermittent schedule than with a split dose schedule. The best antitumor efficacy was 
obtained with the schedules allowing the administration of the highest amount of drug. In 
addition, this compound was found to penetrate the blood brain barrier and marked antitumor 
activity was obtained in nude mice bearing intracranial glioblastomas. 
 
More information on the preclinical data is available in the clinical Investigator’s brochure (20). 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 25 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
4.1.2 Summary of clinical data 
 
In single agent, 3 Phase I studies were conducted to determine the schedule and the recommended 
dose, one study investigating the disposition of radiolabeled cabazitaxel, one Phase 2 study in 
patients with metastatic breast cancer (MBC), and one Phase 3 study in patients with mCRPC. 
One Phase I/II study has been conducted with cabazitaxel plus prednisone in combination with 
capecitabine. 
 
 
4.1.2.1 Phase 1 
 
The 3 Phase 1 studies in solid tumors (TED6188, TED6189, TED6190) have been completed. 
There were 2 partial responses in patients with prostate cancer in Phase 1 studies evaluating the 
every 3 week schedule; 2 PR out of 8 patients with metastatic HRPC in TED6190 at 25 mg/m2 
suggesting potential biological and clinical activity in patients with prostate cancer. 
 
The safety profile was comparable in TED6188 and TED6190, with the intermittent schedule 
(1•hour infusion every 3 weeks). The dose limiting toxicity (DLT) of cabazitaxel was neutropenia 
and its infectious complications at the highest dose tested, 30 mg/m² in TED6188 and 25 mg/m² in 
TED6190. 
 
As a result, the dose levels of 20 mg/m² and 25 mg/m² every 3 weeks were defined as the 
recommended doses for further clinical development with the intermittent schedule. 
 
In TED6189 with the weekly schedule, the maximum tolerated dose (MTD) was reached at 
12 mg/m², at which the DLT was diarrhea.  As a result, the dose level of 10 mg/m² was defined as 
the recommended dose for further clinical development with this weekly schedule. 
 
In TCD6945 the recommended dose was defined as cabazitaxel 20 mg/m² on D1 and capecitabine 
1000 mg/m² twice daily from D1 to D14, every 3 weeks. DLT were all grade 4 neutropenia lasting 
more than 7 days. 
 
 
4.1.2.2 Phase 2 
 
One Phase 2 study in patients with taxane- and/or anthracycline-resistant metastatic breast cancer 
has been completed (ARD6191). In this study patients were treated with a starting dose of 
20 mg/m2 cabazitaxel every 3 weeks with the option to dose-escalate cabazitaxel based on 
favorable tolerability at Cycle 1. In 20 of 71 patients, the cabazitaxel dose was escalated from 20 
to 25 mg/m2 after the first cycle. The most frequently occurring toxicities overall were Grade 3 
and 4 neutropenia (73.2%), fatigue (50.7%), nausea (43.7%), diarrhea (39.4%), myalgia (25.4%), 
anorexia (25.4%), weight loss (25.4%), and vomiting (23.9%). The overall response rate was 
14.1% with 2 complete responses (CR) and 8 partial responses (PR). 
 
 
4.1.2.3 Phase 3 
 
One Phase 3 study was conducted in mCRPC patients previously treated with docetaxel 
containing regimen. This study compared cabazitaxel (CBZ) plus prednisone to mitoxantrone 
(MTX) plus prednisone (EFC6193). A total of 755 patients were randomized (378 patients in 
 
 
Property of the Sanofi Group - strictly confidential 
Page 26 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
CBZ arm and 377 patients in MTX arm). A statistically significant increase in OS was observed 
in patients treated with CBZ plus prednisone compared to patients treated with MTX plus 
prednisone, with a HR of 0.70 (95%CI: 0.59 – 0.83), a log-rank p-value of 0.0001. The median 
OS was 15.1 months (95%CI: 14.1 – 16.3) in CBZ arm versus 12.7 months (95%CI: 11.6 – 13.7) 
in MTX arm. 
 
The secondary endpoints also demonstrated a net benefit in favor of CBZ treated patients 
compared with MTX treated patients. Progression-free survival, defined as the earliest date of 
radiological tumor progression, PSA progression, pain progression, or symptom deterioration or 
death due to any cause, was statistically significantly longer in the CBZ group compared with the 
MTX group (p<0.0001, HR = 0.74 [95% CI, 0.64 - 0.86]), and median progression-free survival 
was 2.8 months versus 1.4 months. Response rates for PSA and tumor assessments, as well as the 
time to PSA and tumor progression when defined as radiological progression or death were 
statistically significant in favor of CBZ. Pain response and time to pain progression were not 
statistically different between CBZ and MTX, for which the primary basis for approval was pain 
relief and control. 
 
Treatment emergent AEs were experienced by 95.7% of patients in the CBZ group and 88.4% of 
patients in the MTX group; 57.4% of patients in the CBZ group and 39.4% of patients in the MTX 
group had at least one Grade 3-4 TEAE. In the CBZ group 39.1% of patients had at least 1  
Serious Adverse Event (SAE) compared with 20.8% of patients in the MTX group. Study 
treatment discontinuation due to a TEAE was reported in 18.3% of patients in the CBZ group and 
8.4% of patients in the MTX group. 
 
The most frequent toxicity in the CBZ group were neutropenia and its clinical consequences of 
febrile neutropenia and infections. Based on laboratory assessments, 81.7% of patients in the CBZ 
group and 58.0% of patients in the MTX group had grade 3-4 neutropenia.  Patients treated with 
CBZ also had higher rates of infections Grade 3-4 with or without concomitant severe neutropenia 
(10.2% CBZ, 5.1% MTX) and febrile neutropenia (7.5% CBZ, 1.3% MTX). 
 
Gastrointestinal disorders of all types (Grade 3-4) were more common in the CBZ group (12.4% 
CBZ, 1.6% MTX). Notably, Grade 3-4 diarrhea was more common on CBZ (6.2%) compared 
with MTX (0.3%). Incidence of Grade 3-4 stomatitis (0% in both groups) and mucositis (0.3% in 
both groups) was similar in both treatment groups. 
 
Adverse events in the renal and urinary disorders System Organ Class (SOC) (Grade 3-4) also 
were more common in the CBZ group (8.6% CBZ, 2.4% MTX). These events consisted of renal 
failure and impairment (3.2% CBZ, 0.3% MTX) as well as renal obstructive disorders (0.8% 
CBZ, 0.5% MTX). In the CBZ group, 15 patients were reported to have acute renal Adverse 
Events (AEs) Grade 3-4, the etiology of which was multifactorial consisting of pre-renal, renal, or 
obstructive causes. According to laboratory values, the incidence of all grade /grade 3-4 creatinine 
increase was 15.6%/1.3% in CBZ arm and 11.6%/0.5% in MTX. In addition, more hematuria was 
reported in CBZ arm versus MTX arm (62 patients/16.7% versus 14 patients/3.8%). In CBZ arm, 
no clear possible explanation such as local infection/obstruction/progression, or 
anticoagulation/aspirin therapy, or thrombocytopenia was found for 21 patients. In prior studies 
conducted in metastatic breast cancer, a total of 6 patients (2 in the ARD6191 and 4 in the 
TCD6945) experienced cystitis without local infection including 5 hemorrhagic cystitis (3 cystitis 
 
 
Property of the Sanofi Group - strictly confidential 
Page 27 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
were documented with biopsy). Of note, in human the urinary excretion of cabazitaxel is about 
3.7% of the dose with 2.3% excreted as unchanged drug. 
 
Death within 30 days due to AE occurred in 18 patients (4.9%) in the CBZ group and 3 patients 
(<1.0%) in the MTX group. Of the 18 deaths in the CBZ group, 7 were the result of neutropenia 
and/or infection, 5 were due to cardiac events (2 cardiac arrest, 1 cardiac failure, 1 dyspnea and 
1 ventricular fibrillation), 1 was due to dehydration and hydro-electrolyte imbalance, 3 were pre- 
or post-renal events leading to renal failure, and 2 were due to other causes, including a death of 
unknown etiology and a death from a cerebral hemorrhage following a fall in a patient taking 
concomitant clopidrogrel. 
Based on the results of this study, a dossier to register cabazitaxel in hormone refractory 
metastatic prostate cancer patients previously treated with Taxotere® containing regimen has been 
submitted in several countries worldwide Cabazitaxel in combination with prednisone or 
prednisolone is currently approved in the United States, the European Union, Canada, 
Switzerland, and numerous other countries in Latin America, Asia, and the Middle East. 
 
 
4.2 
STUDY RATIONALE 
 
Metastatic CRPC is a heterogeneous disease and not all patients benefit from available treatments 
to the same extend. In COU AA 301 study, about 30% of patients experienced radiological 
progression with abiraterone acetate/prednisone at 3 months (18, 5). In AFFIRM, about 25% 
experienced radiological progression with enzalutamide at 3 months (6). Retrospective data based 
on a small number of patients suggest that 30% of patients treated with enzalutamide experience 
PSA progression at 3 months (21). Retrospective studies also suggest there is high level of cross- 
resistance between abiraterone and enzalutamide in post-docetaxel setting. Patients progressing on 
abiraterone (post-docetaxel) may have a marginal response to enzalutamide (22, 23, 24, 25) and 
vice-versa (26, 27). In contrast, retrospective studies suggest that cabazitaxel has a high anti- 
tumor activity in patients progressing on AR targeted agents (28, 29, 30). 
 
Despite the retrospective data suggesting the cross-resistance between abiraterone acetate and 
enzalutamide, the switch to the second AR targeted agent before the use of chemotherapy is still 
part of the standard medical practice. 
 
Docetaxel is the first-line chemotherapy in all international guidelines (31, 32, 20). However, 
many physicians currently use an AR targeted agent either before or after Docetaxel. It is not 
known if prescribing docetaxel between 2 AR targeted agents may restore some sensitivity to AR 
targeted agents. 
 
Cabazitaxel is a novel taxane which has been developed to overcome docetaxel resistance. 
Cabazitaxel has been shown to be as effective as docetaxel but 10 fold more potent than docetaxel 
in chemotherapy-resistant cell lines and tumors (33). Furthermore, cabazitaxel, unlike paclitaxel 
and docetaxel, has been shown to pass the blood-brain barrier in vivo thereby being potentially 
active in patients with cerebral or leptomeningeal metastatic disease. The efficacy of cabazitaxel 
in mCRPC has been demonstrated in TROPIC trial, an international, open label Phase III trial in 
which 755 patients with mCRPC who progressed during or after docetaxel were randomized to 
receive either intravenous cabazitaxel 25 mg/m2 over 1 h (N = 378) or mitoxantrone 12 mg/m2 
 
 
Property of the Sanofi Group - strictly confidential 
Page 28 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
over 1530 min (N = 377) every 3 weeks for ten cycles, in combination with prednisone 10 mg 
daily (16). The trial met its primary endpoint, with a statistically significant (p <0.0001) 
improvement in median OS in patients receiving cabazitaxel (15.1 months; 95% CI, 14.1-16.3 
months) compared to patients receiving mitoxantrone (12.7 months; 95% CI, 11.6-13.7 months). 
The hazard ratio (HR) for death was 0.70 (95% CI, 0.59-0.83; p < 0.0001), corresponding to a 
30% reduction in the risk of death with cabazitaxel compared to mitoxantrone. Median 
progression-free survival, a composite measure defined as the time between randomization and 
the date of disease progression (PSA or tumor or pain progression) or death, was 2.8 months (95% 
CI, 2.4-3.0) in the cabazitaxel group and 1.4 months (95% CI, 1.4-1.7) in the mitoxantrone group 
(HR, 0.74; 95% CI, 0.64-0.86; p<0.0001). PSA response and tumor response were also 
significantly higher with cabazitaxel than with mitoxantrone. An updated OS analysis of 
confirmed that the survival benefit of cabazitaxel was maintained in the long term with 15.9% of 
patients remaining alive over 2 years with cabazitaxel versus only 8.2% with mitoxantrone. 
 
The biological heterogeneity of the mCRPC clearly indicates the importance of distinguishing 
patients with primary resistance to AR targeted therapy with appropriate monitoring during the 
treatment.  Promising published data have shown that a biomarker signature (including presence 
of AR splice variant) in circulating tumor cells could predict resistance to AR targeted agents 
(34). 
 
The aim of this randomized, open-label study is to compare the efficacy of cabazitaxel versus an 
AR targeted agent (abiraterone acetate or enzalutamide, depending on what was received first), in 
patients previously treated with docetaxel and rapidly progressing with an AR targeted agents 
(progression within 12 months on abiraterone acetate or enzalutamide, before or after docetaxel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 29 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
5 
STUDY OBJECTIVES 
 
 
5.1 
PRIMARY 
 
To compare the radiographic Progression-Free Survival (rPFS) [Using Response Evaluation 
Criteria In Solid Tumors (RECIST) 1.1 for tumor lesions and Prostate Cancer Working Group 2 
(PCWG2) criteria for bone scan lesions (1, 2) or  death due to any cause] with chemotherapy 
(Cabazitaxel plus prednisone)  (Arm A) versus AR targeted therapy (enzalutamide or abiraterone 
acetate plus prednisone) (Arm B) in mCRPC patients who have been treated with docetaxel and 
who had disease progression while receiving AR targeted therapy within 12 months of AR 
treatment initiation (≤12 months)(either before or after docetaxel). 
 
 
5.2 
SECONDARY 
• 
To compare efficacy of cabazitaxel plus prednisone to enzalutamide or abiraterone acetate 
plus prednisone for: 
- 
PSA response rate, 
- 
Time to PSA progression (TTPP), 
- 
Progression-free survival, 
- 
Objective tumor response (RECIST1.1 criteria in patients with measurable disease), 
- 
Duration of tumor response, 
- 
Pain intensity palliation, 
- 
Time to pain progression, 
- 
Symptomatic Skeletal Events (SSEs) rate, 
- 
Time to occurrence of Symptomatic Skeletal Events (SSEs), 
- 
OS. 
• 
To compare Health-Related Quality Of Life (HRQOL) according to FACT-P 
questionnaire. 
• 
To compare Health status/utility (EQ-5D-5L). 
• 
To evaluate the correlation of a signature of resistance to AR targeted agents with clinical 
outcomes, via the analysis of Circulating Tumor Cells (CTCs) phenotypes as well as 
expression and localization of proteins including AR isoforms in CTCs. 
• 
To evaluate safety in the 2 treatment arms. 
 
 
5.3 
EXPLORATORY 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 30 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
6 
STUDY DESIGN 
 
This is a prospective, multicenter, multinational, randomized, open label phase IV study, 
comparing the efficacy of cabazitaxel at 25 mg/m² plus prednisone (Arm A) versus either 
enzalutamide at 160 mg once daily or abiraterone acetate at 1000 mg once daily plus prednisone 
(Arm B). Patients who rapidly failed a prior AR-targeted agent are defined as patients who have 
disease progression while receiving AR targeted therapy within 12 months of AR treatment 
initiation (≤12 months), (either before or after docetaxel). 
 
 
6.1 
DESCRIPTION OF THE PROTOCOL 
 
Treatment allocation will be performed by an Interactive Voice/Web Response System 
(IVRS/IWRS). All eligible patients will be randomly assigned to either Arm A or B in a 1:1 
proportion. 
 
Randomization will be stratified by: ECOG performance status (0-1 Vs. 2), time from AR targeted 
agent initiation to progression (]0; 6 months] Vs. ]6; 12 months]), timing of AR targeted agent 
(before Vs. after docetaxel). 
 
For patients who received docetaxel re-challenge, the last sequence of treatment must be 
considered for “the timing of AR targeted agent (before Vs. after docetaxel)” stratification factor. 
 
 
6.2 
DURATION OF STUDY PARTICIPATION 
 
 
6.2.1 Duration of study participation for each patient 
 
Each patient will be treated until radiographic disease progression, unacceptable toxicity, or 
patient’s refusal of further study treatment. The study period will include the screening phase, the 
study treatment period (until 30 days after last cabazitaxel or abiraterone acetate or enzalutamide 
administration) and the follow-up period. Cabazitaxel will be administered every 3 weeks. The 
comparators will be given orally continuously. The first study treatment should be administered 
within 7 calendar days after randomization. The time between biological work-up and first cycle 
should not exceed 8 days. If it is the case, hematology and biochemistry should be done again 
before first cycle in order to check that eligibility criteria are still met. After study treatment 
discontinuation, patient will be followed every 12 weeks (+/-1 week) until death, cut-off date or 
withdrawal of patient’s consent, whichever comes first. During the follow-up period, ongoing 
related AEs at end of treatment and all (serious or non-serious) new AEs related to study 
treatment will be collected and followed until resolution or stabilization. 
 
Patients still on study treatment at the main analysis cut-off date can continue treatment until at 
least 1 treatment discontinuation criterion as defined in Section 10.3.2 is met. 
 
All efforts should be made to document radiographic progression before initiation of further 
therapy. In case of treatment discontinuation due to reason other than radiographic progressive 
disease (for example discontinuation due to adverse event), the choice of further therapy, if any, is 
let to investigator, and data concerning first further therapy must be documented. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 31 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
6.2.2 Determination of end of clinical trial (all patients) 
 
The study is event driven and the final cut-off date will be when 196 rPFS events have occurred 
(expected to occur around 12 months after the last patient in). 
 
The end of clinical trial will be last patient last visit. 
 
 
6.3 
INTERIM ANALYSIS 
 
No interim analysis is planned. 
 
 
6.4 
STUDY COMMITTEES 
 
• 
A Steering Committee (SC), including Study Chairmen and sponsor representatives, will 
be responsible for: 
 
- 
Supervising the progress of the trial towards its overall objectives, 
 
- 
Reviewing at regular intervals relevant information that may affect the study conduct. 
 
• 
A translational SC will be responsible for supervising the biomarkers part. This committee 
will include Study Chairmen and Sponsor representatives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 32 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
7 
SELECTION OF PATIENTS 
 
Eligible patients with mCRPC will be recruited by the appropriate service at each participating 
institution. Participation is voluntary. The consenting physician will inform patients of their 
diagnosis, current treatment options, including standard treatment, and the risks, benefits and 
experimental nature of this treatment program. 
 
 
7.1 
INCLUSION CRITERIA 
 
All the following conditions must be met by the subject to be eligible in this study: 
I 01. 
Histologically confirmed prostate adenocarcinoma. 
I 02. 
Metastatic disease. 
 
I 03. 
Effective castration with serum testosterone levels < 0.5 ng/mL (1.7 nmol/L). If the patient 
has been treated with LHRH agonists or antagonist (ie, without orchiectomy), then this 
therapy should be continued. 
 
I 04. 
Progressive disease by at least one of the following: 
 
a) Progression in measurable disease (RECIST 1.1 criteria). Patient with measurable 
disease must have at least one lesion that can be accurately measured in at least one 
dimension (longest diameter to be recorded). Each lesion must be at least 10 mm when 
measured by CT [CT scan thickness no greater than 5 mm] or MRI. Lymph nodes 
should be ≥15 mm in short axis. As defined by PCWG2, if lymph node metastasis is 
the only evidence of metastasis, it must be ≥ 20 mm in diameter when measured by 
spiral CT or MRI. Previously irradiated lesions, primary prostate lesion and bone 
lesions will be considered non-measurable disease (see Appendix A), and/or 
 
b) Appearance of 2 or more new bone lesions (PCWG2). They must be confirmed by 
other imaging modalities (CT; MRI) if ambiguous results and/or 
 
c) Rising PSA defined (PCWG2) as at least two consecutive rises in PSA to be 
documented over a reference value (measure 1) taken at least one week apart. The 
first rising PSA (measure 2) should be taken at least 7 days after the reference value. 
A third confirmatory PSA measure is required (2nd beyond the reference level) to be 
greater than the second measure and it must be obtained at least 7 days after the 2nd 
measure. If this is not the case, a fourth PSA measure is required to be taken and be 
greater than the 2nd measure. The third (or the fourth) confirmatory PSA should be 
taken within 4 weeks prior to randomization (see Appendix B). 
 
I 05. 
Having received prior docetaxel for at least 3 cycles (before or after an AR targeted 
therapy). Docetaxel administration in combination with Androgen Deprivation Therapy 
(ADT) in metastatic hormone-sensitive disease is considered a prior exposure (3). 
Docetaxel re-challenge is allowed. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 33 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
I 06. 
Having progressive disease (PD) (according to I04) while receiving AR targeted therapy 
with abiraterone acetate or enzalutamide within 12 months of AR treatment initiation (≤12 
months) even if treatment duration is longer than 12 months. Patients treated with 
Abiraterone acetate + ADT in metastatic hormone-sensitive setting are eligible for CARD 
if they have progressed within 12 months with the AR-targeted agent. Patients having PSA 
progression only (as per PCWG 2) within 12 months are eligible. 
 
I 07. 
A PSA value of at least 2 ng/mL is required at study entry. 
 
I 08. 
Prior AR targeted therapy (abiraterone acetate or enzalutamide) must be stopped at least 
2 weeks before study treatment. 
 
I 09. 
Signed informed consent. 
 
 
7.2 
EXCLUSION CRITERIA 
 
Patients who have met all the above inclusion criteria listed in Section 7.1 will be screened for the 
following exclusion criteria which are sorted and numbered in the following 2 subsections: 
 
 
7.2.1 Exclusion criteria related to study methodology 
 
E 01.   Prior chemotherapy other than docetaxel for prostate cancer, except estramustine and 
except adjuvant/neoadjuvant treatment completed >3 years ago. 
 
E 02.   Less than 28 days elapsed from prior treatment with chemotherapy, immunotherapy, 
radiotherapy or surgery to the time of randomization. 
 
E 03. Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from 
any prior anticancer therapy of Grade >1(National Cancer Institute Common Terminology 
Criteria [NCI CTCAE] v4.0) at the time of randomization (see Appendix C). 
 
E 04.   Less than 18 years (or country's legal age of majority if the legal age is >18 years). 
 
E 05.   Eastern Cooperative Oncology Group performance status (ECOG PS)>2 (ECOG 2 must be 
related to prostate cancer, not to other comorbidities (see Appendix D). 
 
E 06. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, 
pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which treatment 
has been completed ≥5 years ago and from which the patient has been disease-free for 
≥5 years. 
 
E 07.   Participation in another clinical trial and any concurrent treatment with any investigational 
drug within 30 days prior to randomization. 
 
E 08.   Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease 
requiring antiretroviral treatment. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 34 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
E 09.   Patients with reproductive potential who do not agree, in conjunction with their partner, to 
use accepted and effective method of contraception during the study treatment period and 
up to 6 months after the last administered dose. The definition of "effective method of 
contraception" described hereafter: oral contraceptives, combined hormonal intravaginal, 
transdermal, intra uterine device or condoms will be based on respective study treatment 
labelling and country-specific regulatory requirements, and are documented in the 
Informed Consent Form. 
 
 
7.2.2 Exclusion criteria related to study treatments 
 
E 10.   Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone 
acetate or enzalutamide or docetaxel or polysorbate 80. 
 
E 11.   Known history of mineralocorticoid excess or deficiency. 
 
E 12.   History of seizure, underlying brain injury with loss of consciousness, transient ischemic 
attack within the past 12 months, cerebral vascular accident, brain arteriovenous 
malformation, brain metastases or the use of concomitant medications that may lower the 
seizure threshold. 
 
E 13.   Unable to swallow a whole tablet or capsule 
 
E 14.   Inadequate organ and bone marrow function as evidenced by: 
 
a) 
Hemoglobin <10.0 g/dL 
 
b) Absolute neutrophil count <1.5 x 109/L 
 
c) Platelet count <100 x 109/L 
 
d) AST/SGOT and/or ALT/SGPT >1.5 x ULN; 
 
e) Total bilirubin >1.0 x ULN 
 
f) 
Potassium <3.5 mmol/L 
 
g) Child-Pugh Class C 
 
E 15.   Contraindications to the use of corticosteroid treatment. 
 
E 16.   Symptomatic peripheral neuropathy Grade ≥2 (National Cancer Institute Common 
Terminology Criteria [NCI CTCAE] v.4.0). 
 
E 17.   Uncontrolled severe illness or medical condition including uncontrolled diabetes mellitus, 
history of cardiovascular disease (uncontrolled hypertension, arterial thrombotic events in 
the past 6 months , congestive heart failure, severe or unstable angina pectoris, recent 
myocardial infraction within last 6 months or uncontrolled cardiac arrhythmia). 
 
E 18.   Concomitant vaccination with yellow fever vaccine. 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 35 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
8 
STUDY TREATMENTS 
 
Name and formulation details of drugs used in study are summarized in Table 1 below. 
 
 
Table 1 • Study treatments 
 
Drug code 
XRP6258 
- 
 
INN 
cabazitaxel 
prednisone or 
prednisolone 
 
Formulation 
Cabazitaxel is supplied as a sterile, non-pyrogenic, non-aqueous yellowish to 
brownish yellow concentrate for solution for infusion at 60 mg/1.5 mL and packaged 
in a 15 mL clear type I glass vial closed with a rubber closure. The rubber closure is 
crimped to the vial with an aluminum cap covered with a light green plastic flip-off 
cap. Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as 
anhydrous and solvent-free basis, per 1.5 mL of solution. The fill volume has been 
established to include an overfill, [i.e., 1.5 mL (nominal volume) + 0.33 mL]. This 
overfill was determined to ensure that a 10 mg/mL concentration is obtained in the 
premix and that 60 mg dose can be extracted. 
The solvent used for the preparation of the premix is a sterile, non-pyrogenic solution 
containing a 13% w/w ethanol solution in water for injection. This solvent is supplied 
in a 15 mL clear type I glass vial closed with a rubber closure. The rubber closure is 
crimped to the vial with either an aluminum cap covered with a light grey plastic flip- 
off cap or a gold-color aluminum cap covered with a colorless plastic flip-off cap. 
Each vial of solvent is overfilled to ensure that a 10 mg/mL concentration is obtained 
in the Premix and that 60 mg dose can be extracted. [i.e., 4.5 mL (nominal volume) + 
1.17 mL]. The solution is a clear colorless liquid. 
 
Commercially available 
formulation 
(refer to the local 
labeling) 
 
Storage 
conditions 
 
Do not store above 30°C. Do not refrigerate. The solvent was also shown to be 
stable under these conditions. All vials must be kept in their box until use. 
 
Refer to the local 
labeling. 
 
Drug code INN 
Abiraterone Acetate 
prednisone or 
prednisolone 
 
Formulation 
250 mg tablets, white to off-white, oval tablets debossed with AA250 on one side. 
Abiraterone acetate 250 mg tablets are available in high-density polyethylene bottles 
of 120 tablets 
or 
500 mg tablets, Film-coated tablet. Purple, oval-shaped, film-coated tablets 
debossed with “AA” on one side and “500” on the other side. Abiraterone acetate 
500 mg tablets are available in: PVdC/PE/PVC/aluminum blister of 12 filmcoated 
tablets in a cardboard wallet. Each carton contains (60 filmcoated tablets) 5 wallets, 
or PVdC/PE/PVC/aluminum blister of 14 filmcoated tablets in a cardboard wallet. 
Each carton contains (56 filmcoated tablets) 4 wallets. 
 
Commercially available 
formulation 
(refer to the local 
labeling) 
 
Storage 
Refer to the local labeling 
Refer to the local 
labeling 
 
Drug code INN 
Enzalutamide 
 
Formulation 
40 mg capsules, white to off-white oblong soft capsules (approximately 
20 mm x 9 mm) imprinted with "ENZ" in black ink on one side 
 
Storage 
Refer to the local labeling 
 
 
Property of the Sanofi Group - strictly confidential 
Page 36 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
8.1 
INVESTIGATIONAL MEDICINAL PRODUCT 
 
CABAZITAXEL 
 
 
8.1.1 Preparation and administration of cabazitaxel 
 
The preparation of the cabazitaxel (XRP6258) infusion solution for administration requires 
two dilutions prior to administration, the preparation of a premix solution at 60 mg/6 mL (nominal 
concentration). This must be done with a 13% w/w ethanol solution in water for injection (the 
“solvent”) supplied with the cabazitaxel concentrate for solution for infusion (“preparation of the 
premix solution”).  Then the premix solution must be diluted in an infusion vehicle (“preparation 
of the infusion solution”) prior to administration. 
 
An improper preparation may lead to overdose. 
 
Both the Cabazitaxel Injection and supplied diluent vials contain an overfill to compensate for 
liquid loss during preparation. This overfill ensures that after dilution with the entire contents of 
the accompanying diluent, there is an initial diluted solution containing 10 mg/mL Cabazitaxel. 
 
 
8.1.1.1 Preparation of the premix solution under aseptic conditions 
 
Set aside the required number of solvent vials (one solvent vial for each vial of cabazitaxel). For 
each cabazitaxel vial: 
• 
Using a syringe fitted with a needle, aseptically withdraw the ENTIRE CONTENTS of the 
solvent vial and inject it into the corresponding vial of cabazitaxel. 
• 
The addition of the ENTIRE CONTENTS of 1 solvent vial ensures a minimal extractable 
volume of the premix solution of 6 mL, containing 10 mg/mL of cabazitaxel. 
• 
Remove the syringe and needle and gently mix the reconstituted solution by repeated 
inversions for at least 45 seconds. Do not shake. 
• 
Allow the premix solution to stand for a few minutes at room temperature to allow foam to 
dissipate. The solution is homogeneous and contains no visible particulate matter. It is 
normal for foam to persist after this time period. 
 
The premix solution contains 10 mg/mL of cabazitaxel. Then the premix solution must be diluted 
in an infusion vehicle so as to obtain the required dose for administration. 
 
 
8.1.1.2 Preparation of the infusion solution under aseptic conditions 
 
WARNING: Since foam is normally present, the required dose must be accurately adjusted using 
a graduated syringe. 
• 
Aseptically, with a syringe and needle, withdraw the volume of the premix solution 
containing 10 mg/mL of cabazitaxel that corresponds to the required dose (mg) for 
administration of cabazitaxel. 
• 
Inject the required premix volume into a 125 to 500 mL infusion container (containing 
either 5% glucose solution or 0.9% sodium chloride solution). 
 
 
Property of the Sanofi Group - strictly confidential 
Page 37 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
The concentration of the infusion should be between 0.10 mg/mL and 0.26 mg/mL (based on 
Maximum Tolerated Dose of 30 mg/m² and a Body Surface Area [BSA] of 2.1 m²). 
 
• 
Mix the contents of the infusion container manually by gently inverting the bag or bottle. 
 
 
8.1.1.3 Infusion conditions 
 
• 
The recommended infusion duration is 1 hour. The infusion solution should be used within 
8 hours at ambient temperature (including the one hour infusion time) or within a total of 
48 hours if refrigerated (including the 1 hour infusion time). 
 
• 
The infusion solution should be administered at room temperature under normal lighting 
conditions. 
 
• 
Do not use polyvinyl chloride (PVC) infusion containers or polyurethane infusion sets for 
cabazitaxel preparation and administration. 
 
• 
Glass bottles could also be used. 
 
• 
Use and in-line filter of 0.22 µm nominal pore size (also referred to as 0.2 µm) during 
cabazitaxel administration. 
 
 
8.1.1.4 Storage period of premix and infusion solution 
 
• 
The premix solution of cabazitaxel should be used immediately after preparation and 
within 1 hour at ambient temperature. 
 
• 
The infusion solution is stable for 8 hours at ambient conditions (including the 1 hour 
infusion time) or a total of 48 hours if refrigerated, from preparation to end of infusion. 
 
 
8.1.1.5 Recommendation for safe handling 
 
• 
Cabazitaxel is an anti-neoplastic agent and, like other potentially toxic compounds, 
caution should be exercised in handling and preparing cabazitaxel solutions. The use of 
gloves is recommended. 
 
• 
If cabazitaxel concentrate, premix solution, or infusion solution should come into contact 
with skin, wash immediately and thoroughly with soap and water. 
 
• 
If cabazitaxel concentrate, premix solution, or infusion solution should come into contact 
with mucous membranes, wash immediately and thoroughly with water. 
 
 
8.1.2 Dosage and schedule 
 
BSA will be calculated prior to each treatment cycle from body weight in kg, recorded prior to 
each treatment cycle, and height in cm, recorded at baseline. The preferred Dubois and Dubois 
equation is: BSA in units of m2 = wgt in kg 0.425 x hgt. in cm 0.725 x 0.007184. 
 
The treatment should continue for at least 12 weeks (4 cycles) in the absence of radiological 
evidence of disease progression defined in Section 9.1 or unacceptable toxicity or patient 
refusal of further treatment. Subsequently, no decision of treatment discontinuation should be 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 38 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
made in case of PSA increase ALONE or pain increase ALONE, within the first 12 weeks, 
see Section 9.2.1.2. 
 
Each patient will be treated until radiographic progressive disease, unacceptable toxicity, patient’s 
refusal of further study treatment or any other discontinuation criteria as defined in Section 10.3.2. 
 
In case of patient discontinues study treatment due to reason other than radiological progressive 
disease, the investigator may consider not to initiate further anticancer therapy before radiological 
progression is documented (as defined in Section 9.1), in case study treatment discontinuation 
occurs within the 4 first cycles the decision is left to investigator judgment. 
 
Dose adjustment will be permitted for subsequent treatment cycles based on individual patient 
tolerance (see Section 8.1.2.3) Treatment will continue unless any of the Withdrawal Criteria are 
met as described in Section 10.3.2. 
 
 
8.1.2.1 Study treatments 
 
Cabazitaxel 25 mg/m² in dextrose 5% or NaCl 0.9% (for volume see Section 8.1.1.2) 
intravenously on D1 every 3 weeks, plus prednisone (or prednisolone) 10 mg orally given daily. 
 
 
8.1.2.2 Premedication 
 
For cabazitaxel premedication will include an antihistamine (dexchlorpheniramine 5 mg, 
diphenhydramine 25 mg, or other antihistamine), steroid (dexamethasone 8 mg or equivalent 
steroid), and H2 antagonist (ranitidine 50 mg or other H2 antagonist).  These premedications will 
be administered by IV infusion, at least 30 minutes prior to each dose of cabazitaxel. For countries 
where IV antihistamines are not available, oral instead of IV antihistamines can be used according 
to the local practice. 
 
For cabazitaxel appropriate prophylactic antiemetic therapy is left to current hospital practices. 
Primary prophylactic G-CSF at each cycle is required for all patients in Cabazitaxel arm. 
 
8.1.2.3 Dose modification and dose delay 
 
 
8.1.2.3.1 General Rules 
 
Every effort will be made to administer the full dose regimen to maximize dose-intensity. 
 
If possible, toxicities should be managed symptomatically. If toxicity occurs, the appropriate 
treatment will be used to improve signs and symptoms including antiemetics for nausea and 
vomiting, antidiarrheals for diarrhea, and antipyretics, and/or antihistamines for drug fever. 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 39 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Dose reduction 
 
Dose can be reduced for cabazitaxel when necessary as described in following sections. The dose, 
which has been reduced for toxicity, must not be re-escalated. Up to a maximum of 2 dose 
reductions will be allowed per patient. If a third dose reduction is required per the modifications 
below, the patient should discontinue study treatment. Dose levels in case of dose reduction are 
described in Table 2 below. 
 
 
Table 2 • Cabazitaxel dose reduction levels 
 
Initial dose (mg/m²) 
Dose reduction 1 
Dose Reduction 2 
Cabazitaxel 
25 
20 
→ 
15 
 
Chemotherapy Delay 
 
A treatment delay ≥ 4 days should be justified (ie, to be reported in the case report form (CRF)). 
Treatment may be delayed no more than 2 weeks to allow recovery from acute toxicity. In case of 
treatment delay greater than 2 weeks, patient should discontinue study treatment, unless there is 
strong evidence of clinical benefit to justify continuation of dosing with study treatment, and the 
investigator must discuss the rationale with the Sponsor before a decision is taken. 
 
 
8.1.2.3.2 Dose modification and dose delay 
 
The dose cabazitaxel could be modified in case of toxicity. Dose modifications are summarized in 
Table 3. 
 
 
Table 3 • Dose modifications for cabazitaxel* 
 
Toxicity 
Grade 2 
Grade 3 
Grade 4 
 
No dose reduction if isolated and duration ≤7 days. 
If duration more than 7 days or not recovered on D21 
despite prophylactic G-CSF: 
 
 
Neutropenia 
 
 
 
 
 
 
 
 
 
 
Febrile neutropenia or 
If not recovered on D21, delay** next 
infusion until recovery to Grade ≤1 
(neutrophil ≥1.5 x 109/L). 
- 1st episode: No dose reduction required. 
- 2nd episode; reduce by 1 dose level 
Delay** next infusion until ANC ≥1.5 x 109/L and: 
- 1st episode: Reduce dose by 1 dose level and 
continue prophylactic G-CSF treatment in subsequent 
cycles. 
- 2nd episode after first dose reduction: Reduce dose 
by 1 dose level (dose reduction level 2) and continue 
prophylactic G-CSF treatment in subsequent cycles. 
- 3rd episode: Withdraw from study treatment 
 
Delay** next infusion until recovery and ANC 
≥1.5 x 109/L and: 
neutropenic infection 
Not applicable 
- 1st episode: reduce the dose and continue 
prophylactic G-CSF treatment in subsequent cycles. 
- 2nd episode: Withdraw from study treatment 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 40 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Toxicity 
Grade 2 
Grade 3 
Grade 4 
 
Delay** infusion until platelets ≥75 x 109/L. 
If Grade 3 without delay, no dose reduction required. 
 
 
Thrombocytopenia 
 
 
 
 
 
 
 
Diarrhea 
 
 
 
 
 
Stomatitis 
Delay** next infusion until recovery to 
Grade ≤ 1 (platelets ≥75 x 109/L). 
No dose reduction required. 
 
 
 
 
Delay** next infusion until recovery (grade 
≤1) 
No dose reduction required. 
 
 
Delay** next infusion until recovery 
(Grade ≤1) 
No dose reduction required. 
 
 
 
Delay** next infusion until recovery 
If Grade 4 with or without delay, or Grade 3 with delay 
- 1st episode: Reduce dose by 1 dose level. 
- 2nd episode: Reduce dose by 1 more dose level. 
- 3rd episode: Withdraw from study treatment in case 
of recurrence. 
 
Delay** next infusion until recovery (Grade ≤1): 
- 1st episode: Reduce dose by 1 dose level. 
- 2nd episode: Reduce dose by 1 more dose level. 
- 3rd episode: Withdraw from study treatment. 
 
Delay** next infusion until recovery (Grade ≤1): 
- 1st episode: Reduce dose by 1 dose level. 
- 2nd episode: Reduce dose by 1 more dose level. 
- 3rd episode: Withdraw from study treatment. 
 
Delay** next infusion until 
recovery (Grade ≤1): 
Cutaneous Reactions 
(Grade ≤1) 
No dose reduction required. 
- 1st episode: Reduce dose 
by 1 dose level. 
- 2nd episode: Withdraw from 
study treatment. 
Withdraw from study 
treatment. 
 
Creatinine increase 
Withdraw from study treatment in case of any degradation of renal function to renal failure ≥ CTCAE 
Grade 3 (>3.0 baseline; >3.0 - 6.0 x ULN) 
 
Neurological toxicity*** 
 
No delay 
Reduce by 1 dose level 
 
Withdraw from study treatment. 
 
Total Bilirubin Elevation 
In case of bilirubin > 1.0 x UNL 
Delay** until recovery to bilirubin ≤1.0 x UNL and reduce dose: 
If > 1 to ≤ 1.5 x (ULN), reduce dose to dose reduction 1 
If > 1.5 to ≤ 3 x ULN, reduce dose to dose reduction 2 
If > 3 X ULN, withdraw from study treatment 
 
Transaminases 
Elevation 
 
In case of AST/ALT > 1.5 x ULN, delay** 
until recovery to AST/ALT ≤1.5 x UNL and 
reduce dose by 1 dose level (2 dose 
reductions are allowed). 
 
 
Withdraw from study treatment. 
 
Hypersensitivity 
No dose reduction. See Table 4 for management of hypersensitivity due to 
study drug. 
Withdraw from study treatment in case of 2nd Grade 3 episode. 
 
* Dose reduction levels provided in Table 2 
 
Withdraw from study 
treatment. 
** maximum of 2 weeks delay, otherwise the patient will be withdrawn from study treatment, unless discussed and accepted by sponsor 
*** Including hearing disorders 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 41 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
8.1.2.3.3 Specific recommendations 
 
 
8.1.2.3.3.1 Hypersensitivity 
 
Hypersensitivity reactions that occur despite premedication are very likely to occur within a few 
minutes of start of the first or of the second infusion of cabazitaxel. Therefore, during the first and 
the second infusions, careful evaluation of general sense of well-being and of blood pressure and 
heart rate will be performed for at least the first 10 minutes, so that immediate intervention would 
occur in response to symptoms of an untoward reaction. 
 
Facilities and equipment for resuscitation along with the medications (ie, antihistamine, 
corticosteroids, aminophylline, and epinephrine) must be immediately available.  If a reaction 
occurs, the specific treatment that can be medically indicated for a given symptom 
(eg, epinephrine in case of anaphylactic shock, aminophylline in case of bronchospasm, etc.) will 
be instituted. In addition, it is recommended to take the measures listed below. 
 
 
Table 4 • Interventions in case of hypersensitivity reaction 
 
 
 
Mild symptoms: 
Symptom Severity 
Intervention Recommendation 
 
Consider decreasing the rate of infusion until recovery of 
Localized cutaneous reaction such as mild pruritus, flushing, rash 
 
 
 
Moderate symptoms: 
Any symptom such as generalized pruritus, flushing, rash, dyspnea, 
back pain during infusion, hypotension with systolic blood pressure 
(BP) >80 mm Hg not listed above (mild symptoms) or below (severe 
symptoms). 
 
 
Severe symptoms, such as: 
Bronchospasm, generalized urticaria, systolic BP ≤80 mm Hg, 
angioedema 
symptoms, stay at bedside, 
Then, complete study drug infusion at the initial planned 
rate 
 
Stop study drug infusion, 
Give diphenhydramine 50 mg i.v. and/or i.v. 
dexamethasone 10 mg, 
Resume study drug infusion within 3 hours following 
recovery of hypersensitivity reaction. Administer study 
drug over 2 hours for all subsequent treatments. 
 
• 
Stop study drug infusion; 
• 
Give IV diphenhydramine 50 mg and/or i.v. 
dexamethasone 10 mg and/or epinephrine as 
needed. 
• 
In case of severe hypersensitivity reaction, 
rechallenge must be performed more than 3 
hours after recovery and premedication should 
be readministered. 
• 
If severe reaction recurs despite additional 
premedication, the patient will go off protocol 
  
therapy.  
 
Anaphylaxis (Grade 4 reaction) 
NO FURTHER PROTOCOL THERAPY. 
 
 
 
Management of subsequent cycles 
 
The recommended pretreatment for subsequent infusions is 50 mg diphenhydramine i.v. or other 
i.v. H1 antihistaminic agent and 10 mg dexamethasone i.v. 30 minutes prior to study drug 
infusion. For patients who experience moderate or severe hypersensitivity reactions, the study 
 
 
Property of the Sanofi Group - strictly confidential 
Page 42 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
drug should be administered over 2 hours for subsequent treatment courses in addition to 
premedication as noted above. These patients must be informed of the potential risk of recurrent 
allergic reactions and must be carefully monitored. 
 
If the initial reaction is Grade 4 for allergy (anaphylaxis), the patient will receive no further 
treatment and will go off protocol therapy. 
 
If a second severe reaction (Grade 3) recurs despite additional premedications as outlined above, 
the patient will go off protocol therapy. 
 
In case of late occurring hypersensitivity symptoms, e.g., appearance within 1 week after 
treatment of a localized or generalized pruritus, symptomatic treatment may be given (e.g., oral 
antihistamine), additional oral or i.v.  premedication with antihistamine may also be given for the 
next cycle of treatment depending on the intensity of the reaction observed. No dose reductions 
will be made in any case. 
 
 
8.1.2.3.3.2 Hematological toxicities 
 
Blood counts will be performed in case of fever or infection. Blood counts should be monitored 
weekly for the first 3 cycles to determine if dosage modification is needed. Study treatment should 
not be given to patients with neutrophil counts <1,500 cells/mm3. 
 
Deaths due to sepsis following severe neutropenia have been reported in patients treated with 
cabazitaxel. Neutropenic complications should be managed promptly with antibiotic support and 
use of G-CSF according to ASCO guidelines (35). Infections concomitant with Grade 3-4 
neutropenia should be reported with the term “neutropenic infection” in the eCRF. 
 
No dose modification will be made for anemia. Caution is recommended in patients with 
haemoglobin <10 g/dl, and appropriate measures should be taken as clinically indicated. Patients 
will be supported appropriately by the treating physician (the investigator can refer to ASCO 
guidelines (36). 
 
 
8.1.2.3.3.3 Gastrointestinal disorders and diarrhea: 
 
Nausea, vomiting and severe diarrhea, at times, may occur. Death related to diarrhea and 
electrolyte imbalance occurred in the randomized clinical trial. 
 
Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, 
including fatal outcome, have been reported. Risk may be increased with neutropenia, age, steroid 
use, concomitant use of NSAIDs, anti-platelet therapy or anti-coagulants, and patients with prior 
history of pelvic radiotherapy, adhesions, ulceration and GI bleeding. 
 
No prophylaxis should be given; loperamide should not be prescribed prophylactically. Patients 
should stop any laxative treatment and avoid food and beverage, which might accelerate intestinal 
transit. 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 43 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Diarrhea can be life threatening and may lead to dehydration, electrolyte imbalance, or sepsis. 
Diarrhea should be treated promptly with loperamide.  Patients with diarrhea should be carefully 
monitored, and should be given fluid and electrolyte replacement if they become dehydrated. 
Loperamide should be given to patients when they leave hospital. 
 
Diarrhea ≥Grade 3 in the absence of neutropenia ≥Grade 3: 
 
In addition to the general precautions and prompt treatment with loperamide, patients should be 
given antibiotic support if they develop ileus, fever or neutropenic complications. Subsequent 
chemotherapy treatments should be delayed in patients until return of pretreatment bowel function 
for at least 24 hours without need for anti-diarrheal medication. Subsequent doses of study drug 
should be decreased by 1 dose level according to Table 3. 
 
Diarrhea ≥Grade 3 associated with neutropenia ≥Grade 3: 
 
In addition to prompt treatment with loperamide and fluid and electrolyte replacement, aggressive 
treatment with antibiotic support is recommended.  CBC should be assessed every 3 days [-1/+0] 
until ANC resolves to ≥1500/μL. Subsequent chemotherapy treatments should be delayed in such 
patients for up to 2 weeks until return of pretreatment bowel function for at least 24 hours without 
need for anti-diarrheal medication and until ANC resolves to ≥1500/μL. Following recovery, the 
dose of study drug should be reduced by 1 dose level Table 3. 
 
 
8.1.2.3.3.4 Urinary disorders 
 
An imbalance in the incidence of hematuria was observed in the Phase III study in second line 
mCRPC (EFC6193). More hematuria was reported in cabazitaxel arm versus mitoxantrone arm 
(62 patients/16.7% versus 14 patients/3.8%). In cabazitaxel arm, no clear possible explanation 
such as local infection/obstruction/progression, or anticoagulation/aspirin therapy, or 
thrombocytopenia was found for 21 patients. In addition, in prior studies conducted in metastatic 
breast cancer, a total of 6 patients (2 in the ARD6191 and 4 in the TCD6945) experienced cystitis 
without local infection including 5 hemorrhagic cystitis (3 cystitis were documented with biopsy). 
Therefore, in case of hematuria with no clear possible explanation any efforts should be done to 
document the cause (eg, urine cultures, urinary tract ultrasonography, and if no cause identified 
cystoscopy plus or minus biopsy). Hematuria should be confirmed by microscopic examination. 
 
 
8.1.2.3.3.5 Other toxicities 
 
For ≥Grade 3 toxicities except fatigue, local reaction, fluid retention, anemia and other toxicities 
that merely are uncomfortable but do not cause serious morbidity to patients, chemotherapy 
should be held for a maximum of 2 weeks from the planned date of reinfusion until resolution to 
≤Grade 1, then reinstituted, if medically appropriate. A dose reduction of subsequent doses will be 
left to the investigator’s judgment. These patients will be withdrawn from study treatment if 
>2 dose reductions are needed. Any measures such as frozen gloves or socks or scalp cooling cap 
to prevent nail toxicity or alopecia are left to the investigator judgment. 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 44 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
8.2 
OTHER IMP(S) 
 
Commercially available formulation of abiraterone acetate and enzalutamide will be used. 
 
 
8.2.1 Administration 
 
For abiraterone acetate and enzalutamide, refer to the package insert or summary of product 
characteristics for details on description, administration, and precautions for use. 
 
 
8.2.2 Dosage and schedule 
 
Abiraterone acetate: Patients who were previously treated with enzalutamide before study entry, 
will receive abiraterone acetate at the dose of 1000 mg (4 tablets 250 mg or 2 tablets 500 mg) PO 
continuously once daily from D1 to D21. It must be taken on an empty stomach. No food should 
be consumed for at least 2 hours before the dose is taken and for at least 1 hour after the dose is 
taken.  The tablets should be swallowed whole with water, plus prednisone 5 mg orally twice 
daily. A cycle is defined as a 3 week period. 
 
OR 
 
Enzalutamide: Patients who were previously treated with abiraterone acetate before study entry, 
will receive enzalutamide at the dose of 160 mg (4 capsules) PO continuously once daily from D1 
to D21, with or without food, capsules should be swallowed whole. A cycle is defined as a 3 week 
period. 
 
 
8.2.2.1 Dose Reductions and Delay due to Toxicity related to Abiraterone Acetate 
 
In clinical studies, Abiraterone acetate was generally tolerated without dose interruptions or 
reductions. The most common Abiraterone acetate-related AEs include fatigue (cortisol reduced 
by CYP17 inhibition) and mineralocorticoid-related hypertension, fluid retention, and 
hypokalemia (compensatory adrenocorticotrophic hormone [ACTH] drive). In this study, 
prednisone is expected to mitigate these effects through cortisol supplementation and abrogation 
of the ACTH drive. 
 
 
Table 5 • Abiraterone dose reduction level 
 
Initial dose (mg) 
Dose Reduction (mg) 
Abiraterone 
1000 (4 tablets 250 or 2 tablets 500) 
→ 
500 (2 tablets 250 or 1 tablet 500) 
 
One dose reduction is allowed for AEs. At dose reduction, the dose will be reduced by either 
2 tablets of 250 mg, (from 4 tablets 250 mg (1000 mg) to 2 tablets 250 (500 mg)), or by 1 tablet 
500 mg (from 2 tablets 500 mg (1000 mg) to 1 tablet 500 mg). An Abiraterone acetate dose of 
lower than 500 mg/D is not allowed. Study drug should not be resumed until resolution of the AE 
is documented. 
 
Treatment may be delayed no more than 2 weeks to allow recovery from acute toxicity. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 45 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
8.2.2.2 Management of Toxicity related to Abiraterone Acetate 
 
For additional information refer to the ZYTIGA (abiraterone acetate) package insert for details on 
description, preparation, administration, and precautions for use. 
 
 
8.2.2.2.1  Management of Hypokalemia 
 
At the initial observation of Grade 1 or 2 hypokalemia (serum potassium <3.5 mmol/L or below 
lower limit of normal range, but ≥3.0 mM), oral potassium supplement will be initiated. The dose 
of potassium supplement must be carefully titrated to maintain serum potassium from 3.5 to 
5.0 mmol/L, inclusive. Any subject with low potassium during the study or a history of 
hypokalemia from a preexisting or concurrent medical condition will undergo at least weekly 
laboratory electrolyte evaluation until recovery to the range ≥3.0 mmol/L. The investigator should 
consider maintaining potassium ≥4.0 mmol/L in these subjects Table 6. 
 
If any subject experiences Grade 3 symptomatic hypokalemia (serum potassium levels <3.0 to 
2.5 mM, NCI CTCAE version 4.0) or life-threatening hypokalemia with potassium levels 
<2.5 mM (NCI CTCAE version 4.0, hypokalemia Grade 4), Abiraterone acetate treatment will be 
withheld and the subject will be hospitalized for IV potassium replacement and cardiac 
monitoring. Re initiation of Abiraterone acetate treatment after normalization of potassium levels 
must be discussed with and approved by the Sponsor’s medical monitor Table 6. 
 
 
Table 6 • Management of Hypokalemia 
 
 
Serum K+ 
 Grade of 
Hypokalemia 
Action 
Further Action or Maintenance 
 
Low potassium or 
history of 
hypokalemia 
 
Weekly (or more frequent) 
laboratory electrolyte evaluations 
 
Titrate dose to maintain a serum potassium 
≥3.5 mM ≤5.0 mM (maintenance of subjects 
at ≥4.0 mM is recommended) 
 
<3.5 mM to 3.0mM 
Grade 1 or 2 
Initiate oral or IV potassium 
supplementation 
Consider monitoring magnesium 
and replacement if needed 
 
<3.0 mM to 2.5 mM 
Grade 3 
Withhold Abiraterone acetate (and 
initiate oral or IV potassium and 
cardiac monitoring 
Consider monitoring magnesium 
and replacement if needed 
 
<2.5 mM 
Grade 4 
Withhold Abiraterone acetate and 
initiate oral or IV potassium and 
cardiac monitoring 
Consider monitoring magnesium 
and replacement if needed 
 
Titrate dose to maintain a serum potassium 
≥3.5 mM to ≤5.0 mM (maintenance of 
subjects at ≥4.0 mM is recommended) 
 
 
Call the Sponsor’s medical monitor prior to re-
initiating study drug 
 
 
 
 
Call the Sponsor’s medical monitor prior to re-
initiating study drug 
 
IV=intravenous; mM=millimolar. 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 46 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
8.2.2.2.2 Management of Hypertension 
 
• 
If Grade 1 or 2 AEs occur, management per investigator. No Abiraterone acetate dose 
reduction. 
 
• 
If Grade 3 or 4 AEs occur, withhold Abiraterone acetate. Adjust or add medications to 
mitigate the toxicity or consider the specific mineralocorticoid receptor blocker, 
eplerenone (the dose not to exceed 200 mg/D). When hypertension resolves to ≤Grade 1, 
resume study drug at full dose. 
 
• 
If toxicity recurs, withhold Abiraterone acetate, and adjust or add medications to mitigate 
the toxicity. When toxicity resolved to ≤ Grade 1, resume Abiraterone acetate with the 
dose level reduction (2 tablets, 250 mg or 1 tablet 500 mg of Abiraterone acetate). 
 
• 
If toxicity recurs despite optimal medical management and the dose reduction, discontinue 
Abiraterone acetate. 
 
 
8.2.2.2.3 Management of Fluid Retention/ Edema 
 
• 
If lower limbs edema occurs, supportive management per investigator. No Abiraterone 
acetate dose reduction. 
 
• 
If Grade 3 pulmonary edema requiring supplemental oxygen occurs, withhold Abiraterone 
acetate. Adjust or add medications to mitigate the toxicity and consider the specific 
mineralocorticoid receptor blocker, eplerenone (the dose not to exceed 200 mg/D). When 
toxicity resolves to ≤ Grade 1, resume Abiraterone acetate at full dose. 
 
• 
If toxicity recurs, withhold Abiraterone acetate, and adjust or add medications to mitigate 
the toxicity. When toxicity resolved to ≤ Grade 1, resume Abiraterone acetate with the 
dose level reduction (2 tablets, 250 mg or 1 tablet 500 mg of Abiraterone acetate). 
 
• 
If toxicity recurs despite optimal medical management and the dose reduction, discontinue 
Abiraterone acetate. 
 
 
8.2.2.2.4 Management of Abnormal Liver Function Tests 
 
For patients who develop hepatotoxicity during treatment (alanine aminotransferase [ALT] 
increases or aspartate aminotransferase [AST] increases above 5 times the upper limit of normal 
[ULN]), treatment should be withheld immediately. Re-treatment following return of liver 
function tests to the patient’s baseline may be given at a reduced dose of 500 mg (two tablets 
250 mg or 1 tablet 500 mg) once daily. For patients being re-treated, serum transaminases should 
be monitored at a minimum of every two weeks for three months and monthly thereafter. If 
hepatotoxicity recurs at the reduced dose of 500 mg daily, treatment should be discontinued. If 
patients develop severe hepatotoxicity (ALT or AST 20 times the ULN) anytime while on 
therapy, treatment should be discontinued and patients should not be re-treated. 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 47 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
8.2.2.2.5 Management of Non-Mineralocorticoid Based Side Effects 
 
• 
If Grade 1 to 2 toxicities occur, give supportive care per institutional guidelines. No 
Abiraterone acetate dose reduction. 
 
• 
If Grade 3 or higher toxicities occur, including headache (interferes with activities of daily 
living), nausea (total parenteral nutrition/IV fluids), vomiting (6 or more episodes in 
24 hours, total parenteral nutrition/IV fluids), diarrhea (IV fluids, hospitalization, 
hemodynamic collapse), or any other toxicity judged related to Abiraterone acetate is 
observed where the subjects safety is jeopardized, hold Abiraterone acetate. 
 
 • When toxicity resolves to ≤ Grade 1, resume Abiraterone acetate at full dose. 
 
• 
If toxicity recurs, withhold Abiraterone acetate, and adjust or add medications to mitigate 
the toxicity. When toxicity resolved to ≤ Grade 1, resume Abiraterone acetate with the 
dose level reduction (2 tablets 250 mg or 1 tablet 500 mg of Abiraterone acetate). 
 
• 
If toxicity recurs despite aggressive medical management and dose level reduction, 
discontinue Abiraterone acetate. 
 
 
8.2.2.3 Drug interactions related to abiraterone acetate 
 
(see Appendix I). 
 
Co-administration of a strong CYP3A4 inducer, decreases exposure of abiraterone by 55%. Avoid 
concomitant strong CYP3A4 inducers during abiraterone acetate treatment. 
 
Abiraterone acetate is an inhibitor of the hepatic drug-metabolizing enzyme CYP2D6. Avoid co- 
administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index. 
 
 
8.2.2.4 Dose Reductions and Delay due to Toxicity related to enzalutamide 
 
For additional information refer to the XTANDI (enzalutamide) package insert for details on 
description, preparation, administration, and precautions for use. 
 
If a patient experiences a ≥ Grade 3 toxicity or an intolerable adverse reaction, dosing should be 
withheld for one week or until symptoms improve to ≤ Grade 2, then resumed at the same or a 
reduced dose (120 mg or 80 mg) if warranted. Up to two (2) dose reductions are allowed for AEs. 
 
Treatment may be delayed no more than 2 weeks to allow recovery from acute toxicity. 
In case of seizure, the patient must discontinue from treatment. 
 
Table 7 • Enzalutamide dose reduction levels 
 
Initial dose (mg) 
Dose reduction 1 
Dose Reduction 2 
Enzalutamide 
160 (4 capsules) 
→ 
120 (3 capsules) 
→ 
80 (2 capsules) 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 48 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
8.2.2.5 Drug interactions related to enzalutamide 
 
(see Appendix I). 
 
Co-administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the composite area under 
the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide by 
2.2-fold in healthy volunteers. Avoid concomitant strong CYP2C8 inhibitors during enzalutamide 
treatment. 
 
Co-administration of enzalutamide with strong or moderate CYP2C8 inducers (e.g., rifampin) 
may alter the plasma exposure of enzalutamide and should be avoided. 
 
Co-administration of a strong CYP3A4 inhibitor (itraconazole) increased the composite AUC of 
enzalutamide and should be avoided. 
 
Co-administration of enzalutamide with strong CYP3A4 inducers (e.g., carbamazepine, 
phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) may decrease the plasma exposure of 
enzalutamide and should be avoided. Moderate CYP3A4 inducers (e.g., bosentan, efavirenz, 
etravirine, modafinil, nafcillin) and St. John’s Wort may also reduce the plasma exposure of 
enzalutamide and should be avoided. 
 
Concomitant use of enzalutamide with narrow therapeutic index drugs that are metabolized by 
CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, 
quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-
mephenytoin) should be avoided, as enzalutamide may decrease their exposure. 
 
 
8.3 
NON INVESTIGATIONAL MEDICINAL PRODUCT 
 
Prednisone or prednisolone as associated product during treatment with cabazitaxel and 
abiraterone: 
 
Commercially available products will be used (oral route). The choice of the product is left to the 
investigator’s decision. The package insert or summary of product characteristics for details on 
description, administration and precautions for use will be used. 
 
G-CSF in patients in Cabazitaxel arm: 
 
Commercially available products will be used. The choice of the product is left to the 
investigator’s decision. For any G-CSF product, the package insert or summary of product 
characteristics for details on description, administration, and precautions for use will be used. 
 
 
8.4 
BLINDING PROCEDURES 
 
 
8.4.1 Methods of blinding 
 
Not applicable. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 49 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
8.5 
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP 
 
 
8.5.1 Patient number and treatment number 
 
Patients who meet all inclusion criteria and none of the exclusion criteria are deemed eligible for 
randomization. 
 
Randomization and treatment allocation(s) will be performed centrally by an interactive 
voice/Web response system (IVRS/IWRS). A randomized patient is a patient with a patient 
number and a treatment allocated by the IVRS/IWRS. 
 
 
8.5.2 Allocation of treatment(s) 
Treatment will be allocated by the IVRS/IWRS to either arm in a 1:1 ratio. 
Randomization will be stratified by: 
• 
ECOG performance status (0-1 Vs. 2); 
• 
Time from AR targeted agent initiation to progression (]0; 6months] Vs. ]6; 12 months]); 
• 
Timing of AR targeted agent (before Vs. after docetaxel). 
 
For patients who received docetaxel re-challenge, the last sequence of treatment must be 
considered for “the timing of AR targeted agent (before Vs. after docetaxel)” stratification factor. 
 
 
8.6 
PACKAGING AND LABELING 
 
This is an open label study. The Investigational Medicinal Product (cabazitaxel) will be packaged 
in: 
• 
Sterile, single-use vials. 
 
Packaging is in accordance with the administration schedule. The content of the labeling is in 
accordance with the local regulatory specifications and requirements. 
 
For infusion conditions, see Section 8.1.1.3. 
 
For abiraterone acetate and enzalutamide, the content of the labeling is in accordance with the 
local regulatory specifications and requirements. 
 
 
8.7 
STORAGE CONDITIONS AND SHELF LIFE 
 
Cabazitaxel (concentrate for solution for infusion) as packaged should not be stored above 30°C. 
Do not refrigerate. 
 
The solvent was also shown to be stable under these conditions. 
All vials must be kept in their box until use. 
Abiraterone acetate and Enzalutamide: refer to the package insert (PI) or the summary of product 
characteristics (SmPC). 
 
Property of the Sanofi Group - strictly confidential 
Page 50 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
8.8 
RESPONSIBILITIES 
 
The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the 
IMP will be responsible for ensuring that the IMP used in the clinical trial is securely maintained 
as specified by the Sponsor and in accordance with applicable regulatory requirements. 
 
All IMPs will be dispensed in accordance with the Investigator's prescription and it is the 
Investigator's responsibility to ensure that an accurate record of IMP issued and returned is 
maintained. 
 
Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance, 
pertaining documentation, labeling, expiration date, etc) should be promptly notified to the 
Sponsor. Some deficiencies may be recorded through a complaint procedure. 
 
A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the 
Sponsor. In this case, the Investigator will be responsible for promptly addressing any request 
made by the Sponsor, in order to recall IMP and eliminate potential hazards. 
 
Under no circumstances will the Investigator supply IMP to a third party, allow the IMP to be 
used other than as directed by this clinical trial protocol, or dispose of IMP in any other manner. 
 
 
8.8.1 Treatment accountability and compliance 
 
The investigator or pharmacist will inventory and acknowledge receipt of all shipments of the 
IMP. The study drug must be kept in a locked area with restricted access. The study drug must be 
stored and handled in accordance with the manufacturer's instructions. The investigator or 
pharmacist will also keep accurate records of the quantities of the study drugs dispensed and used 
by each patient. The study monitor will periodically check the supplies of study drugs held by the 
investigator or pharmacist to verify accountability of all study drugs used. At the conclusion of the 
study, all unused study drugs and all medication containers will preferably be destroyed at the 
investigational site (at a locally authorized facility) according to local regulation unless other 
arrangements have been approved by the Sponsor. Destruction of unused vials will occur only 
after drug accountability has been performed and written permission for destruction has been 
obtained. Used medication vials may be destroyed during the conduct of the study as required by 
the institution. 
 
The investigator or sub-investigator will supervise administration of the investigational drug. Any 
delegation of this responsibility must follow Section 13.1. 
 
The person responsible for drug dispensing is required to maintain adequate records of all study 
drugs. These records (eg, drug inventory form) include the date the study medication is received 
from the Sponsor, dispensed for patient, and destroyed or returned to the Sponsor as detailed in 
Section 8.8.2).  The fixed label portions of all the cabazitaxel vials administered to patients must 
be completed (patient number, date of infusion).  The batch number/Kit number on the vial must 
be recorded on the CRF/drug accountability form. 
 
The person responsible for drug administration to the patient will record precisely the dose, date, 
and time the drug is administered to the patient. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 51 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
8.8.2 Return and/or destruction of treatments 
 
Partially used cabazitaxel, abiraterone acetate and enzalutamide (when applicable) will be 
destroyed on site according to standard practices of the site. 
 
Unused Cabazitaxel, abiraterone acetate and enzalutamide (when applicable) will be destroyed on 
site after final batch accountability has been validated by the sponsor monitoring team 
representative and only after having received written authorization from the sponsor. 
 
In the event of a potential defect in the quality of IMP, it may be necessary for the Sponsor to 
initiate a recall procedure. In this case, the Investigator will be responsible for promptly 
addressing any request made by the Sponsor, in order to recall IMP and eliminate potential 
hazards. 
 
 
8.9 
CONCOMITANT MEDICATION 
 
Concomitant medications should be kept to a minimum during the study. However, if these are 
considered necessary for the patient's welfare and are unlikely to interfere with the IMP, they may 
be given at the discretion of the investigator and recorded in the e-CRF. 
 
The following concomitant treatments are not permitted during this study: 
 
• 
Concurrent treatment with other investigational drugs. 
 
• 
Concurrent treatment with any other anticancer therapy including immunotherapy, 
targeted therapy or biological therapies. 
 
• 
Concurrent treatment with strong inhibitors of cytochrome P450 3A4, such as 
ketoconazole, itraconazole, clarythromycin. For patients who were receiving treatment 
with such agents, a one-week washout period is required prior to randomization (see 
Appendix I). 
 
• 
Concurrent treatment with potent strong or moderate inducers of cytochrome P450 3A4, 
such as the antiepileptic drugs carbamazepine, phenytoin, phenobarbital, and St John Wort 
(millepertuis). For patients who were receiving treatment with such agents, a two-week 
washout period is required prior to randomization (see Appendix I). 
 
• 
Concurrent treatment with CYP2D6 substrates and that have a narrow therapeutic window 
(see Appendix I). 
 
• 
Concurrent treatment with strong or moderate inducers or strong inhibitors of CYP2C8 
(see Appendix I). 
 
• 
Concurrent treatment with CYP3A4, CYP2C9 and CYP2C19 with a narrow therapeutic 
index (see Appendix I). 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 52 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
The following concomitant treatments are permitted during this study: 
 
• 
LH-RH agonists that are ongoing prior to study entry. In addition, patients who are treated 
with LH-RH agonists (ie, without orchiectomy) should continue this therapy during the 
study treatment period. 
 
• 
The use of bisphosphonates and denosumab are allowed, however the dose must be stable 
for 4 weeks prior to enrollment and during the study treatment period (though 
bisphosphonate treatment may be discontinued during the study treatment period). 
 
• 
Ancillary treatment must be given as medically indicated; they must be specified in the 
CRF. 
 
• 
Primary prophylactic G-CSF is required at each cycle for all patients in Cabazitaxel arm. 
 
• 
Patients with severe diarrhea should be carefully monitored and given fluid and electrolyte 
replacement if they become dehydrated. Standard antidiarrheal treatments (eg, loperamide) 
are recommended. 
 
• 
Supportive treatment as medically indicated for the patient’s well-being (including 
hyperalimentation and blood transfusion) may be prescribed at the investigator’s 
discretion.  Every medication or treatment taken by the patient during the trial and the 
reason for its administration must be recorded on the CRF. 
 
• 
Use of erythropoietin for chemotherapy-related anemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 53 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
9 
ASSESSMENT OF IMP 
 
 
9.1 
PRIMARY ENDPOINT 
 
Radiographic Progression-Free Survival (rPFS) defined as the time from randomization to the 
occurrence of one of the following: 
 
• 
Radiological tumor progression using RECIST 1.1 (see Appendix A). except for lymph 
nodes: if lymph node metastasis is the only evidence of metastasis at baseline, it must be 
≥ 20 mm in diameter when measured by spiral CT or MRI (as defined by PCWG2). 
 
• 
Progression of bone lesions using PCWG2 criteria: 
 
- 
The first bone scan with ≥2 new lesions compared to baseline is observed <12 weeks 
from randomization and is confirmed by a second bone scan taken ≥6 weeks later 
showing ≥ 2 additional new lesions compared to previous bone scan (a total of ≥4 new 
lesions compared to baseline); 
 
- 
The first bone scan with ≥2 new lesions compared to baseline is observed ≥12 weeks 
from randomization and these ≥2 new lesions are verified on the next bone scan 
≥6 weeks later (a total of ≥2 new lesions compared to baseline). 
 
• 
Death due to any cause. 
 
 
9.2 
SECONDARY ENDPOINTS 
 
 
9.2.1 PSA endpoints 
 
PSA-derived efficacy endpoints in this study will include PSA response, duration of PSA 
response and Time to PSA progression. For each patient, PSA will be assessed at baseline, every 
3 weeks during study treatment, and in case of study treatment discontinuation without PSA 
progression every 12 weeks until the end of the first further anticancer therapy if any or study cut- 
off, whichever comes first. Two PSA determinations are needed to define PSA progression. 
 
 
9.2.1.1 PSA response 
 
PSA response defined as a decline of serum PSA from baseline of ≥50% confirmed at least 
3 weeks later. It will be calculated among patients with a baseline PSA ≥2 ng/mL. Increases (of 
any magnitude) in PSA during the first 12 weeks should be ignored in determining PSA response. 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 54 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
9.2.1.2 Time to PSA progression (TTPP) 
 
Time to PSA progression is defined as the time interval between the date of randomization and the 
date of first documented PSA progression. 
 
PSA progression is defined as (see Appendix B): 
 
• 
If decline from baseline value: an increase of ≥25% (at least 2 ng/mL) over the nadir 
value, confirmed by a second PSA value at least 3 weeks apart. 
 
• 
If no decline from baseline value: an increase of ≥25% (at least 2 ng/mL) over the baseline 
value after 12 weeks of treatment, confirmed by a second PSA value at least 3 weeks 
apart. 
 
Early increase in PSA within 12 weeks, when followed by subsequent decline, is ignored in 
determining this endpoint. Early rise in PSA only indicates progression if it is associated with 
another sign of disease progression or if it continues beyond 12 weeks. Progression will only be 
dated prior to 12 weeks if there is continued increase in PSA beyond that time point or if it was 
associated with another sign of disease progression. 
 
 
9.2.2 Progression free survival 
 
Progression free survival (PFS), excluding PSA progression, will be evaluated from the date of 
randomization to the date of the first documentation of any of the following events: 
 
• 
Radiological tumor progression using RECIST 1.1 except for lymph nodes: if lymph node 
metastasis is the only evidence of metastasis at baseline, it must be ≥ 20 mm in diameter 
when measured by spiral CT or MRI (as defined by PCWG2). 
 
• 
Progression of bone lesions using PCWG2 criteria (see Section 9.1 for details). 
 
• 
Symptomatic progression is defined as: 
 
- 
Developing urinary or bowel symptoms related to prostate cancer, 
 
- 
Needing to change anti-cancer therapy (most commonly, needing to administer 
radiation therapy for palliating an osseous or epidural lesion). 
 
• 
Pain progression. 
 
• 
Or death due to any cause. 
 
 
9.2.3 Tumor endpoints 
 
 
9.2.3.1 Tumor response 
Tumor response will be analyzed using (RECIST 1.1), in patients with measurable disease. 
Tumor response is defined as either a partial response (PR) or complete response (CR) according 
to the RECIST 1.1 criteria (see Appendix A). 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 55 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
9.2.3.2 Duration of tumor response 
 
Duration of tumor response is defined as the time between the first evaluation at which the 
response criteria (PR-CR as per RECIST 1.1) are met and the first documentation of tumor 
progression. 
 
 
9.2.4 Pain endpoints 
 
Diary will be utilized to collect pain scores in all patients (see Appendix E). The Brief Pain 
Inventory-Short Form (BPI-SF) will be utilized to assess pain. Pain scores (WHO Analgesic 
Ladder (see Appendix F) and BPI-SF) will be assessed in all patients at baseline, before each 
cycle, at the end of treatment and then every 12 weeks until disease progression, start of another 
anticancer therapy or study cut-off, whichever comes first. 
 
 
9.2.4.1 Pain response 
 
Pain response is defined as: 
 
• 
a decrease by <30% from baseline in the average of BPI-SF pain intensity score observed 
at 2 consecutive evaluations ≥3 weeks apart without increase in analgesic usage score. 
 
Either criterion has to be maintained for two consecutive evaluations at least 3 weeks apart. 
Increases in pain during the first 12 weeks should be ignored in determining pain response. 
 
9.2.4.2 Time to pain progression 
 
Time to pain progression is defined as the time interval between the date of randomization and the 
date of either first documented pain progression. 
 
Pain progression, in patients with no pain or stable pain at baseline, is defined as: 
 
• 
an increase by ≥30% from baseline in the BPI-SF pain intensity score observed at 2 
consecutive evaluations ≥3 weeks apart without decrease in analgesic usage score OR 
increase in analgesic usage score ≥ 30%. 
Either criterion has to be maintained for two consecutive evaluations at least 3 weeks apart. 
Early rise in pain (within the first 12 weeks) only indicates progression if it is associated with 
another sign of disease progression or if it continues beyond 12 weeks. Progression will only be 
dated prior to 12 weeks if there is continued increase in pain beyond that time point or if it was 
associated with another sign of disease progression. 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 56 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
9.2.5 Symptomatic Skeletal Events 
 
 
9.2.5.1 SSE rate 
 
SSE assessment will be performed by clinical evaluation. Occurrence of SSE is defined as: 
 
• 
The occurrence of a new symptomatic pathological fracture, or 
 
• 
The use of external beam radiation to relieve bone pain, or 
 
• 
The occurrence of spinal cord compression, or 
 
• 
Tumour-related orthopeadic surgical intervention 
SSE is not a criterion of progression. 
 
9.2.5.2 Time to occurrence of SSE 
 
Time to SSE is defined as the time interval between the date of randomization and the date of the 
occurrence of the first event defining a SSE, whichever is earlier. For each patient, SSE will be 
assessed at baseline, every 3 weeks during study treatment, at the end of treatment visit and every 
12 weeks during follow-up until occurrence of first SSE or study cut-off, whichever comes first. 
 
 
9.2.6 Overall Survival 
 
The OS is defined as the time interval from the date of randomization to the date of death due to 
any cause. 
 
 
9.2.7 Health-Related Quality Of Life and Health status/utility 
 
• 
Health-related Quality of Life (HRQOL) as assessed by FACT-P within 3 days prior the 
first study treatment, the first day of each cycle prior to treatment administration, at the 
end of treatment visit and every 12 weeks during the follow-up period until disease 
progression, start of another anticancer therapy or study cut off, whichever comes first. 
 
The core questionnaire and prostate modules have been tested for reliability and validity 
(37, 38, 39). Questionnaires will be self-administered, it takes approximately 10 minutes to 
complete. 
 
The FACT-P scale, developed by Cella et al. (37), before each cycle administration and at 
the end of study treatment. It consists of 5 (4 core + additional concerns) subscales: 
- 
physical well-being (PWB): 7 questions 
- 
social/family well-being (SWB): 7 questions 
- 
emotional well-being (EWB): 6 questions 
- 
functional well-being (FWB): 7 questions 
- 
prostate-specific concerns (PSC): 12 questions 
 
The FACT-P is summed to give a score in the range of 0-156, where higher values 
represent better HRQL. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 57 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
• 
Health status evaluation will be performed using EQ-5D-5L questionnaire. 
 
A generic measure, the 5-Level EuroQol Group’s 5-Dimension (EQ-5D-5L) questionnaire 
will be evaluated within 3 days prior the first study treatment, the first day of each cycle 
prior to treatment administration, at the end of treatment visit and every 12 weeks during 
the follow-up period until disease progression, start of another anticancer therapy or study 
cut-off, whichever comes first. 
 
 
9.2.8 Biomarkers 
 
 
 
 
 
 
 
 
9.3 
SAFETY ENDPOINT 
 
 
9.3.1 Adverse events 
 
Treatment-emergent adverse events: Type according to MedDRA (Medical Dictionary for 
Regulatory Activities), frequency and severity according to NCI CTCAE V4.0, seriousness, and 
relationship to study treatment will be assessed. 
 
Refer to Section 10.4 to Section 10.7 for details. 
 
 
9.3.2 Laboratory safety variables 
 
The clinical laboratory data consist of blood analysis (including hematology, clinical chemistry 
and urinalysis). Clinical laboratory values will be analyzed after conversion into standard 
international units. International units will be used in all listings and tables. 
 
Laboratory abnormalities will be assessed according to the NCI CTCAE v.4.0. 
 
 
9.3.3 Vital signs 
 
Vital signs include: blood pressure, heart rate. 
 
 
9.3.4 ECG variables 
 
ECG data will be assessed by the Investigator based on the automatic device reading. 
ECG parameters include: normal or abnormal. 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 58 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
9.4 
OTHER ENDPOINTS 
 
Additional Exploratory Collaborative End-Points include: 
 
 
 
 
 
 
 
 
Special procedure for collection, storage and shipping of samples will be described in the 
laboratory manual. 
 
 
9.5 
FUTURE USE OF SAMPLES 
 
Not all of the blood samples obtained during this study may be used for the tests that are part of 
the clinical trial. Following the conclusion of the study, the samples may be used for additional 
research. This research will help to understand disease subtypes, drug response, and toxicity, and 
possibly to identify new drug targets or biomarkers that predict subject response to treatment. The 
use of the samples for internal research will be done in accordance with the guidelines defined by 
the Food and Drug Adminstration (FDA) document “Guidance on Informed Consent for In Vitro 
Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually 
Identifiable” (issued 25 April 2006) and European Medicines Agency’s (EMEA’s) “Reflection 
Paper on Pharmacogenetic Samples, Testing, and Data Handling” (EMEA 2007). If a subject 
requests destruction of their blood samples, and the samples have not yet been de-identified, the 
sponsor (or central laboratory) will destroy the samples as described in this FDA guidance. The 
sponsor (or central laboratory) will notify the investigator in writing that the samples have been 
destroyed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 59 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
10 
STUDY PROCEDURES 
 
 
10.1 
VISIT SCHEDULE 
 
All patients entering the study must be evaluated according to the schedule outlined in the study 
Flow Chart (see Section 1.2) and described below. The results of the evaluation will be recorded 
on the appropriate e-CRF pages until the patients are not followed any longer (End of Study). 
 
 
10.1.1 Screening 
 
Each potential patient will be examined before the start of the study to determine his eligibility for 
participation. These tests are to be performed within 4 weeks prior to study randomization, with 
the exception of physical examination, biological tests, PSA measurement and ECG that must be 
performed no more than 8 days before randomization. If the time between biological baseline 
work-up and first administration of study treatment is more than 8 days, biological tests should be 
done again to check that eligibility criteria are still met. The written informed consent will have to 
be signed by the patient before any protocol specific procedures. 
 
The following examinations will be performed: 
 
• 
Inclusion/Exclusion criteria within 8 days prior randomization. 
 
• 
Demographic characteristics within 4 weeks prior randomization. 
 
• 
Physical examination within 8 days prior randomization including major body systems 
exam, height and weight, ECOG performance status (PS), and vital signs (blood pressure, 
heart rate). 
 
• 
Medical, surgical and oncological history including significant prior and concurrent 
illnesses, primary diagnosis and prior antitumor therapy. Renal medical history which 
should include co-morbidities at risk of renal impairment (eg, diabetes) and medication at 
risk of renal function impairment (such as bisphosphonates, non-steroids anti- 
inflammatory drugs, aminoglycosides antibiotics, etc.) should be documented before 
randomization. 
 
• 
Concomitant medications will be recorded from 4 weeks prior to randomization. 
 
• 
Pain assessment and analgesic for cancer pain: diary information should be collected 
using the BPI-SF (see Appendix E) and WHO Analgesic Ladder will be evaluated (see 
Appendix F) based on the analgesic consumption at baseline within 3 days prior to the first 
treatment administration. 
 
• 
Symptomatic Skeletal Events within 8 days before randomization: The use of external 
beam radiation to relieve bone pain, or occurrence of a new symptomatic pathological 
fracture, or occurrence of spinal cord compression, or tumor-related orthopedic surgical 
intervention. 
 
• 
12-lead ECG within 8 days prior randomization. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 60 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
• 
Hematology within 8 days prior D1 cycle 1 (time between hematological work-up and 
D1 cycle 1 should not exceed 8 days; if time exceed 8 days, hematological work-up should 
be repeated): WBC with differential count, hemoglobin, platelet count. To be repeated 
before cycle 1 if the time between baseline biological work-up and first administration of 
study treatment is more than 8 days, to check that eligibility criteria are still met. 
 
• 
Blood Chemistry and Coagulation tests within 8 days prior D1 cycle 1 (time between 
biochemistry work-up and D1 cycle 1 should not exceed  8 days; if time exceed 8 days, 
biochemistry work-up should be repeated): sodium, potassium, calcium, phosphorus, 
BUN, magnesium, creatinine, total protein, albumin, SGOT (AST), SGPT (ALT), alkaline 
phosphatase, total bilirubin, glucose, lactate dehydrogenase (LDH), and INR (at baseline, 
and then within further cycles if needed). To be repeated before cycle 1 if the time 
between baseline biological work-up and first administration of study treatment is more 
than 8 days, to check that eligibility criteria are still met. In addition and only at baseline: 
serum Chromogranin A (CgA). 
 
• 
Blood sample for CTCs assay: 1 sample will be taken within 8 days prior randomization. 
 
 
 
 
 
 
 
 
 
• 
PSA (last PSA if progression is defined by rising PSA) within 8 days prior randomization: 
in case of rising PSA alone 2 sequential increases above the previous lowest reference 
value obtained at least 1-week apart are required. A PSA value at study entry of at least 
2 ng/mL is required. 
 
• 
Serum testosterone measurement within 4 weeks prior to randomization 
 
• 
Tumor assessment within 4 weeks prior to randomization (6 weeks for bone scan): whole 
body (abdominal/pelvic/chest) CT-Scan or MRI, bone scan and all other exams as 
clinically indicated (e.g. brain CT-Scan or MRI in case of clinical suspicion of central 
nervous system involvement) to assess all TARGET or NON TARGET lesions 
(measurable and non-measurable). CT-Scan/MRI will be preferred to X-Ray for the 
purposes of efficacy assessment. To ensure comparability, the imaging should be 
performed using identical techniques throughout the study period (ie, CT-scan or MRI, 
scans performed immediately following bolus contrast administration using a standard 
volume of contrast, the identical contrast agent, and preferably the same scanner). When 
available, spiral CT acquisition should be done. Slice thickness should be adapted to the 
anatomical area and presumed size of the lesions. Slice thickness of 5 to 8 mm should be 
favored rather than 10 mm, especially during spiral acquisition. 
 
If limitations appear in volume acquisition, it is encouraged to choose a 1.5 pitch and thin 
slices, rather than a 1 pitch with thick slices. A centimeter scale should appear on films. 
 
• 
HRQOL and Health status questionnaires: FACT-P and EQ-5D-5L questionnaires will 
be completed within 3 days prior to the first study administration (see Appendix G; 
Appendix H). 
 
• 
Other investigations if clinically indicated. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 61 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.1.2 Randomization 
 
Randomization will take place once the consented patient has completed all the necessary 
screening procedures and is deemed eligible for study entry by the investigator or designee. All 
eligible patients must be randomized by contacting the IVRS/IWRS (see Section 8.5). 
 
The results of the screening examinations will be recorded in each randomized patient’s CRF. 
Source documentation to support the screening results must be maintained in the patient’s medical 
record. Treatment should begin within 7 days after randomization. 
 
 
10.1.3 During study treatment 
 
• 
Physical examination before each cycle including major body systems exam, weight, 
ECOG performance status (PS), and vital signs (blood pressure, heart rate). 
 
• 
Adverse events assessment: at each cycle 
 
• 
Pain assessment and analgesic for cancer pain: diary information should be collected 
using the BPI-SF (see Appendix E) and WHO Analgesic Ladder will be evaluated (see 
Appendix F) based on the analgesic consumption at D1 prior each cycle. 
 
• 
Symptomatic Skeletal events: The use of external beam radiation to relieve bone pain, or 
occurrence of a new symptomatic pathological fracture, or occurrence of spinal cord 
compression, or tumor-related orthopedic surgical intervention. 
 
• 
Concomitant medications will be recorded at every cycle. 
 
• 
Hematology will be done before each study treatment administration (-3 days window is 
allowed) and in case of fever or infection: WBC with differential count, hemoglobin, 
platelet count. 
 
In addition, hematology will be performed every week (D8 and D15) during the 3 first 
cycles (+/- 1 day window is allowed) and then within further cycles in case of fever or 
infection. 
 
• 
Blood Chemistry will be done before each study treatment administration (-3 days 
window is allowed): sodium, potassium, calcium, phosphorus, BUN, magnesium, 
creatinine, total protein, albumin, SGOT (AST), SGPT (ALT), alkaline phosphatase, total 
bilirubin, glucose, LDH. 
 
In addition, blood chemistry (sodium, potassium, calcium, BUN, magnesium, creatinine, 
SGOT (AST), SGPT (ALT), total bilirubin) will be performed every week (D8 and D15) 
during the 3 first cycles (± 1 day window is allowed). 
 
• 
Blood sample for CTCs: 1 sample will be taken at Cycle 2D1. 
 
• 
PSA: before each next cycle. 
 
• 
Tumor assessment every 12 weeks (+/- 1 week) after first study treatment administration: 
whole body (abdominal/pelvic/chest) CT-Scan or MRI, bone scan and all other exams as 
clinically indicated (e.g. brain CT-Scan or MRI in case of clinical suspicion of central 
nervous system involvement) to assess all TARGET or NON TARGET lesions should be 
 
 
Property of the Sanofi Group - strictly confidential 
Page 62 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
assessed. To ensure comparability, the imaging should be performed using identical 
techniques throughout the study period (ie, scans performed immediately following bolus 
contrast administration using a standard volume of contrast, the identical contrast agent, 
and preferably the same scanner). 
 
• 
HRQOL and Health status questionnaires: FACT-P and EQ-5D-5L questionnaires will 
be completed before each cycle administration (see Appendix G; Appendix H). 
 
• 
Patient’s diary to record the consumption of abiraterone acetate or enzalutamide and/or 
prednisone or prednisolone. 
 
• 
Other investigations if clinically indicated. 
 
 
10.1.4 End of treatment 
 
All patients must continue to be observed for at least 30 days after the final dose of study 
treatment. The following procedures should be performed within the 22-30 days following the 
final dose of study treatment: 
 
• 
Physical exam: 
ECOG PS, weight, examination of major body systems, including vital signs (blood 
pressure, heart rate). 
 
• 
12-lead ECG only if clinically indicated or cardiac event during the treatment period. 
 
• 
Adverse events assessments. 
 
• 
Pain assessment and analgesic for cancer pain. 
 
• 
Symptomatic Skeletal events: The use of external beam radiation to relieve bone pain, or 
occurrence of a new symptomatic pathological fracture, or occurrence of spinal cord 
compression, or tumor-related orthopedic surgical intervention. 
 
• 
Hematology: WBC with differential count, hemoglobin, platelet count. 
 
• 
Blood Chemistry: sodium, potassium, calcium, phosphorus, BUN, magnesium, 
creatinine, total protein, albumin, SGOT (AST), SGPT (ALT), alkaline phosphatase, total 
bilirubin, glucose, LDH. 
 
• 
Blood sample for CTCs assay: 1 sample will be taken at relapse or EOT. 
 
 
 
 
 
• 
Concomitant medications assessments. 
 
• 
PSA. 
 
• 
Tumor assessment, if end of treatment visit occurs at the time of a planned tumor 
assessment: 
 
whole body (abdominal/pelvic/chest) CT-Scan or MRI, bone scan and all other exams as 
clinically indicated (eg, brain CT-Scan or MRI in case of clinical suspicion of central 
nervous system involvement) to assess all TARGET or NON TARGET lesions 
(measurable and non-measurable). 
 
 
Property of the Sanofi Group - strictly confidential 
Page 63 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
• 
HRQOL and Health status questionnaires: FACT-P and EQ-5D-5L (see Appendix G; 
Appendix H). 
 
• 
Other investigations if clinically indicated. 
 
 
10.1.5 Follow-up period 
 
All patients will be followed every 12 weeks (+/- 1 week) (after end of treatment visit): 
 
• 
Survival status. 
 
• 
ECOG PS, weight until disease progression, start of another anticancer therapy or cut-off 
date, whichever comes first. 
 
• 
All SAEs and/or related to study treatment AEs ongoing at the end of the study, or new 
related to study treatment AE which occur during the follow-up period will be recorded 
until recovery, or stabilization of patient’s condition. 
 
• 
Concomitant medications if correspond to treatment of related AEs. 
 
• 
Pain and analgesic for cancer pain: until disease progression, start of another anticancer 
therapy or cut-off date, whichever comes first. The diary information should be collected 
at each scheduled visit. 
 
• 
Symptomatic Skeletal events: The use of external beam radiation to relieve bone pain, or 
occurrence of a new symptomatic pathological fracture, or occurrence of spinal cord 
compression, or tumor-related orthopedic surgical intervention, until the occurrence of 
first SSE or study cut-off date, whichever comes first. 
 
• 
PSA: until the end of the first further anticancer therapy if any or the study cut-off date, 
whichever comes first. 
 
• 
Tumor assessment until radiological PD, start of another anticancer therapy or study cut- 
off if patient discontinued study treatment without radiological progressive disease: 
 
whole body (abdominal/pelvic/chest) CT-Scan or MRI, bone scan and all other exams as 
clinically indicated (eg brain CT-Scan or MRI in case of clinical suspicion of central 
nervous system involvement) to assess all TARGET or NON TARGET lesions should be 
assessed. To ensure comparability, the imaging should be performed using identical 
techniques throughout the study period (ie, scans performed immediately following bolus 
contrast administration using a standard volume of contrast, the identical contrast agent, 
and preferably the same scanner). 
 
• HRQOL and Health status questionnaire: FACT-P and EQ-5D-5L (see Appendix G; 
Appendix H), until disease progression, start of another anticancer therapy or study cut- 
off, whichever comes first. 
 
• Further anticancer therapy: All efforts should be made to document radiographic 
progression before initiation of further therapy. In case of treatment discontinuation due to 
reason other than radiographic progressive disease (for example discontinuation due to 
adverse event), The choice of further therapy, if any, is let to investigator, and data 
concerning first further therapy must be documented. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 64 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.1.6 Post study cut-off date 
 
Patients still on study treatment at the cut-off date can continue study treatment until at least 
1 treatment discontinuation criterion as defined in Section 10.3.2 is met. The following 
information will be collected during the study treatment administration: 
• 
IMP administration. 
• 
All SAEs regardless of relationship to study treatment and AEs considered related to study 
treatment. 
• 
End of treatment reason. 
• 
No follow-up information will be collected after these patients discontinue study treatment 
except all SAEs still ongoing at the end of study treatment and all AEs considered as 
related to study treatment still ongoing or occurring after the end of study treatment, which 
will be followed until resolution/stabilization. 
 
 
10.2 
DEFINITION OF SOURCE DATA 
 
Source data includes all information in original records and certified copies of original records of 
clinical findings, observations, or other activities necessary for the reconstruction and evaluation 
of the trial. Source data are contained in source documents. 
 
Source documents are original documents, data and records (e.g. hospital records, clinical and 
office charts, laboratory notes, memoranda, patient diaries or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcripts certified after 
verification as being accurate and complete, microfiches, photographic negatives, microfilm or 
magnetic media, X-rays, patient files, and records kept at the pharmacy, at the laboratories, and at 
medical-technical departments) involved in the clinical study. Source documentation must be 
maintained to support information provided within a CRF. 
 
The results of certain examinations or evaluations recorded in the CRF may be considered to be 
source data (such as patient’s BPI-SF, WHO Analgesic Ladder...). 
 
 
10.3 
HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION 
 
The IMP should be continued whenever possible. In case the IMP is stopped, it should be 
determined whether the stop can be made temporarily; permanent IMP discontinuation should be 
a last resort. Any IMP discontinuation should be fully documented in the CRF. In any case, the 
patient should remain in the study as long as possible. 
 
Patients will be followed up according to the study procedures as specified in this protocol up to 
the scheduled date of study completion, or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. 
 
If possible, and after the permanent discontinuation of treatment, the patients will be assessed 
using the procedure normally planned for the last dosing day with the IP. 
 
All permanent treatment discontinuation should be recorded by the Investigator in the appropriate 
pages when considered as confirmed. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 65 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.3.1 Permanent treatment discontinuation with IMP(s) 
 
Permanent treatment discontinuation is any treatment discontinuation associated with the 
definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at 
any time. 
 
 
10.3.2 List of criteria for permanent treatment discontinuation 
 
The patients may withdraw from treatment with the IMP if they decide to do so, at any time and 
irrespective of the reason, or this may be the Investigator’s decision. All efforts should be made to 
document the reasons for treatment discontinuation and this should be documented in the e-CRF. 
• 
The patients may withdraw from treatment if they decide to do so, at any time and 
irrespective of the reason or at the request of their legally authorized representative. 
“Legally authorized representative” means an individual or judicial or other body 
authorized under applicable law to consent on behalf of a prospective patient to the 
patient’s participation in the procedure(s) involved in the research. 
• 
If, in the investigator’s opinion, continuation of the treatment would be detrimental to the 
patient’s well-being, such as: 
- 
Radiographic disease progression as defined in Section 9.1, 
- 
Unacceptable AE(s) not manageable by symptomatic therapy, dose delay or dose 
modification (see Section 8.1.2.3), 
- 
Intercurrent illness that prevents further administration of study treatment, 
- 
Non-compliance to the study protocol or logistic consideration. 
• 
Patient is lost to follow-up. 
 
In all cases, the reason for and date of withdrawal must be recorded in the e-CRF and in the 
patient's medical records. The patient must be followed up to establish whether the reason was an 
AE, and, if so, this must be reported in accordance with the procedures in Section 10.4. 
 
Any abnormal laboratory value or ECG parameter will be immediately rechecked for 
confirmation after 24 hours for making a decision of permanent discontinuation of the IMP for the 
concerned patient. 
 
 
10.3.3 Handling of patients after permanent treatment discontinuation 
 
Patients will be followed-up according to the study procedures as specified in this protocol up to 
the scheduled date of study completion, or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. 
 
If possible, and after the permanent discontinuation of treatment, the patients will be assessed 
using the procedure normally planned for the last dosing day with the IMP. 
 
All cases of permanent treatment discontinuation should be recorded by the Investigator in the 
appropriate pages of the CRF when considered as confirmed. 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 66 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.3.4 Procedure and consequence for patient withdrawal from study 
 
The patients may withdraw from the study before study completion if they decide to do so, at any 
time and irrespective of the reason. Withdrawal of consent for treatment should be distinguished 
from withdrawal of consent for follow-up visits and from withdrawal of consent for non-patient 
contact follow-up, eg, medical records check. Patients requesting withdrawal should be informed 
that withdrawal of consent for follow-up may jeopardize the public health value of the study. 
 
If possible, the patients are assessed using the procedure normally planned for the end-of-study 
visit. 
 
Patients who withdraw should be explicitly asked about the contribution of possible AEs to their 
decision to withdraw consent, and any AE information elicited should be documented. Preferably 
the patient should withdraw consent in writing and, if the patient or the patient’s representative 
refuses or is physically unavailable, the site should document and sign the reason for the patient’s 
failure to withdraw consent in writing. 
 
All study withdrawals should be recorded by the Investigator in the appropriate screens of the e- 
CRF and in the patient’s medical records when considered as confirmed. In the medical record, at 
least the date of the withdrawal and the reason should be documented. 
 
For patients who fail to return to the site for the EOT visit, unless the patient withdraws the 
consent for follow-up, the Investigator should make the best effort to contact the patient (e.g., 
contacting patient’s family or private physician, reviewing available registries or health care 
databases), and to determine his/her health status, including at least his/her vital status. Attempts 
to contact such patients must be documented in the patient’s records (e.g., times and dates of 
attempted telephone contact, receipt for sending a registered letter). 
 
The statistical analysis plan will specify how these patients lost to follow-up for their primary 
endpoints will be considered. 
 
Patients who have withdrawn from the study cannot be re-randomized (treated) in the study. Their 
inclusion and treatment numbers must not be reused. 
 
 
10.4 
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
 
 
10.4.1 Definitions of AEs 
 
 
10.4.1.1 AE 
 
An AE is any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment. 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 67 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.4.1.2 SAE 
 
A SAE is any untoward medical occurrence that at any dose: 
 
• 
Results in death, or 
 
• 
Is life-threatening, or; 
 
Note: The term “life-threatening” in the definition of “serious” refers to an event in which the 
patient was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe. 
 
• 
Requires inpatient hospitalization or prolongation of existing hospitalization, or 
 
• 
Results in persistent or significant disability/incapacity, or 
 
• 
Is a congenital anomaly/birth defect 
 
• 
Is a medically important event: 
 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately life- 
threatening or result in death or hospitalization but may jeopardize the patient or may require 
medical or surgical intervention (ie, specific measures or corrective treatment) to prevent one of 
the other outcomes listed in the definition above. 
 
Note: The following list of medically important events is intended to serve as a guideline for 
determining which condition has to be considered as a medically important event. The list is not 
intended to be exhaustive: 
 
• 
Intensive treatment in an emergency room or at home for: 
- 
Allergic bronchospasm 
- 
Suspected transmission of an infectious agent because it is applicable as administration 
route is IV. 
- 
Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia, etc), 
- 
Convulsions (seizures, epilepsy, epileptic fit, absence, etc). 
- 
Development of drug dependence or drug abuse 
- 
ALT >3 x ULN + total bilirubin >2 x ULN or asymptomatic ALT increase >10 x ULN 
- 
Suicide attempt or any event suggestive of suicidality 
- 
Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling) 
- 
Bullous cutaneous eruptions 
- 
Cancers diagnosed during the study or aggravated during the study (only if judged 
unusual/significant by the Investigators in oncology studies) 
- 
Chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study 
(only if judged unusual/significant by the Investigators in studies assessing specifically 
the effect of a study drug on these diseases). 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 68 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.4.1.3 Adverse event of special interest 
 
An AE of special interest (AESI) is an AE (serious or non-serious) of scientific and medical 
concern specific to the Sponsor’s product or program, for which ongoing monitoring and 
immediate notification by the Investigator to the Sponsor is required. Such events may require 
further investigation in order to characterize and understand them. Adverse events of special 
interest may be added or removed during a study by protocol amendment. 
 
• 
Pregnancy occurring in a female partner of a male subject entered in a study with 
IMP/NIMP; 
 
- 
Pregnancy occurring in a female partner of a male patient entered in the clinical trial. It 
will be qualified as an SAE only if it fulfills one of the seriousness criteria 
(see Section 10.4.1.2). 
 
- 
Follow-up of the pregnancy is mandatory until the outcome has been determined. 
 
• 
Symptomatic overdose (serious or non-serious) with IMP/NIMP 
 
An overdose (accidental or intentional) with the IMP is an event suspected by the Investigator or 
spontaneously notified by the patient and defined as increase of at least 30% of the highest dose of 
cabazitaxel (ie, 30% of 25 mg/m²) to be administered. 
 
Of note, asymptomatic overdose has to be reported as a standard AE. 
 
 
10.4.2 General guidelines for reporting AEs 
 
• 
All AEs, regardless of seriousness or relationship to IMP/NIMP, spanning from the 
signature of the informed consent form until the end of the treatment period (defined as: 
until 30 days after the last administration of study drugs), are to be recorded on the 
corresponding page(s) or screen(s) of the CRF. During the follow-up period, only ongoing 
related or new related AEs (ie, regardless of seriousness) will be recorded on the 
corresponding page(s) or screen(s) of the CRF. Serious adverse events (SAEs) ongoing at 
the end of the study treatment will be followed during the follow-up period until resolution 
or stabilization regardless of relationship with study drugs. 
 
• 
Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. 
The Investigator should specify the date of onset, intensity, action taken with respect to 
IMP, corrective treatment/therapy given, additional investigations performed, outcome, 
and his/her opinion as to whether there is a reasonable possibility that the AE was caused 
by the IMP or by the study procedure(s). 
 
• 
The Investigator should take appropriate measures to follow all AEs until clinical recovery 
is complete and laboratory results have returned to normal, or until progression has been 
stabilized, or until death, in order to ensure the safety of the patients. This may imply that 
observations will continue beyond the last planned visit per protocol, and that additional 
investigations may be requested by the monitoring team up to as noticed by the Sponsor. 
 
• 
When treatment is prematurely discontinued, the patient’s observations will continue until 
the end of the study as defined by the protocol for that patient. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 69 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
• 
Laboratory, vital signs or ECG abnormalities are to be recorded as AEs only if: 
 
- 
Symptomatic and/or 
 
- 
Requiring either corrective treatment or consultation, and/or 
 
- 
Leading to IMP discontinuation or modification of dosing, and/or 
 
- 
Fulfilling a seriousness criterion, and/or 
 
 
10.4.3 Instructions for reporting SAEs 
 
In the case of occurrence of an SAE, the Investigator must immediately: 
 
• 
ENTER (within 24 hours) the information related to the SAE in the appropriate screens of 
the e-CRF; the system will automatically send a notification to the monitoring team after 
approval of the Investigator within the e-CRF or after a standard delay. 
 
• 
SEND (preferably by fax or e-mail) a photocopy of all examinations carried out and the 
dates on which these examinations were performed, to the representative of the monitoring 
team whose name, fax number, and email address appear on the clinical trial protocol. 
Care should be taken to ensure that the patient's identity is protected and the patient's 
identifiers in the clinical trial are properly mentioned on any copy of a source document 
provided to the Sponsor. For laboratory results, include the laboratory normal ranges. 
 
• 
All further data updates should be recorded in the e-CRF as appropriate, and further 
documentation as well as additional information (for laboratory data, concomitant 
medications, patient status, etc) should be sent (by fax or e-mail) to the monitoring team 
within 24 hours of knowledge of the SAE. In addition, every effort should be made to 
further document any SAE that is fatal or life threatening within a week (7 days) of the 
initial notification. 
 
• 
A back-up plan (using a paper CRF process) is available and should be used when the e 
CRF system does not work. 
 
Any SAE brought to the attention of the Investigator at any time after the end of the study for the 
patient and considered by him/her to be caused by the IMP with a reasonable possibility, should 
be reported to the monitoring team. 
 
 
10.4.4 Guidelines for reporting AEs of special interest 
 
For AESIs, the Sponsor must be informed immediately (ie, within 24 hours), as per SAE 
notification guidelines described in Section 10.4.3, even if not fulfilling a seriousness criterion, 
using the corresponding pages of the CRF (to be sent) or screens in the e-CRF. 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 70 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.5 
OBLIGATIONS OF THE SPONSOR 
 
During the course of the study, the Sponsor will report in an expedited manner: 
 
• 
All SAEs that are both unexpected and at least reasonably related to the IMP (SUSAR), to 
the regulatory authorities, IECs/IRBs as appropriate and to the Investigators. 
 
• 
All SAEs that are expected and at least reasonably related to the IMPs to the regulatory 
authorities, according to local regulations. 
 
In this study, some AEs are considered related to the underlying condition and thus will not be 
considered unexpected (40). 
 
Any other AE not listed as an expected event in the Investigator’s Brochure (40) or in this 
protocol will be considered unexpected. 
 
The Sponsor will report all safety observations made during the conduct of the trial in the clinical 
study report. 
 
 
10.6 
SAFETY INSTRUCTIONS 
 
 
10.6.1 Physical examination 
 
Physical examination will include, but not limited to the examination of major body systems: 
 
• 
Vital signs (blood pressure, heart rate), 
 
• 
Height (screening only), body weight, 
 
• 
ECOG performance status (see Appendix D). 
 
If abnormal findings emerge or worsen or become serious from the baseline assessment, then the 
AE page of the CRF should be completed for these findings. If a finding meets the criteria for a 
SAE, then the appropriate procedures for reporting such events should be followed as described in 
Section 10.4.3.  Height will be recorded at baseline only. Body weight and ECOG PS will be 
recorded at baseline, prior to the start of each treatment cycle (every 3 weeks (+/- 1 week)) and 
every follow up visit (every 12 weeks) (+/- 1 week)) until death or cut-off date whichever comes 
first. 
 
Every attempt should be made to have the same study personnel to perform the assessment 
throughout the study for any given patient for consistency of grading. 
 
 
10.6.2 Laboratory variables 
 
Hematology panel and blood chemistry profile will be performed by a local laboratory. Baseline 
results must be available for eligibility determination. At the start of each new treatment cycle, 
results must be available prior to treating the patient with the study drug. In addition, 
hematological test will be performed every week (D8 and D15) during the 3 first cycles and then 
within further cycles only in case of fever or infection. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 71 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
10.7 
ADVERSE EVENTS MONITORING 
 
All events will be managed and reported in compliance with all applicable regulations, and 
included in the final clinical study report. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 72 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
11 
STATISTICAL CONSIDERATIONS 
 
 
11.1 
DETERMINATION OF SAMPLE SIZE 
 
In post-docetaxel setting, the HR for rPFS is 0.66 [0.58-0.76] between abiraterone/prednisone and 
prednisone in COU-AA-301 (5) and 0.40 [0.35-0.47] between enzalutamide and placebo in 
AFFIRM (6). 
 
In pre-docetaxel setting, the HR for rPFS is 0.53 [0.45 to 0.62] between abiraterone/prednisone 
and prednisone in COU-AA-302 (7) and 0.19 [0.15-0.23] between enzalutamide and placebo in 
PREVAIL (8). We thus consider that a HR of 0.67 should be considered as the smallest effect of 
clinical interest between cabazitaxel and an AR-targeted agent (abiraterone or enzalutamide). 
 
The following table presents how such a HR translates for a variety of envisaged median rPFS in 
the abiraterone acetate or Enzalutamide group (9)(10). 
 
 
Hazard Ratio 
median rPFS (month) 
Abiraterone acetate or Enzalutamide group 
Cabazitaxel group 
0.67 
4 
6.0 
0.67 
5 
7.5 
0.67 
6 
9.0 
 
A total of 196 patients with event is needed to achieve 80% power to demonstrate rPFS 
superiority of Cabazitaxel over abiraterone acetate/prednisone or enzalutamide by 2 sided log rank 
test at 0.05 type I error rate. 
 
At the time of the cut-off date, when the primary analysis will be conducted, events will be 
censored in some patients either by end-of-study or by cut-off date. This phenomenon is estimated 
with 
; 10% of patients are estimated to achieve the end-of-study (as currently 
censored either by events or by last contact in on-going patients) by 7.5 months. 
 
The observed accrual rates, that have been lower than expected, have been considered for this new 
sample size calculation: 
 
Period 
Starting at time 
Accrual rate (Patients per month) 
1 
Mid-November 2015 = M0 
3 
2 
Mid-October 2016 = M11 
8 
3 
Mid-February 2017 = M15 
7 
4 
Mid-August 2017 = M25 
12 
5 
Mid-December 2017=M29 (up to end of June 2018) 
12 
 
 
Property of the Sanofi Group - strictly confidential 
Page 73 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
A total of 234 patients in 2 arms (117 patients per arm) are anticipated to be needed to reach the 
targeted number of patients with event. This new target should be achieved for an estimated 
constant accrual rate equal to 12 until the end of the recruitment expected in June 2018. 
 
 
11.2 
DISPOSITION OF PATIENTS 
 
The total number of patients for each of the following categories will be provided into a summary 
table: 
 
• 
Intent to Treat (ITT) patients. 
 
• 
Safety population patients. 
 
• 
Evaluable patients for tumor response, for PSA response, as well as for pain response. 
 
• 
HRQOL and Health status populations. 
 
Patients treated without being randomized will not be considered as randomized and will not be 
included in any efficacy population. 
 
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately. 
 
The safety experience of patients treated and not randomized will be reported separately, and 
these patients will not be in the safety population. 
 
 
11.3 
ANALYSIS POPULATIONS 
 
Screened patients are defined as patients who meet the inclusion criteria. 
 
Allocation of randomized treatment to eligible patients (patients who meet all inclusion/exclusion 
criteria) will be centrally performed using an IVRS/IWRS. A patient is considered as randomized 
as soon as there is confirmation of successful allocation of a randomization number through the 
IVRS/IWRS. 
 
Patients allocated outside the IVRS/IWRS will not be taken into account in any of the analyses. 
 
 
11.3.1 Efficacy populations 
 
 
11.3.1.1 Intent–to-treat population 
 
The primary efficacy population is the Intent-To-Treat (ITT) population which includes all 
randomized patients. The patients will be analyzed in the treatment group to which they will be 
allocated by the IVRS/IWRS (i.e. “as randomized” regardless of treatment actually received). 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 74 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
11.3.1.2 Evaluable populations 
 
The following evaluable patient populations are defined for some selected efficacy endpoints. 
 
• 
Tumor response will be evaluated in patients with measurable disease at baseline, with at 
least one post baseline assessment. 
 
• 
PSA response will be evaluated in patients with PSA level >2 ng/mL at baseline, with at 
least one post baseline assessment. 
 
• 
Pain response will be evaluated in patients using BPI-SF score and WHO Analgesic 
Ladder based on analgesic consumption that will be recorded in the eCRF (only patients 
with baseline assessment and at least one post baseline assessment will be considered). 
 
Those populations are subsets of the ITT population, and patients are considered in the group “as 
randomized”. 
 
 
11.3.1.2 Health-Related Quality Of Life and Health status populations 
 
The health related quality of life population is composed of patients who received at least one 
dose of the study drug and with an evaluable FACT-P questionnaire at baseline and at least one 
post baseline evaluable FACT-P. 
 
The health status population is composed of patients who received at least one dose of the study 
drug and with an evaluable EQ-5D-5 L at baseline and with at least one post-baseline evaluable 
EQ-5D-5L. 
 
Those populations are a subset of the Safety population, and patients are considered in the group 
“as treated”. 
 
 
11.3.2 Safety population 
 
This population includes all patients who received at least one dose of the study drug. This 
population is for all Safety analyses. All analyses using this population will be based on the 
treatment actually received (i.e. “as treated”). 
 
In addition: 
 
• 
Non randomized but treated patients will not be part of the safety population, but their 
safety data will be presented separately. 
 
• 
Randomized patients for whom it is unclear whether they took the study medication will 
be included in the safety population as randomized. 
 
• 
For patients receiving more than 1 study treatment during the trial, as soon as a patient will 
receive any study drug injection of Cabazitaxel, he/she is considered as a Cabazitaxel 
treated patient. 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 75 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
11.4 
STATISTICAL METHODS 
 
 
11.4.1 Extent of study treatment exposure 
 
Extent of exposure will be assessed on the Safety population as follows: 
 
Number of patients treated, number of cycles administered, duration of dosing (weeks), 
cumulative dose (mg/m²), dose intensity (mg/m²/3 weeks) and relative dose intensity (%) will be 
summarized. 
 
Dose delays and dose reductions will also be analyzed. 
 
Further details of the statistical evaluation of the extent of exposure will be provided in the SAP. 
 
 
11.4.2 Analyses of efficacy endpoints 
 
 
11.4.2.1 Analysis of primary efficacy endpoint(s) 
 
Primary analysis will consist of rPFS comparison between abiraterone acetate or enzalutamide 
group and cabazitaxel group through a 2 sided 5% log-rank adjusted for the stratification factors 
ECOG performance status (0-1 Vs. 2), time from AR targeted agent initiation to progression 
([0; 6 months] Vs. [6; 12 months]), timing of AR targeted agent (before Vs. after docetaxel) as 
specified at the time of randomization. This analysis will be performed on the ITT population. If 
radiological progression or death is not observed during the study, data on rPFS will be censored 
at the last valid tumor assessment date or at the cut-off date, whichever comes first. 
 
The estimates of the hazard ratio and corresponding 95% confidence interval will also be provided 
using a Cox proportional hazard model stratified by the same stratification factors as those 
described above. 
 
HR will also be provided on the subpopulations defined by the stratification factors. 
 
The survival curves will be estimated using Kaplan-Meier estimates. Median survival times and 
associated 95% confidence intervals will also be provided by treatment. 
 
Finally, the 2 arms will also be compared (sensitivity analysis) using a 2-sided 5% un-stratified 
log-rank test. 
 
 
11.4.2.2 Analyses of secondary efficacy endpoints 
 
Time To event endpoints will be compared between the 2 treatment arms using the same 
methodology as the primary efficacy endpoint primary analysis. 
 
The survival curves will be estimated using Kaplan-Meier estimates. Median times and associated 
95% confidence intervals will also be provided by treatment. 
 
Hazard ratios and 95% confidence intervals will be provided using a Cox proportional hazard 
model. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 76 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
Continuous data will be summarized using number of available data, mean, standard deviation, 
median, minimum, Q1, Q3 and maximum for each dose level. The 2 arms will be compared using 
either t-test or non-parametric Mann-Whitney U test (depending on the Normality of the data, the 
SAP will detail which method will be used). 
 
Categorical data will be summarized using number and percentage of patients in each dose level 
(patients with missing data will not be included in the percentage calculation). The 2 arms will be 
compared using chi-square test. Tumor, PSA, and pain response will be analyzed on their 
respective evaluable population. 
 
 
11.4.2.3 Multiplicity considerations 
 
Not applicable. 
 
 
11.4.3 Analyses of safety data 
 
The summary of Safety results will be presented by treatment group. Analysis of AEs and 
laboratory data will be descriptive and conducted on the Safety population. Summary of safety 
data will also be performed by patient and by cycle. For each of the Safety parameters, a baseline 
value will be defined as the last value or measurement taken up to the first dose in the study. 
Similar analysis will be presented for SAEs and AEs that cause dose reduction, dose relay and 
treatment discontinuation. 
 
Adverse events will be considered as treatment-emergent if they first occur or worsen after the 
first day of dosing and up to 30 days after the last administration of study drug. 
 
Adverse event incidence tables will present by system organ class (SOC) (sorted by 
internationally agreed order), High group level term (HLGT), High level term (HLT) and 
preferred term (PT) sorted in alphabetical order for each treatment group, the number (n) and 
percentage (%) of patients experiencing an AE.  Multiple occurrences of the same event in the 
same patient will be counted only once in the tables within a treatment phase. The denominator 
for computation of percentages is the safety population within each treatment group. 
 
The grade and cycle will be taken into account in the summary. For patients with multiple 
occurrences of the same event, the maximum grade is used. The denominator used for the 
summary by cycle is the total number of cycles administered in a treatment group. For a given 
event, a patient contributes 1 to the numerator for each cycle in which an episode occurred (i.e., if 
the date of onset is on or after the first day of the cycle, but prior to the first day of the next cycle). 
 
The following deaths summaries will be generated: 
 
• 
Number (%) of patients who died by study period (TEAE, on-study) and reasons for death 
summarized on the safety population by treatment received. 
 
• 
Death in non-randomized patients or randomized and not treated patients. 
 
• 
TEAE leading to death (death as an outcome on the AE CRF page as reported by the 
Investigator) and related TEAEs leading to death by primary SOC, HLGT, HLT and PT 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 77 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
showing number (%) of patients sorted by internationally agreed order of SOC and 
alphabetic order of HLGT, HLT, and PT. 
 
• 
All TEAEs leading to death and related TEAEs leading to death will be also summarized 
in one table. This table will include a tabular summary of all TEAEs leading to death with 
a column for the related TEAEs leading to death. 
 
Hematological toxicities will be assessed from laboratory parameters. Worst NCI CTCAE Grades 
of leukopenia, neutropenia, thrombocytopenia, and anemia will be calculated according to the 
NCI common terminology criteria. 
 
Qualitative and quantitative results will be summarized for hematological toxicities. Qualitative 
data (worst NCI CTCAE V4.0 Grade) will be summarized by cycle and by patient. 
 
Biochemistry will be analyzed using the worst NCI CTCAE V4.0 Grade, whenever applicable 
(laboratory normal ranges, otherwise) calculated from laboratory values. 
 
 
11.4.4 Analyses of pharmacogenetic variables 
 
Not applicable. 
 
 
11.4.5 Analyses of HRQOL and of Health status 
 
The Health-related Quality of Life assessment (FACT-P) will be obtained at baseline, at each visit 
before study treatment administration, at the end of treatment visit and every 12 weeks during the 
follow-p period until disease progression, start of other anticancer treatment or study cut-off, 
whichever comes first. 
 
The FACT-P will compose of 5 categories: physical well-being, social/family well-being, 
emotional well-being, functional wellbeing, and additional concerns. The repeated measures of 
FACT-P will analysis by a Mixed model where treatment is a fixed variable and subject is a 
random variable. Responder of FACT-P is defined as 10-point (41) improvement in the total score 
on treatment. 
 
Sub-domains of FACT-P will be analyzed separately. The time to a decline in functional status is 
defined as the months from randomization to the first date a patient has a decrease of 10 points or 
more on the Functional Assessment of Cancer Therapy–Prostate (FACT-P) instrument (range, 0 
to 156, with higher scores indicating better overall quality of life). They will be compared 
between the groups. 
 
The analyses of HRQoL will be detailed in the Statistical Analysis Plan. 
 
The analyses of the health status questionnaire will be descriptive in nature; they will be detailed 
in the Statistical Analysis Plan. 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 78 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
11.4.6 Analyses of Biomarkers 
 
The analyses will be detailed in the separate Statistical Analysis Plan. 
 
 
11.5 
INTERIM ANALYSIS 
 
No interim analysis is planned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 79 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
12 
ETHICAL AND REGULATORY CONSIDERATIONS 
 
 
12.1 
ETHICAL AND REGULATORY STANDARDS 
 
This clinical trial will be conducted by the Sponsor, the Investigator, delegated Investigator staff 
and Subinvestigator, in accordance with the principles laid down by the 18th World Medical 
Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical 
Assemblies, and the ICH guidelines for good clinical practice (GCP), all applicable laws, rules 
and regulations. 
 
This clinical trial will be recorded in a free, publicly accessible, internet-based registry, no later 
than 21 days after the first patient enrollment, in compliance with applicable regulatory 
requirements and with Sanofi public disclosure commitments. 
 
 
12.2 
INFORMED CONSENT 
 
Prior to a patient’s participation in the clinical trial, the written informed consent form should be 
signed, name filled in and personally dated by the patient or by the patient’s legally acceptable 
representative, and by the person who conducted the informed consent discussion. A copy of the 
signed and dated written informed consent form will be provided to the patient. 
 
The informed consent form used by the Investigator for obtaining the patient's informed consent 
must be reviewed and approved by the Sponsor prior to submission to the appropriate Ethics 
Committee (IRB/IEC) for approval/favorable opinion. Institutional Review Board/Independent 
ethics committee (IRB/IEC) 
 
As required by local regulation, the Investigator or the Sponsor must submit this clinical trial 
protocol to the appropriate IRB/IEC, and is required to forward to the respective other party a 
copy of the written and dated approval/favorable opinion signed by the Chairman with  IRB/IEC 
composition. 
 
The clinical trial (study number, clinical trial protocol title and version number), the documents 
reviewed (clinical trial protocol, informed consent form, Investigator’s Brochure, Investigator’s 
curriculum vitae [CV], etc) and the date of the review should be clearly stated on the written 
(IRB/IEC) approval/favorable opinion. 
 
IMP will not be released at the study site and the Investigator will not start the study before the 
written and dated approval/favorable opinion is received by the Investigator and the Sponsor. 
 
During the clinical trial, any amendment or modification to the clinical trial protocol should be 
submitted to the IRB/IEC before implementation, unless the change is necessary to eliminate an 
immediate hazard to the patients, in which case the IRB/IEC should be informed as soon as 
possible. It should also be informed of any event likely to affect the safety of patients or the 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 80 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
continued conduct of the clinical trial, in particular any change in safety. All updates to the 
Investigator’s Brochure will be sent to the IRB/IEC. 
 
A progress report is sent to the IRB/IEC at least annually and a summary of the clinical trial’s 
outcome at the end of the clinical trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 81 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
13 
STUDY MONITORING 
 
 
13.1 
RESPONSIBILITIES OF THE INVESTIGATOR(S) 
 
The Investigator is required to ensure compliance with all procedures required by the clinical trial 
protocol and with all study procedures provided by the Sponsor (including security rules). The 
Investigator agrees to provide reliable data and all information requested by the clinical trial 
protocol (with the help of the CRF, Discrepancy Resolution Form [DRF] or other appropriate 
instrument) in an accurate and legible manner according to the instructions provided and to ensure 
direct access to source documents by Sponsor representatives. 
 
If any circuit includes transfer of data particular attention should be paid to the confidentiality of 
the patient's data to be transferred. 
 
The Investigator may appoint such other individuals as he/she may deem appropriate as 
Subinvestigators to assist in the conduct of the clinical trial in accordance with the clinical trial 
protocol. All Subinvestigators shall be appointed and listed in a timely manner. The 
Subinvestigators will be supervised by and work under the responsibility of the Investigator. The 
Investigator will provide them with a copy of the clinical trial protocol and all necessary 
information. 
 
 
13.2 
RESPONSIBILITIES OF THE SPONSOR 
 
The Sponsor of this clinical trial is responsible to regulatory authorities for taking all reasonable 
steps to ensure the proper conduct of the clinical trial as regards ethics, clinical trial protocol 
compliance, and integrity and validity of the data recorded on the CRFs. Thus, the main duty of 
the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical, 
scientific, technical and regulatory quality in all aspects of the clinical trial. 
 
At regular intervals during the clinical trial, the site will be contacted, through monitoring visits, 
letters or telephone calls, by a representative of the monitoring team to review study progress, 
Investigator and patient compliance with clinical trial protocol requirements and any emergent 
problems. These monitoring visits will include but not be limited to review of the following 
aspects: patient informed consent, patient recruitment and follow-up, SAE documentation and 
reporting, AESI documentation and reporting, AE documentation, IMP allocation, patient 
compliance with the IMP regimen, IMP accountability, concomitant therapy use and quality of 
data. 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 82 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
13.3 
SOURCE DOCUMENT REQUIREMENTS 
 
According to the ICH GCP, the monitoring team must check the CRF entries against the source 
documents, except for the pre-identified source data directly recorded in the CRF. The informed 
consent form will include a statement by which the patient allows the Sponsor’s duly authorized 
personnel, the Ethics Committee (IRB/IEC), and the regulatory authorities to have direct access to 
original medical records  which support the data on the CRFs (eg, patient's medical file, 
appointment books, original laboratory records, etc). These personnel, bound by professional 
secrecy, must maintain the confidentiality of all personal identity or personal medical information 
(according to confidentiality and personal data protection rules). 
 
 
13.4 
USE AND COMPLETION OF CRFS AND ADDITIONAL REQUEST 
 
It is the responsibility of the Investigator to maintain adequate and accurate CRFs (according to 
the technology used) designed by the Sponsor to record (according to Sponsor instructions) all 
observations and other data pertinent to the clinical investigation in a timely manner. All CRFs 
should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of 
data. 
 
Should a correction be made, the corrected information will be entered in the e-CRF overwriting 
the initial information. An audit trail allows identifying the modification. 
 
Data are available within the system to the Sponsor as soon as they are entered in the e-CRF. 
 
The computerized handling of the data by the Sponsor may generate additional requests (DRF) to 
which the Investigator is obliged to respond by confirming or modifying the data questioned. The 
requests with their responses will be managed through the e-CRF. 
 
 
13.5 
USE OF COMPUTERIZED SYSTEMS 
 
The complete list of computerized systems used for the study is provided in a separate document 
which is maintained in the Sponsor and Investigator study files. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 83 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
14 
ADDITIONAL REQUIREMENTS 
 
 
14.1 
CURRICULUM VITAE 
 
A current copy of the curriculum vitae describing the experience, qualification and training of 
each Investigator and Subinvestigator will be signed, dated and provided to the Sponsor prior to 
the beginning of the clinical trial. 
 
 
14.2 
RECORD RETENTION IN STUDY SITES 
 
The Investigator must maintain confidential all study documentation, and take measures to 
prevent accidental or premature destruction of these documents. 
 
The Investigator should retain the study documents at least 15 years after the completion or 
discontinuation of the clinical trial. 
 
However, applicable regulatory requirements should be taken into account in the event that a 
longer period is required. 
 
The Investigator must notify the Sponsor prior to destroying any study essential documents 
following the clinical trial completion or discontinuation. 
 
If the Investigator's personal situation is such that archiving can no longer be ensured by him/her, 
the Investigator shall inform the Sponsor and the relevant records shall be transferred to a 
mutually agreed upon designee. 
 
 
14.3 
CONFIDENTIALITY 
 
All information disclosed or provided by the Sponsor (or any company/institution acting on their 
behalf), or produced during the clinical trial, including, but not limited to, the clinical trial 
protocol, personal data in relation to the patients, the CRFs, the Investigator's Brochure and the 
results obtained during the course of the clinical trial, is confidential, prior to the publication of 
results. The Investigator and any person under his/her authority agree to undertake to keep 
confidential and not to disclose the information to any third party without the prior written 
approval of the Sponsor. 
 
However, the submission of this clinical trial protocol and other necessary documentation to the 
Ethics committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same 
obligation of confidentiality. 
 
The Subinvestigators shall be bound by the same obligation as the Investigator. The Investigator 
shall inform the Subinvestigators of the confidential nature of the clinical trial. 
 
The Investigator and the Subinvestigators shall use the information solely for the purposes of the 
clinical trial, to the exclusion of any use for their own or for a third party's account. 
 
 
Property of the Sanofi Group - strictly confidential 
Page 84 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
14.4 
PROPERTY RIGHTS 
 
All information, documents and IMP provided by the Sponsor or its designee are and remain the 
sole property of the Sponsor. 
 
The Investigator shall not and shall cause the delegated Investigator staff /Subinvestigator not to 
mention any information or the Product in any application for a patent or for any other intellectual 
property rights. 
 
All the results, data, documents and inventions, which arise directly or indirectly from the clinical 
trial in any form, shall be the immediate and exclusive property of the Sponsor. 
 
The Sponsor may use or exploit all the results at its own discretion, without any limitation to its 
property right (territory, field, continuance). The Sponsor shall be under no obligation to patent, 
develop, market or otherwise use the results of the clinical trial. 
 
As the case may be, the Investigator and/or the Subinvestigators shall provide all assistance 
required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent, 
including signature of legal documents. 
 
 
14.5 
DATA PROTECTION 
 
• 
The patient's personal data, which are included in the Sponsor database shall be treated in 
compliance with all applicable laws and regulations; 
 
• 
When archiving or processing personal data pertaining to the Investigator and/or to the 
patients, the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by any unauthorized third party. 
 
• 
The Sponsor also collects specific data regarding Investigator as well as personal data 
from any person involved in the study which may be included in the Sponsor’s databases, 
shall be treated by both the Sponsor and the Investigator in compliance with all applicable 
laws and regulations. 
 
 
14.6 
INSURANCE COMPENSATION 
 
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsorship.  This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investigator and the collaborators from any 
obligation to maintain their own liability insurance policy. An insurance certificate will be 
provided to the IECs/IRBs or regulatory authorities in countries requiring this document. 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 85 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
14.7 
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES 
 
For the purpose of ensuring compliance with the clinical trial protocol, Good Clinical Practice and 
applicable regulatory requirements, the Investigator should permit auditing by or on the behalf of 
the Sponsor and inspection by regulatory authorities. 
 
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study 
records for review, being understood that these personnel is bound by professional secrecy, and as 
such will not disclose any personal identity or personal medical information. 
 
The Investigator will make every effort to help with the performance of the audits and inspections, 
giving access to all necessary facilities, data, and documents. 
 
As soon as the Investigator is notified of a planned inspection by the authorities, he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection. 
 
The confidentiality of the data verified and the protection of the patients should be respected 
during these inspections. 
 
Any result and information arising from the inspections by the regulatory authorities will be 
immediately communicated by the Investigator to the Sponsor. 
 
The Investigator shall take appropriate measures required by the Sponsor to take corrective 
actions for all problems found during the audit or inspections. 
 
 
14.8 
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE 
 
 
14.8.1 By the Sponsor 
 
The Sponsor has the right to terminate the participation of either an individual site or the study at 
any time, for any reason, including but not limited to the following: 
 
• 
The information on the product leads to doubt as to the benefit/risk ratio; 
 
• 
Patient enrollment is unsatisfactory; 
 
• 
The Investigator has received from the Sponsor all IMP, means and information necessary 
to perform the clinical trial and has not included any patient after a reasonable period of 
time mutually agreed upon; 
 
• 
Non-compliance of the Investigator or Subinvestigator, delegated staff with any provision 
of the clinical trial protocol, and breach of the applicable laws and regulations or breach of 
the ICH GCP; 
 
• 
The total number of patients are included earlier than expected; 
 
In any case the Sponsor will notify the Investigator of its decision by written notice. 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 86 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
14.8.2 By the Investigator 
 
The Investigator may terminate his/her participation upon thirty (30) days' prior written notice if 
the study site or the Investigator for any reason becomes unable to perform or complete the 
clinical trial. 
 
In the event of premature discontinuation of the study or premature close-out of a site, for any 
reason whatsoever, the appropriate IRB/IEC and regulatory authorities should be informed 
according to applicable regulatory requirements. 
 
 
14.9 
CLINICAL TRIAL RESULTS 
 
The Sponsor will be responsible for preparing a clinical study report and to provide a summary of 
study results to the Investigator. 
 
 
14.10 PUBLICATIONS AND COMMUNICATIONS 
 
The Investigator undertakes not to make any publication or release pertaining to the study and/or 
results of the study prior to the Sponsor’s written consent, being understood that the Sponsor will 
not unreasonably withhold its approval. 
 
As the study is being conducted at multiple sites, the Sponsor agrees that, consistent with 
scientific standards, a primary presentation or publication of the study results based on global 
study outcomes shall be sought. However, if no multicenter publication is submitted, underway or 
planned within twelve (12) months of the completion of this study at all sites, the Investigator 
shall have the right to publish or present independently the results of this study in agreement with 
other Investigators and stakeholders. The Investigator shall provide the Sponsor with a copy of 
any such presentation or publication for review and comment at least 30 days in advance of any 
presentation or submission for publication.  In addition, if requested by the Sponsor, any 
presentation or submission for publication shall be delayed for a limited time, not to exceed 90 
days, to allow for filing of a patent application or such other justified measures as the Sponsor 
deems appropriate to establish and preserve its proprietary rights. 
 
The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publication without the prior written consent of the Sponsor. The Sponsor 
shall not use the name(s) of the Investigator and/or the collaborators in advertising or promotional 
material or publication without having received his/her and/or their prior written consent(s). 
 
The Sponsor has the right at any time to publish the results of the study. 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 87 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
15 
CLINICAL TRIAL PROTOCOL AMENDMENTS 
All appendices attached hereto and referred to herein are made part of this clinical trial protocol. 
The Investigator should not implement any deviation from, or changes of the clinical trial protocol 
without agreement by the Sponsor and prior review and documented approval/favorable opinion 
from the IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) 
to clinical trial patients, or when the change(s) involves only logistical or administrative aspects of 
the trial. Any change agreed upon will be recorded in writing, the written amendment will be 
signed by the Investigator and by the Sponsor and the signed amendment will be filed with this 
clinical trial protocol. 
 
Any amendment to the clinical trial protocol requires written approval/favorable opinion by the 
IRB/IEC prior to its implementation, unless there are overriding safety reasons. 
 
In some instances, an amendment may require a change to the informed consent form. The 
Investigator must receive an IRB/IEC approval/favorable opinion concerning the revised informed 
consent form prior to implementation of the change and patient signature should be re-collected if 
necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 88 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
16 
BIBLIOGRAPHIC REFERENCES 
 
1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz L.H, Sargent D, Ford R et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 
2009;45:228-47. 
 
2. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA  et al. Design and end 
points of clinical trials for patients with progressive prostate cancer and castrate levels of 
testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin 
Oncol 2008; 26(7):1148-59. 
 
3. Parker C, Gillessen S, Heidenreich A & Horwich A, on behalf of the ESMO Guidelines 
Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Onco 2015;26(Sup 5):v69–77. 
 
4. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM et al. Effect of radium- 
223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate 
cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet 
Oncol 2014; 15(7):738–46. 
 
5. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ et al. Abiraterone acetate for 
treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of 
the COU-AA-301 randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 
2012;13(10): 983-92. 
 
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with 
enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; (13)367:1187-97. 
 
7. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza Pet al. Abiraterone in 
Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013; (2)368:138- 
48. 
 
8. Beer TM, Armstrong AJ, Stenberg CN, et al. Enzalutamide in men with chemotherapy-naïve 
metastatic prostate cancer (mCRPC): Results of phase 3 PREVAIL study. Poster ASCO 2014 
annual meeting, January 30-February 1, 2014, San Francisco, CA 
 
9. Gurprataap Singh Sandhu, Rahul Atul Parikh, Leonard Joseph Appleman, David Friedland. 
Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer 
(mCRPC) Abstract 240 Poster ASCO GU 2014 Annual meeting, Jan 30-February 1, 2014, San 
Francisco, CA, J Clin Oncol 32, 2014 (suppl 4 ; abst 240) 
 
10. Matthew R.Smith, et al. Response to androgen signaling (AS)-directed therapy after treatment 
with abiraterone acetate (AA) in patients with metastatic castrate-resistant prostate cancer 
(mCRPC): Post hoc analysis of study COU-AA-302 Abstract 21. Poster ASCO GU 2014 
Annual meeting, Jan 30-February 1, 2014, San Francisco, CA, abstract 21. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 89 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
11. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P. Estimates of the cancer 
incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92. 
 
12. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 2008;101 Suppl 
2:11-5. 
 
13. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi K et al. Docetaxel plus 
prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 
2004;351(15):1502-12. 
 
14. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al. Docetaxel and 
estramustine compared with mitoxantrone and prednisone for advanced refractory prostate 
cancer. N Engl J Med 2004;351(15):1513-20. 
 
15. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF. Docetaxel plus 
prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in 
the TAX 327 study. J Clin Oncol 2008;26 (2):242-5. 
 
16. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus 
cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after 
docetaxel treatment: a randomised open-label trial. Lancet. 2010; (9747) 376:1147–54. 
 
17. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T 
Immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; (5) 363: 411-22. 
 
18. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and 
increased survival in metastatic prostate cancer. N. Engl. J Med 2011; 364(21): 1995-2005. 
 
19. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter 
radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23. 
 
20. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V and Panel Members. 
Prostate cancer: ESMO Consensus Conference Guidelines 2012. Annals of Oncology 2013; 
24(5):1141–1162. 
 
21. Rathkopf D and Scher H. Androgen receptor antagonists in castration-resistant prostate 
cancer. Cancer J. 2013;19(1):43-9. 
 
22. Schrader AJ, Boegemannb M, Ohlmannc CH, Schnoellera TJ, Krabbeb LM, Hajilic T et al. 
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and 
abiraterone. Eur Urol. 2013; (1)65:30-6. 
 
23. Bianchini D , Lorentea D, Rodriguez-Vidab A, Omlina A, Pezaroa C, Ferraldeschia R et al. 
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration- 
resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 
2014; 50(1):78-84. 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 90 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
24. Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M and Iversen P. Enzalutamide 
treatment in patients with metastatic castration-resistant prostate cancer progressing after 
chemotherapy and abiraterone acetate. Scand J Urol Nephro 2014;48(3):268-75. 
 
25. Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P et al. 
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic 
castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. 
Cancer 2014;120(7): 968-75. 
 
26. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C et al. Antitumour activity 
of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after 
docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24(7):1807-12. 
 
27. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL and Chi KN. Clinical activity of 
abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing 
after enzalutamide. Ann Oncol 2013;24(7):1802-07. 
 
28. Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D et al. Activity of 
cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next- 
generation endocrine agents. Eur Urol 2013;66(3):459-65. 
 
29. Angelergues et al. ASCO 2013 (abstract  5063). 
 
30. Al Nakouzia N, Le Moulecb S, Albigèsc L, Wanga C, Beuzebocd P, Gross-Goupile M et al. 
Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen 
receptor pathway targeted therapies. 2015 ; 68 (2):228-35 
 
31. EAU guidelines on prostate cancer (2014 update); www.uroweb.org 
 
32. NCCN guidelines on prostate cancer (version 2 2014); www.nccn.org 
 
33. Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C et al. Preclinical 
antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin 
Cancer Res 2013;19(11): 2973-83. 
 
34. Bambury R, Landers M, Louw J, Jendrisak A, Danila D, Rathkopf D, Arslan Z, Schreiber N, 
Krupa R, Marrinucci D, Dittamore R, Scher H.I. Characteristics of de novo Resistance to 
Androgen Targeting Therapeutics (AR Tx) through Circulating Tumor Cells (CTCs) analyses 
in metastatic Castration Resistant Prostate Cancer (mCRPC) patients. Abstract 237P. Poster 
ESMO 2014, Annual meeting, 26-30 September 2014, Madrid, ESP 
 
35. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of ASCO guideline 
recommendations for the use of white blood growth factors. Journal of Oncology Practice; 
vol.2, issue 4; 196-201 
 
36. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL et al. Use of 
epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 91 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
Oncology/American Society of Hematology clinical practice guidelines update. J Clin Oncol 
2008;26 (1):132-49. 
 
37. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The functional assessment 
of cancer therapy (FACT) scale: development and validation of the general measure. J Clin 
Oncol. 1993;11(3):570-9. 
 
38. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men 
with prostate cancer using the functional assessment of cancer therapy-prostate instrument. 
Urology. 1997;50(6):920-28. 
 
39. Sommers DS, Ramsey SD. A review of quality-of-life evaluations in prostate cancer. 
Pharmacoeconomics 1999;16(2):127-40. 
 
40. Investigator's Brochure. Edition 14. 26 June 2014. 
 
41. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating Clinically Meaningful Changes 
for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of 
Patients with Metastatic Hormone-Refractory Prostate Cancer. Value in Health 
2009;12(1):124-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 92 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
17 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 93 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix A 
Modified Response Evaluation Criteria in Solid Tumors (RECIST1.1) 
 
Detailed information is provided in reference (1). 
 
Definitions 
 
At baseline, tumor lesions/lymph nodes will be categorized measurable or non-measurable as 
follows: 
 
Measurable: 
 
- 
Tumor lesions: Must be accurately measured in at least one dimension (longest 
diameter in the plane of measurement is to be recorded) with a minimum size of: 
 
- 
10 mm by CT scan (CT scan slice thickness no greater than 5 mm). 
 
- 
10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measurable). 
 
- 
20 mm by chest X-ray. 
 
- 
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a 
lymph node must be ≥15 mm in short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm). At baseline and in follow-up, 
only the short axis will be measured and followed (see Special Issue 15). See also 
notes below on “Baseline documentation of target and non-target lesions” for 
information on lymph node measurement. 
 
Non-measurable 
 
- 
All other lesions, including small lesions (longest diameter <10 mm or pathological 
lymph nodes with 10 to <15 mm short axis) as well as truly non-measurable lesions. 
Lesions considered truly non-measurable include: leptomeningeal disease, ascites, 
pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement 
of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measurable by reproducible imaging techniques. 
 
Special considerations regarding lesion measurability 
 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular 
comment: 
 
Bone lesions: 
 
- 
Bone scan, PET scan or plain films are not considered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence 
or disappearance of bone lesions. 
 
- 
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components, that can be evaluated by cross sectional imaging techniques such as CT or 
 
 
Property of the Sanofi Group - strictly confidential 
Page 94 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
MRI can be considered as measurable lesions if the soft tissue component meets the 
definition of measurability described above. 
 
- 
Blastic bone lesions are non-measurable. 
 
Cystic lesions: 
 
- 
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they 
are, by definition, simple cysts. 
 
- 
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non- 
cystic lesions are present in the same patient, these are preferred for selection as target 
lesions. 
 
Lesions with prior local treatment: 
 
- 
Tumour lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion. Study protocols should detail the conditions 
under which such lesions would be considered measurable. 
 
Methods of measurement 
 
• Measurement of lesions 
 
All measurements should be recorded in metric notation, using calipers if clinically 
assessed. All baseline evaluations should be performed as close as possible to the 
treatment start and never more than 4 weeks before the beginning of the treatment. 
 
• Method of assessment 
 
The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at baseline and during follow-up. Imaging based 
evaluation should always be done rather than clinical examination unless the lesion(s) 
being followed cannot be imaged but are assessable by clinical exam. 
 
- 
Clinical lesions: Clinical lesions will only be considered measurable when they are 
superficial and 10 mm diameter as assessed using calipers (e.g. skin nodules). For the 
case of skin lesions, documentation by color photography including a ruler to estimate 
the size of the lesion is suggested. As noted above, when lesions can be evaluated by 
both clinical exam and imaging, imaging evaluation should be undertaken since it is 
more objective and may also be reviewed at the end of the study. 
 
- 
Chest X-ray: Chest CT is preferred over chest X-ray, particularly when progression is 
an important endpoint, since CT is more sensitive than X-ray, particularly in 
identifying new lesions. However, lesions on chest X-ray may be considered 
measurable if they are clearly defined and surrounded by aerated lung. 
 
- 
CT, MRI: CT is the best currently available and reproducible method to measure 
lesions selected for response assessment. This guideline has defined measurability of 
 
 
Property of the Sanofi Group - strictly confidential 
Page 95 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
lesions on CT scan based on the assumption that CT slice thickness is 5 mm or less. 
when CT scans have slice thickness greater than 5 mm, the minimum size for a 
measurable lesion should be twice the slice thickness. MRI is also acceptable in certain 
situations (e.g. for body scans). 
 
- 
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be 
used as a method of measurement. Ultrasound examinations cannot be reproduced in 
their entirety for independent review at a later date and, because they are operator 
dependent, it cannot be guaranteed that the same technique and measurements will be 
taken from one assessment to the next. If new lesions are identified by ultrasound in 
the course of the study, confirmation by CT or MRI is advised. If there is concern 
about radiation exposure at CT, MRI may be used instead of CT in selected instances. 
 
- 
Endoscopy, laparoscopy: The utilisation of these techniques for objective tumour 
evaluation is not advised. However, they can be useful to confirm complete 
pathological response when biopsies are obtained or to determine relapse in trials 
where recurrence following complete response or surgical resection is an endpoint. 
 
- 
Tumour markers: Tumour markers alone cannot be used to assess objective tumour 
response. If markers are initially above the upper normal limit, however, they must 
normalise for a patient to be considered in complete response. Specific guidelines for 
both CA-125 response (in recurrent ovarian cancer) and PSA response (in recurrent 
prostate cancer), have been published. In addition, the Gynecologic Cancer Intergroup 
has developed CA125 progression criteria which are to be integrated with objective 
tumour assessment for use in first-line trials in ovarian cancer. 
 
- 
Cytology, histology: These techniques can be used to differentiate between PR and CR 
in rare cases if required by protocol (for example, residual lesions in tumour types such 
as germ cell tumours, where known residual benign tumours can remain). When 
effusions are known to be a potential adverse effect of treatment (e.g. with certain 
taxane compounds or angiogenesis inhibitors), the cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens during treatment can be 
considered if the measurable tumour has met criteria for response or stable disease in 
order to differentiate between response (or stable disease) and progressive disease. 
 
Tumor response evaluation 
 
To assess objective response or future progression, it is necessary to estimate the overall tumour 
burden at baseline and use this as a comparator for subsequent measurements. Only patients with 
measurable disease at baseline should be included in protocols where objective tumour response is 
the primary endpoint. Measurable disease is defined by the presence of at least 1 measurable 
lesion. In studies where the primary endpoint is tumour progression (either time to progression or 
proportion with progression at a fixed date), the protocol must specify if entry is restricted to 
those with measurable disease or whether patients having non-measurable disease only are also 
eligible. 
 
For baseline documentation of target and non-target lesions, see Section 9.1 in reference (1). 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 96 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
Response Criteria 
 
For special notes on the assessment of target and non-target lesions in reference (1). 
 
Table 1 
 
 
 
Complete Response 
(CR) 
 
Partial Response 
(PR): 
 
Progressive Disease 
(PD): 
Evaluation of target lesions 
 
Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must 
have reduction in short axis to <10 mm.s 
 
At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline 
sum diameters. 
 
At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum 
on study (this includes the baseline sum if that is the smallest on study). In addition to the relative 
increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the 
appearance of one or more new lesions is also considered progression). 
 
Stable Disease (SD): 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as 
reference the smallest sum diameters while on study 
 
 
 
 
 
Table 2 
 
 
 
Complete Response 
(CR): 
Evaluation of non-target lesions 
 
Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must 
be non-pathological in size (<10 mm short axis). 
 
Non-CR/non-PD 
Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the 
normal limits. 
 
Progressive Disease 
(PD): 
 
Unequivocal progression (see comments below) of existing non-target lesions. (Note: the appearance 
of one or more new lesions is also considered progression). 
 
Although a clear progression of “non-target” lesions only is exceptional, in such circumstances, the opinion of the treating 
physician should prevail and the progression status should be confirmed later on by the review panel (or study chair). 
 
New lesions: the appearance of new malignant lesions denotes disease progression in reference 
(1). 
 
Evaluation of best overall response (1) 
 
It is assumed that at each protocol specified time point, a response assessment occurs. The 
following table provides a summary of the overall response status calculation at each time point 
for patients who have measurable disease at baseline. 
 
The best overall response is determined once all the data for the patient is known. 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 97 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
Best response determination in trials where confirmation of complete or partial response IS NOT 
required: Best response in these trials is defined as the best response across all time points (for 
example, a patient who has SD at first assessment, PR at second assessment, and PD on last 
assessment has a best overall response of PR). When SD is believed to be best response, it must 
also meet the protocol specified minimum time from baseline. If the minimum time is not met 
when SD is otherwise the best time point response, the patient’s best response depends on the 
subsequent assessments. For example, a patient who has SD at first assessment, PD at second and 
does not meet minimum duration for SD, will have a best response of PD. The same patient lost to 
follow-up after the first SD assessment would be considered inevaluable. 
 
Best response determination in trials where confirmation of complete or partial response IS 
required: Complete or partial responses may be claimed only if the criteria for each are met at a 
subsequent time point as specified in the protocol (generally 4 weeks later). In this circumstance, 
the best overall response can be interpreted as in Table 4. 
 
Table 3 
 
Target lesions 
Non-target lesions 
 New 
lesions 
Overall response 
 
CR 
CR 
No 
CR 
 
CR 
Non-CR/non-PD 
No 
PR 
 
CR 
Not evaluated 
No 
PR 
 
PR 
Non-PD or not all evaluated 
No 
PR 
 
SD 
Non-PD or not all evaluated 
No 
SD 
 
Not all evaluated 
Non PD 
No 
NE 
 
PD 
Any 
Yes or No 
PD 
 
Any 
PD 
Yes or No 
PD 
 
Any 
Any 
Yes 
PD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 98 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
Table 4 
 
Overall response 
Overall response 
BEST overall response 
First time point 
Subsequent time point 
CR 
CR 
CR 
CR 
PR 
SD, PD or PRa 
CR 
SD 
SD provided minimum criteria for SD duration met, otherwise, PD 
CR 
PD 
SD provided minimum criteria for SD duration met, otherwise, PD 
CR 
NE 
SD provided minimum criteria for SD duration met, otherwise NE 
PR 
CR 
PR 
PR 
PR 
PR 
PR 
SD 
SD 
PR 
PD 
SD provided minimum criteria for SD duration met, otherwise, PD 
PR 
NE 
SD provided minimum criteria for SD duration met, otherwise NE 
NE 
NE 
NE 
a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria relative to baseline, 
makes the disease PD at that point (since disease must have reappeared after CR). Best response would depend on whether minimum duration 
for SD was met. However, sometimes ‘CR’ may be claimed when subsequent scans suggest small lesions were likely still present and in fact the 
patient had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 99 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix B 
PSA eligibility changes and progression 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 100 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix C 
National Cancer Institute Common Terminology Criteria for Adverse 
Events (9) 
 
 
 
1. Toxicity grade should reflect the most severe degree occurring during the evaluated 
period, not an average. 
 
2. When 2 criteria are available for similar toxicities, the one resulting in the more severe 
grade should be used. 
 
3. The evaluator must attempt to discriminate between disease / treatment and related signs / 
symptoms. 
 
4. An accurate baseline prior to therapy is essential. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 101 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix D 
ECOG performance status scale 
 
 
 
Grade 
Description 
 
0 
Normal activity. Fully active, able to carry on all pre-disease performance without restriction. 
 
1 
Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry 
out work of a light or sedentary nature (e.g., light housework, office work). 
 
2 
In bed < 50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work 
activities. Up and about more than 50% waking hours. 
 
3 
In bed > 50% of the time. Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours. 
 
4 
100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 
 
5 
Dead 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 102 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix E 
Brief Pain Inventory (Short Form) 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 103 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 104 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix F 
WHO analgesic ladder for cancer pain 
 
(http://www.who.int/cancer/palliative/painladder/en/index.html). 
 
 
 
Adjuvant: To help calm fears and anxiety, adjuvant analgesics may be added at any step of the ladder 
 
 
WHO analgesic ladder 
step 
Score on numerical rating 
scale 
Analgesics of choice 
 
1 (mild pain) 
<3 out of 10 
paracetamol and NSAIDs 
 
2 (mild to moderate pain) 
3 to 6 out of 10 
weak opioids( eg codeine or dihydrocoideine) plus 
paracetamol and NSAIDs 
 
3 (severe pain) 
> 6 out of 10 
strong opioids (eg morphine, alfentanil, diamorphine, 
fentanyl, hydromorphone or oxycodone) plus 
paracetamol and NSAIDs 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 105 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix G     EVALUATION OF QUALITY OF LIFE BY FACT-P 
(version 4 – 19 November 2007) 
 
 
 
Below is a list of statements that other people with your illness have said are important. 
Please circle or mark one number per line to indicate your response as it applies to 
the past 7 days. 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential                                                                                               Page 106 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
By circling one (1) number per line, please indicate how true each statement has been 
for you during the past 7 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 107 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
By circling one (1) number per line, please indicate how true each statement has been 
for you during the past 7 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 108 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix H 
EQ-5D-5L QUESTIONNAIRE 
 
English version for the UK 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 109 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 110 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix I 
CYP 3A4 inhibitors and CYP 3A4 inducers (Updated November 
2011) 
 
List of strong CYP 3A inhibitors 
 
 
INHIBITORS 
Maximum AUC 
fold increase 
(AUC ratio) 
 
Substrate for the observed 
Maximum AUC fold increase 
Inhibitor Classification 
 
Telaprevir 
77,98 / 9,0 
tacrolimus / midazolam 
Strong 
 
Indinavir/RIT 
36,50 
alfentanil 
Strong 
 
Tipranavir/RIT 
26,91 
midazolam 
Strong 
 
Ritonavir 
26,41 
midazolam 
Strong 
 
Cobicistat (GS-9350) 
19,03 
midazolam 
Strong 
 
Indinavir 
16,25 
vardenafil 
Strong 
 
Ketoconazole 
15,90 
midazolam 
Strong 
 
Troleandomycin 
14,80 
midazolam 
Strong 
 
Danoprevir/RIT 
13.42 
midazolam 
Strong 
 
Saquinavir/RIT 
12,48 
midazolam 
Strong 
 
Itraconazole 
10,80 
midazolam 
Strong 
 
Voriconazole 
9,40 
midazolam 
strong 
 
Mibefradil 
8,86 
midazolam 
strong 
 
Clarithromycin 
8,39 
midazolam 
Strong 
 
Lopinavir/RIT 
7,71 
aplaviroc 
Strong 
 
Elvitegravir/RIT 
6,80 
midazolam iv 
Strong 
 
Posaconazole 
6,23 
midazolam 
Strong 
 
Telithromycin 
6,0 
midazolam 
Strong 
 
Grapfruit Juice 
5,95 
midazolam 
Strong 
 
Conivaptan 
5,76 
midazolam 
Strong 
 
Nefazodone 
5,44 
midazolam 
Strong 
 
Nelfinavir 
5.29 
simvastatin 
Strong 
 
Saquinavir 
5.18 
midazolam 
Strong 
 
Boceprevir 
5.05 
midazolam 
Strong 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 111 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
List of strong CYP 3A inducers 
 
Inducers 
 % AUC 
decrease 
Substrate for the observed % 
AUC decrease 
Inducer Classification 
 
Rifampin 
99.7 
budesonide 
Strong 
 
Mitotane 
94.5 
midazolam 
Strong 
 
Avasimibe 
93.5 
midazolam 
Strong 
 
Phenytoin 
89.5 
nisoldipine 
Strong 
 
Carbamazepine 
86.5 
quetiapine 
Strong 
 
Enzalutamide 
85.9 
midazolam 
Strong 
 
St John’s wort* 
80 
midazolam 
Strong 
 
Rifabutin 
Not provided 
delavirdine 
Strong 
 
Phenobarbital 
76.6 
verapamil 
Strong 
 
*An herb (Hypericum perforatum) used for depression, anxiety and/or sleep disorders 
 
List of moderate CYP 3A inducers 
 
Inducers 
 % AUC 
decreas
e 
Substrate for the observed % 
AUC decrease 
Inducer Classification 
 
Ritonavir and St John’s wort 
77.2 
midazolam 
Moderate 
 
Efavirenz 
76 
alfentanil 
Moderate 
 
Tipranavir and ritonavir 
75.6 
saquinavir 
Moderate 
 
Bosentan 
69 
sildenafil 
Moderate 
 
Genistein** 
13.7 
midazolam 
Moderate 
 
Thioridazine 
68.7 
quetiapine 
Moderate 
 
Nafcillin 
62.6 
nifedipine 
Moderate 
 
Lopinavir 
59.7 
amprenavir 
Moderate 
 
Modafinil 
57.6 
triazolam 
Moderate 
 
Estravirine 
56.7 
sildenafil 
Moderate 
 
Lersivirine 
51.4 
midazolam 
Moderate 
 
** Food product 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 112 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
Strong CYP 2C8 inhibitor 
 
Gemfibrozil 
 
Strong and moderate CYP 2C8 inducers 
 
Rifampin, flucloxacillin 
 
List of strong CYP2D6 substrates with a narrow therapeutic index 
 
Thioridazine, pimozide 
 
List of moderate CYP3A substrates with a narrow therapeutic index 
 
Alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, fentanyl, 
pimozide, quinidine, sirolimus, tacrolimus, terfenadine 
 
List of CYP2C9 substrates with a narrow therapeutic index 
 
Warfarin, phenytoin 
 
List of CYP2C19 substrates with a narrow therapeutic index 
 
S-mephenytoin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 113 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix J 
COUNTRY-SPECIFIC REQUIREMENTS 
 
Amendment 02 – France (31 March 2016) 
 
Rationale: 
 
The following modifications are made as per French Health Authorities (ANSM) request. 
 
- 
I01. Has been modified in order to enroll patients with only histologically confirmed 
prostate adenocarcinoma and not cytologically according to French guidelines. 
 
- 
I03. Has been clarified/added in order to continue an effective castration with LHRH 
agonists or antagonists for patients without surgical castration (orchiectomy). 
 
No impact on the Written Subject Information. 
 
In Section Clinical Trial Summary 
Study Population – Inclusion criteria 
 
I01. Histologically confirmed prostate adenocarcinoma 
 
I03. Effective castration with serum testosterone levels < 0.5 ng/mL (1.7 nmol/L). If the patient 
has been treated with LHRH agonists or antagonist (ie, without orchiectomy), then this 
therapy should be continued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 114 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
 
 
Appendix K 
PROTOCOL AMENDMENT HISTORY 
Amendment 01 – 29 October 2015 
Reason for amendment: 
 
• 
Change to secondary objectives 
 
Rationale: In addition to Health status assessed by EQ-5D-5L, Health-Related Quality Of 
Life assessed by FACT-P questionnaire is added as it is the most appropriate questionnaire 
in prostate cancer. 
 
• 
Change to exploratory objectives 
 
 
 
 
• 
Change to the inclusion/Exclusion criteria 
 
Rationale: 
 
- 
In I05, the minimum dose exposure to docetaxel is specified. At least 3 cycles are 
needed to consider a prior treatment with docetaxel. It is also specified that docetaxel 
administration in combination with ADT in metastatic hormone-sensitive disease is 
considered a prior exposure. As per ESMO guidelines, ADT plus docetaxel is 
recommended as first-line treatment of metastatic hormone-naive disease in men fit 
enough for chemotherapy [1, A] (Parker C et al. Ann Oncol. 2015;26 (Suppl 5):v69- 
v77). 
 
- 
In I06, time to disease progression with a first AR-targeted agent has been extended 
from 6 to 12 months. Published retrospective data suggest that patients with acquired 
resistance to AR-targeted agents poorly respond to another targeted agent ((Loriot et 
al. Annals Oncol 2013, 24: 1807–1812; Bianchini et al. Eur J Cancer 2014, 50: 78– 
84). In addition, unpublished retrospective data suggest that patients having disease 
progression within 6-12 months with a first AR-targeted agent in post-docetaxel 
setting may poorly respond to another AR-targeted agent. In pre-docetaxel setting, 
patients having disease progression within 6-12 months with abiraterone or 
enzalutamide are considered ‘rapid progressors’ and may also poorly respond to 
another AR-targeted agent. Consequently, time to progression with a first AR-targeted 
agent has been extended from 6 to 12 months (with a stratification ]0; 6 months] Vs. 
]6; 12 months]) to evaluate the optimal management of such patients. 
 
- 
In E02, was clarified for immunotherapy. Previous immunotherapy is allowed. 
 
- 
In E09, was modified as per NoMA (Norwegian Medicines Agency) request to give 
more details about the method of contraception. 
 
 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 115 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
- 
In E14 (h), creatinine clearance < 50 mL/min has been removed according to the last 
Smpc update. Cabazitaxel is minimally excreted through the kidney. No dose 
adjustment is necessary in patients with renal impairment, not requiring hemodialysis. 
 
- 
In E16, was clarified in order to exclude patients with symptomatic peripheral 
neuropathy Grade 2 as well as patients with Grade > 2 according to the Smpc (dose 
modifications). 
 
- 
In E18, concomitant vaccination with yellow fever vaccine, was added according to 
the Smpc and as per NoMA (Norwegian Medicines Agency) request. 
 
• 
Change to stratification factors 
 
Rationale: to replace a stratification factor (metastatic Spread (Low Vs. High) by time 
from AR targeted agent initiation to progression (]0; 6 months] Vs. ]6; 12 months]) due to 
the extent of the study population who has disease progression within 12 months of AR 
targeted treatment initiation instead of 6 months. 
 
 
 
 
 
 
 
• 
Change to dose modification and dose delay 
 
Rationale: Table 3 has been modified for creatinine increase, bilirubin elevation and 
transaminases elevation according to the last Smpc update (July 24th, 2015) regarding 
patients with renal and hepatic impairment. 
 
• 
Change to assessment schedule 
 
Rationale: To add data collection regarding the response to first further anticancer therapy 
to better document the treatment sequences. To delete urine dipstick according to the last 
Smpc update regarding patients with renal impairment. Cabazitaxel is minimally excreted 
through the kidney. No dose adjustment is necessary in patients with renal impairment, not 
requiring hemodialysis. 
 
• 
Change to procedure and consequence for patient withdrawal from study 
 
Rationale: FDA recommendation on withdrawal of consent for follow-up should be 
accompanied by documentation of the reason for withdrawal. Withdrawal of consent for 
treatment should be distinguished from withdrawal of consent for follow-up visits and 
from withdrawal of consent for non-patient contact follow-up, e.g., medical records 
checks. Subjects requesting withdrawal should be informed that withdrawal of consent for 
follow-up will jeopardize the public health value of the study. 
In addition, other minor changes are listed in the description of changes (next section). 
 
Written Subject Information has been updated to reflect the modifications related to the 
description of the study, the pregnancy, the biomarker testing and the utilization and 
protection of personal data. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 116 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
Amendment 02 France – 31 March 2016 
Reason for amendment: 
Rationale: 
 
The following modifications are made as per French Health Authorities (ANSM) request. 
 
• 
I01. Has been modified in order to enroll patients with only histologically confirmed 
prostate adenocarcinoma and not cytologically according to French guidelines. 
 
• 
I03. Has been clarified/added in order to continue an effective castration with LHRH 
agonists or antagonists for patients without surgical castration (orchiectomy). 
 
No impact on the Written Subject Information. 
Amendment 03 – 11 May 2018 
Reason for amendment: 
 
• 
To introduce name and address of: Coordinating Investigator and Sponsor in cover 
page 
 
• 
Clarification of the definition of rPFS in the Primary Objective and Primary 
Endpoint sections 
 
Rationale: 
 
The definition of radiological Progression-Free Survival (rPFS) has to be consistent 
throughout the protocol. The definition of primary objective and corresponding primary 
endpoint in the tabulated clinical trial summary has thus been aligned with definition of 
primary endpoint provided in section 9.1 of the protocol. 
 
Moreover, in section 9.1, definition of rPFS has been clarified to reflect the PCWG2 with 
regards to progression of bone lesions and definition of measurability of lymph node. 
 
• 
Clarification of the definition of PFS 
 
Rationale: 
 
Progression Free survival comprises currently the Radiological tumor progression event 
using RECIST 1.1. Definition of this event is updated and detailed to be in line with 
section 9.1. 
 
• 
To clarify and adapt the Inclusion criteria based on recent guidelines updates 
 
Rationale: 
 
- 
In I 01, as per ESMO guidelines (Ann Oncol 2015, 26 (suppl 5) V69-V77), prostate 
cancer diagnosis has to be confirmed by histology, (cytology is not mentioned). This 
point was already modified in local French amendment 2. 
 
- 
In I 03, the sentence: “If the patient has been treated with LHRH agonists or antagonist 
(ie, without orchiectomy), then this therapy should be continued” is added. This 
clarification will be added to be in accordance with ESMO guidelines on management 
 
 
Property of the Sanofi Group - strictly confidential 
Page 117 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
of metastatic CRPC (ESMO guidelines. Annals of Oncology 26 (Supplement 5):v69– 
v77, 2015). LHRH agonists or antagonists were already allowed in section 
concomitant treatments 8.9, but to avoid any ambiguity and add clarity, it is now also 
specified in I03. This point was already modified in local French amendment 2. 
 
- 
In I06, abiraterone acetate + androgen deprivation therapy (ADT) is now indicated in 
Europe for the treatment of metastatic hormone-sensitive prostate cancer. Such 
patients are thus eligible in CARD if they have progressed within 12 months with this 
regimen. It has also been clarified that patients having PSA progression only (as per 
PCWG 2) within 12 months, were eligible, even if total treatment duration with the 
AR-targeted agent was more than 12 months. 
 
• 
Revision of statistical power and accrual rates assumptions, and as a consequence 
reduction of  the sample size 
 
Rationale: 
 
Recruitment rate in the trial is lower than planned. Since statistical hypotheses for sample 
size calculation are still valid (HR of 0.67 between both arms), the Clinical Steering 
Committee agrees to reduce the study power from 90% to 80%. A power of 80% is indeed 
acceptable as per ICH step 9 and was used by important randomized trials in metastatic 
prostate cancer (CHAARTED: CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, 
M Eisenberger and al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate 
Cancer. N Engl J Med. 2015;373:737-46) and (PROSELICA: M Eisenberger, AC Hardy- 
Bessard, CS Kim, L Géczi, D Ford, L Mourey and al. Phase III Study Comparing a 
Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2 in 
Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer – 
PROSELICA. J Clin Oncol. 2017;35:3198-206). The number of patients to be randomized 
and number of patients with rPFS events needed for a power of 80% has been re- 
calculated precisely. Calculation were based on observed accrual rate so far and the further 
accrual rate expected up to the end of recruitment, and censored rate estimation. With a 
power of 80%, 196 rPFS events are needed and 234 patients should be randomized 
(117 per arm). 
 
• 
To introduce the 500mg dosage of the Investigational Medicinal Product(s) (IMP) – 
abiraterone acetate (Zytiga), and adapt dose modification and dose delay accordingly 
and to align dose adaptation rules with revised abiraterone acetate European 
labeling 
 
Rationale: 
 
A new dosage for abiraterone acetate was launched by Janssen-Cilag: abiraterone acetate 
500 mg currently available across Europe. In some countries, only 500 mg dosage is 
available. In order to deal with this new situation and to be in accordance with new 
European labelling of abiraterone acetate 250 and 500 mg, modifications throughout the 
protocol have been made . These modifications have been discussed and agreed by the 
Clinical Steering Committee. 
 
Description and formulation of tablet 500 mg abiraterone acetate have been added and 
monitoring instructions for dose reduction have been adapted accordingly. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 118 
 
 


Amended Clinical Trial Protocol 05 
LPS14201 - cabazitaxel 
01-Mar-2019 
Version number: 1 
 
 
In addition, management of abiraterone acetate adverse events have been aligned on new 
abiraterone acetate European labelling, in particular with regards to: 
 
Dose reduction to 750 mg which has been deleted, and management of hypertension, fluid 
retention/ edema and non-mineralocorticoid based side effects have been revised. 
 
• 
To allow a time window of + or – 1 week for the tumor assessment scheduled every 
12 weeks and the follow up visits for the Body Weight and ECOG PS scheduled prior 
to the start of each treatment cycle 
 
Rationale: time window of + or - 1 week is introduced for tumor assessment during 
treatment and in follow up if applicable, as well as all follow up visit to  increase 
compliance and flexibility for patients. 
 
• 
To clarify Change to procedure and consequence for patient withdrawal from study 
 
Rationale: 
 
CARD study is an event driven study, (section 9.1) and all efforts should be made to 
document radiographic progression before initiation of further therapy. 
 
In case of treatment discontinuation due to reason other than radiographic progressive 
disease (or example discontinuation due to adverse event), the choice of further therapy, if 
any, is let to the investigator, and data concerning further therapy will be documented. 
Accordingly, section 6.2.1 has been modified. 
 
• 
To correct inconsistencies throughout the protocol with regards to general guidelines 
for reporting AEs 
 
Rationale: 
 
As mentioned in the flowchart, the period of safety observation starts from the time the 
patient gives informed consent. All AEs will be recorded until 30 days after the last 
administration of study drugs. During the follow-up period, only ongoing related or new 
related AEs will be recorded. Serious Adverse Events (SAEs) ongoing at the end of the 
study treatment will be followed during the follow-up period until resolution or 
stabilization regardless of relationship with study drugs. 
 
• 
Change in appendices 
 
Rationale: 
 
The version in initial protocol was not the most recent version used and released to 
patients. The correct version is inserted. 
 
Amendment 04 – 08 November 2018 
Reason for amendment: 
This amendment has introduced mainly a new format of Abiraterone acetate 500 mg tablets 
(available in two formats (wallets 60 or 56 tablets, previously only 60 tablets), with no changes 
concerning the immediate packaging or daily dose), and introduced the new address of 
coordinating investigator. 
 
 
 
Property of the Sanofi Group - strictly confidential 
Page 119 
 
 


 
 
 
Signature Page 
 
lps14201-16-1-1-amended-protocol05 
 
 
Approve & eSign 
 
Clinical 
 
 
Approve & eSign 
 
Clinical 
 
 
 

SAP_001.pdf: 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose and must not be 
disclosed, published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company);  ‘affiliated company’ means any corporation, partnership or other entity which at the date 
of communication or afterwards (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or other entity 
According to template: QSD-002643 VERSION 6.0 (06-JUL-2016) 
Page 1 
STATISTICAL ANALYSIS PLAN 
A randomized, open label, multicenter study of Cabazitaxel versus an Androgen 
Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients 
previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent  
XRP6258-LPS14201 
STATISTICIAN: 
Statistical Project Leader: 
DATE OF ISSUE: 20-Jun-2019 
Total number of pages: 
76 
NCT02485691


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 2 
TABLE OF CONTENTS 
STATISTICAL ANALYSIS PLAN ................................................................................................................... 1 
TABLE OF CONTENTS .................................................................................................................................. 2 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS .......................................................................... 5 
1 
OVERVIEW AND INVESTIGATIONAL PLAN ................................................................................ 7 
1.1 
STUDY DESIGN AND RANDOMIZATION ...................................................................................... 7 
1.2 
OBJECTIVES ................................................................................................................................... 8 
1.2.1 
Primary objectives ............................................................................................................................ 8 
1.2.2 
Secondary objectives ....................................................................................................................... 8 
1.2.3 
Exploratory objectives ...................................................................................................................... 9 
1.3 
DETERMINATION OF SAMPLE SIZE ............................................................................................. 9 
1.4 
STUDY PLAN ................................................................................................................................. 10 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL ................................ 11 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN ..................... 12 
2 
STATISTICAL AND ANALYTICAL PROCEDURES .................................................................... 13 
2.1 
ANALYSIS ENDPOINTS ............................................................................................................... 13 
2.1.1 
Demographic and baseline characteristics .................................................................................... 13 
2.1.2 
Prior or concomitant medications (other than anticancer therapies) ............................................. 19 
2.1.3 
Efficacy endpoints .......................................................................................................................... 20 
2.1.3.1 
Primary efficacy endpoint(s) .......................................................................................................... 20 
2.1.3.2 
Secondary efficacy endpoint(s) ...................................................................................................... 20 
2.1.4 
Safety endpoints ............................................................................................................................ 24 
2.1.4.1 
Adverse events variables ............................................................................................................... 24 
2.1.4.2 
Deaths ............................................................................................................................................ 25 
2.1.4.3 
Laboratory safety variables ............................................................................................................ 25 
2.1.4.4 
Vital signs variables ....................................................................................................................... 26 
2.1.4.5 
Electrocardiogram variables .......................................................................................................... 26 
2.1.4.6 
Other safety endpoints ................................................................................................................... 26 
2.1.5 
Pharmacokinetic variables ............................................................................................................. 26 
2.1.6 
Pharmacodynamic/genomics endpoints ........................................................................................ 26 
2.1.7 
Quality-of-life endpoints ................................................................................................................. 26 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 3 
2.1.8 
Health economic endpoints ............................................................................................................ 28 
2.1.9 
Further therapy after discontinuation of investigational medicinal product administration 
during the study .............................................................................................................................. 28 
2.1.10 
Other endpoints .............................................................................................................................. 28 
2.2 
DISPOSITION OF PATIENTS ....................................................................................................... 28 
2.2.1 
Randomization and drug dispensing irregularities ......................................................................... 29 
2.3 
ANALYSIS POPULATIONS ........................................................................................................... 30 
2.3.1 
Efficacy populations ....................................................................................................................... 30 
2.3.1.1 
Intent–to-treat population ............................................................................................................... 30 
2.3.1.2 
Per-protocol population .................................................................................................................. 30 
2.3.1.3 
Other efficacy population ............................................................................................................... 31 
2.3.2 
Safety population ........................................................................................................................... 31 
2.3.3 
Other analysis population (Health related Quality of Life and Health status population) .............. 31 
2.4 
STATISTICAL METHODS ............................................................................................................. 32 
2.4.1 
Demographics and baseline characteristics .................................................................................. 32 
2.4.2 
Prior or concomitant medications (other than anticancer therapies) ............................................. 32 
2.4.3 
Extent of investigational medicinal product exposure and compliance ......................................... 32 
2.4.3.1 
Extent of investigational medicinal product exposure .................................................................... 33 
2.4.3.2 
Compliance .................................................................................................................................... 35 
2.4.4 
Analyses of efficacy endpoints ....................................................................................................... 35 
2.4.4.1 
Analysis of primary efficacy endpoint(s) ........................................................................................ 35 
2.4.4.2 
Analyses of secondary efficacy endpoints ..................................................................................... 38 
2.4.4.3 
Multiplicity issues ........................................................................................................................... 39 
2.4.4.4 
Additional efficacy analysis(es) ...................................................................................................... 40 
2.4.5 
Analyses of safety data .................................................................................................................. 40 
2.4.5.1 
Analyses of adverse events ........................................................................................................... 41 
2.4.5.2 
Deaths ............................................................................................................................................ 43 
2.4.5.3 
Analyses of vital sign variables ...................................................................................................... 43 
2.4.5.4 
Analyses of electrocardiogram variables ....................................................................................... 44 
2.4.5.5 
Analyses of other safety endpoints (laboratory variables) ............................................................. 44 
2.4.6 
Analyses of pharmacokinetic and pharmacodynamic variables .................................................... 44 
2.4.7 
Analyses of quality of life/health economics variables ................................................................... 45 
2.4.7.1 
Health-Related Quality of Life ........................................................................................................ 45 
2.4.7.2 
Health status .................................................................................................................................. 47 
2.4.8 
Further anti-cancer therapy after discontinuation of investigational medicinal product 
administration during the study ...................................................................................................... 48 
2.5 
DATA HANDLING CONVENTIONS .............................................................................................. 48 
2.5.1 
General conventions ...................................................................................................................... 48 
2.5.2 
Data handling conventions for secondary efficacy variables ......................................................... 49 
2.5.3 
Missing data ................................................................................................................................... 49 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 4 
2.5.4 
Windows for time points ................................................................................................................. 51 
2.5.5 
Unscheduled visits ......................................................................................................................... 51 
2.5.6 
Pooling of centers for statistical analyses ...................................................................................... 51 
2.5.7 
Statistical technical issues ............................................................................................................. 51 
3 
INTERIM ANALYSIS ..................................................................................................................... 52 
4 
DATABASE LOCK ........................................................................................................................ 53 
5 
SOFTWARE DOCUMENTATION ................................................................................................. 54 
6 
REFERENCES ............................................................................................................................... 55 
7 
LIST OF APPENDICES ................................................................................................................. 57 
APPENDIX A 
SUMMARY OF STATISTICAL ANALYSES ........................................................................ 58 
APPENDIX B 
TUMOR RESPONSE EVALUATION ................................................................................... 62 
APPENDIX C 
FACT-P SCORING GUIDELINES ....................................................................................... 64 
APPENDIX D 
EQ-5D-5L USER GUIDE ..................................................................................................... 67 
APPENDIX E 
WORLD HEALTH ORGANIZATION ANALGESIC LADDER FOR CANCER PAIN ............ 68 
APPENDIX F 
GMA RFACTOR FILE .......................................................................................................... 70 
APPENDIX G 
PRIOR ANTI-CANCER THERAPY TYPE CLASSIFICATION ............................................ 72 
APPENDIX H 
SPONSOR STANDARDS LLN AND ULN FOR LABORATORY PARAMETERS .............. 76 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 5 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
 
AE: 
adverse event 
ALP: 
alkaline phosphatase 
ALT: 
alanine aminotransferase 
aMDRD: 
abbreviated modification of diet in renal disease 
AR: 
androgen receptor 
AST: 
aspartate aminotransferase 
ATC: 
anatomical therapeutic chemical 
BMI: 
body mass index 
BPI-SF: 
brief pain inventory-short form 
BSA: 
body surface area  
BUN: 
blood urea nitrogen 
CBZ: 
cabazitaxel 
CI: 
confidence interval 
CR: 
complete response 
CTC: 
circulating tumor cell 
CTCAE: 
common terminology criteria for adverse events 
ECG: 
electrocardiogram 
ECOG: 
Eastern Cooperative Oncology Group 
EOT: 
end of treatment 
EWB: 
emotional well-being 
FACT-P: 
functional assessment of cancer therapy-prostate 
FST: 
first subsequent therapy 
FWB: 
functional well-being 
HIFU: 
high intensity focused ultrasound 
HLGT: 
high-level group term 
HLT: 
high-level term 
HR: 
hazard ratio 
HRQL: 
health-related quality of life  
IMP: 
investigational medicinal product 
INR: 
international normalized ratio 
ITT: 
intent-to-treat 
IVRS/IWRS: 
interactive voice/web response system 
LDH: 
lactate dehydrogenase 
LLN: 
lower limit of normal 
mCRPC: 
metastatic castration-resistant prostate cancer 
MedDRA: 
Medical Dictionary for Regulatory Activities 
PCWG2: 
prostate cancer working group criteria 2 
PD: 
progressive disease 
PR: 
partial response 
PS: 
performance status 
PSA: 
prostate-specific antigen 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 6 
PSC: 
prostate-specific concerns  
PT: 
preferred term 
PWB: 
physical well-being 
RBC: 
red blood cells 
RECIST: 
response evaluation criteria in solid tumors 
rPFS: 
radiographic progression-free survival 
SAE: 
serious adverse event 
SC: 
steering committee 
SD: 
stable disease 
SOC: 
system organ class 
SSE: 
symptomatic skeletal event 
SWB: 
social/family well-being 
TEAE: 
treatment-emergent adverse event 
TOI: 
trial outcome index  
TTPP: 
time to PSA progression 
TURP: 
transurethral resection of prostate 
ULN: 
upper limit of normal 
VAS: 
visual analogue scale 
WBC: 
white blood cell 
WHO-DD: 
World Health Organization-Drug Dictionary 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 7 
1 
OVERVIEW AND INVESTIGATIONAL PLAN   
1.1 
STUDY DESIGN AND RANDOMIZATION 
This phase IV study is prospective, multicenter, multinational, randomized, stratified, open label, 
2-parallel-group. 
After a screening phase of up to four weeks, metastatic Castration-Resistant Prostate Cancer 
(mCRPC) patients, previously treated with Docetaxel and who rapidly failed a prior Androgen 
Receptor (AR)-targeted agent (Abiraterone acetate or Enzalutamide), will be randomized by an 
Interactive Voice/Web Response System (IVRS/IWRS) in a 1:1 ratio to one of the two treatment 
groups: cabazitaxel (CBZ) at 25 mg/m² plus prednisone (or prednisolone) 10 mg daily (Arm A) 
versus either Enzalutamide at 160 mg once daily or Abiraterone acetate at 1000 mg once daily 
plus prednisone (or prednisolone) at 5 mg twice daily (Arm B).  
The randomization will be stratified by: 
 Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0-1 versus 2). 
 Time from AR targeted agent initiation to progression ([0; 6 months] versus 
]6; 12 months]).  
 Timing of AR targeted agent (before versus after Docetaxel). 
A total of 234 patients in 2 arms (117 patients per arm) are anticipated to be needed to reach the 
targeted 196 number of patients with event. This new target should be achieved for an estimated 
constant accrual rate equal to 12 until the end of the recruitment expected in June 2018. 
The study is event driven and the main cut-off date will be when 196 rPFS events have occurred. 
End of trial will occur 30 days after the last patient last cycle. Exposure and safety analyses will 
be updated at time of the final database lock. 
A steering committee (SC), including the Study Chairmen and sponsor representatives, will be 
responsible for:  
 Supervising the progress of the trial towards its overall objectives.  
 Reviewing at regular intervals relevant information that may affect the study conduct.  
A translational SC will be responsible for supervising the biomarkers part. This committee will 
include Study Chairmen’s and Sponsor’s representatives. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 8 
1.2 
OBJECTIVES 
1.2.1 Primary objectives 
The primary objective of this study is to compare CBZ plus prednisone versus either Abiraterone 
plus prednisone or Enzalutamide in term of radiographic Progression-Free Survival (rPFS) using 
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for tumor lesions and Prostate 
Cancer Working Group criteria 2 (PCWG2) criteria for bone scan lesions or death due to any 
cause in mCRPC patients who have been treated with Docetaxel and who had disease progression 
while receiving AR targeted therapy within 12 months of AR treatment initiation (≤12 months) 
(either before or after docetaxel). 
1.2.2 Secondary objectives 
Handling multiplicity issues (Section 2.4.4.3) it has been decided to proceed to a hierarchical 
procedure, providing statistical testing for the four main secondary endpoints (OS, PFS, 
Prostate-Specific Antigen [PSA] response rate and Objective tumor response) and conducting 
descriptive analysis for others secondary endpoints. 
 To compare efficacy of CBZ plus prednisone to enzalutamide or abiraterone acetate plus 
prednisone for:  
- 
Overall Survival (OS), 
- 
Progression-Free Survival (PFS), 
- 
PSA response rate, 
- 
Objective tumor response (RECIST 1.1 criteria in patients with measurable disease). 
 To compare efficacy of CBZ plus prednisone to Abiraterone acetate plus prednisone or 
Enzalutamide for : 
- 
Time to PSA Progression (TTPP), 
- 
Duration of tumor response,  
- 
Pain intensity palliation, 
- 
Time to pain progression, 
- 
Symptomatic skeletal events (SSE) rate, 
- 
Time to occurrence of SSEs. 
 To compare Health-Related Quality Of Life (HRQL) according to Functional Assessment 
of Cancer Therapy-Prostate (FACT-P) questionnaire between arms. 
 To compare Health status/utility (EQ-5D-5L) between arms. 
 To evaluate the correlation of a signature of resistance to AR targeted agents with clinical 
outcomes, via the analysis of Circulating Tumor Cells (CTC) phenotypes as well as 
expression and localization of proteins including AR isoforms in CTCs.  
The description of these analyses will be detailed in a separate Statistical Analysis Plan. 
 To evaluate safety in both treatment arms. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 9 
1.2.3 Exploratory objectives 
 
 
 
 
 
 
The description of these analyses will be detailed in a separate Statistical Analysis Plan. 
1.3 
DETERMINATION OF SAMPLE SIZE 
A power reduction from 90% to 80% has been updated in protocol amendment V4, before this 
amendment, a total of 263 patients with event were needed to achieve 90% power to demonstrate 
rPFS superiority of CBZ over abiraterone acetate/prednisone or enzalutamide by 2 sided log rank 
test at 0.05 type I error rate. 
Further assuming the accrual is at a constant rate of 18 patients per month, a total of 324 patients 
in 2 arms (162 patients per arm) are anticipated to be needed to reach the targeted number of 
patients with event. 
Sample size section, has been updated as follow: 
In post-docetaxel setting, the HR for rPFS is 0.66 [0.58-0.76] between abiraterone/prednisone and 
prednisone in COU-AA-301 (1) and 0.40 [0.35-0.47] between enzalutamide and placebo in 
AFFIRM (2).  
In pre-docetaxel setting, the HR for rPFS is 0.53 [0.45 to 0.62] between abiraterone/prednisone 
and prednisone in COU-AA-302 (3) and 0.19 [0.15-0.23] between enzalutamide and placebo in 
PREVAIL (4).  
We thus consider that a HR of 0.67 should be considered as the smallest effect of clinical interest 
between cabazitaxel and an AR-targeted agent (abiraterone or enzalutamide). 
The following table presents how such a HR translates for a variety of envisaged median rPFS in 
the abiraterone acetate or enzalutamide group (5, 6). 
Table 1 - HR translates for a variety of envisaged median rPFS in the abiraterone acetate or 
Enzalutamide group 
Hazard Ratio 
Median rPFS (month) 
Abiraterone acetate or Enzalutamide group 
Cabazitaxel group 
0.67 
4 
6.0 
0.67 
5 
7.5 
0.67 
6 
9.0 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 10 
A total of 196 patients with event is needed to achieve 80% power to demonstrate rPFS 
superiority of cabazitaxel over abiraterone acetate/prednisone or enzalutamide by 2 sided log rank 
test at 0.05 type I error rate. 
At the time of the cut-off date, when the primary analysis will be conducted, events will be 
censored in some patients either by end-of-study or by cut-off date. 
 
 
 
The observed accrual rates, that have been lower than expected, have been considered for this new 
sample size calculation using East 6.4: 
Table 2 - Accrual period 
Period 
Starting at time 
Accrual rate 
1 
Mid-November 2015 = M0 
3 
2 
Mid-October 2016 = M11 
8 
3 
Mid-February 2017 = M15 
7 
4 
Mid-August 2017 = M25 
12 
5 
Mid-December 2017 = M29  
(up to end of June 2018) 
12 
A total of 234 patients in 2 arms (117 patients per arm) are anticipated to be needed to reach the 
targeted number of patients with event. This new target should be achieved for an estimated 
constant accrual rate equal to 12 until the end of the recruitment expected in June 2018. 
1.4 
STUDY PLAN 
This study comprises three periods: 
 Screening period: up to four weeks before randomization. 
 Treatment period: it begins at the first study treatment administration within seven days 
after randomization and ends 30 days after the last treatment administration. Each patient 
will be treated until radiographic disease progression, unacceptable toxicity or patient’s 
refusal of further study treatment. Cabazitaxel will be administered intravenously every 
three weeks. The comparators will be given orally continuously but 3-week cycles are also 
defined for them. 
 Follow-up period: after study treatment's discontinuation, patients will be followed every 
12 weeks until death, cut-off date or withdrawal of patient’s consent, whichever comes 
first. During the follow-up period, all SAEs and/or adverse events (AE) related to study 
treatment and ongoing at the end of the study, or new related to study treatment AE which 
occur during the follow-up period will be collected and followed until resolution or 
stabilization of patient’s condition. Patients still on study treatment at the cut-off date can 
continue treatment until at least one treatment discontinuation criterion as defined in the 
protocol is met. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 11 
For each patient, after the screening visit, a visit per cycle is scheduled with three assessments 
(Day 01, Day 08 and Day 15) for hematology and biochemistry data collection during the 
three first cycles, an end of treatment (EOT) visit and a follow-up visit every 12 weeks until 
death, study cut-off date or withdrawal of patients’ consent.  
 
 
PD: progression disease. 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL  
The statistical section of the protocol was changed in an amendment dated on 08 November 2018. 
 The sample size was calculated based on observed and further expected accrual periods of 
recruitment and observed, further expected accrual rates, furthermore power has been 
decreased from 90% to 80% due to recruitment difficulties. 
Table 3 - Protocol amendment statistical changes 
Amendment  Number 
Date 
Approved 
Rationale 
Description of statistical 
changes 
Protocol amendment V4.0 
08-Nov-2018 
Sample size section revised due 
to recruitment difficulties 
Sample size section revised 
(see Section 1.3) 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 12 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN 
Table 4 - Statistical analysis plan statistical changes 
SAP 
version 
number 
Date 
approved 
Rationale 
Description of statistical changes 
Final 2.0 
20-Jun-2019 
Sample size section revised due to 
recruitment difficulties  
Additional important prognostic factors 
have been identified and included in the 
SAP. 
 
All sample size section following protocol 
amendment (V4.0) (see Section 1.3). 
Baseline definition clarified when assessment was 
not done prior randomization. 
Disease history and clinically relevant 
characteristics at inclusion have been updated. 
All analgesic treatments recorded in clinical 
database to be classified according to the World 
Health Organization (WHO) analgesic ladder for 
cancer pain. Based on this update, pain definition 
has been clarified. 
Type of progression at randomization classified in 
3 categories: PSA progression only (no 
radiological progression, no pain defined by BPI-
SF 0-1 and analgesic level in 0-1), radiological 
progression (± PSA progression), pain 
progression (BPI-SF>1 and/or analgesic Level 2-
3). 
Duration of first ADT has been defined. 
 
 
Some analyses planned in prior SAP 
version have been removed as not 
planned in the protocol. 
Duration in months of pain (intensity and 
interference) palliation AND Time to symptomatic 
deterioration have been removed as secondary 
endpoints were not part of protocol. 
 
 
As this analysis is not planned as per 
protocol, we’ve decided to remove this 
and it’s been replaced by subgroups 
analyses to have a whole picture of the 
impact of prognostic factors on efficacy 
outcome. 
Multivariate cox model for primary endpoint has 
been removed and replaced by subgroup 
analyses for each stratification / prognostics 
factors assessing treatment effect on primary 
endpoint. 
 
 
Due to important decrease of evaluable 
patient cycle after cycle, decision has 
been made to restrict the statistical 
analyses up to the cycles that would 
contain enough observations.  
Analyses made on quality of life questionnaires 
will be done provide up to the cycle for which at 
least 20% of evaluable patients will be reached in 
each treatment group, except end-of treatment 
evaluation that will be provided anyway. Figures 
(bar plot) have been removed. 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 13 
2 
STATISTICAL AND ANALYTICAL PROCEDURES 
2.1 
ANALYSIS ENDPOINTS 
2.1.1 Demographic and baseline characteristics 
The baseline value is generally defined as the last available value before randomization. 
Furthermore, for laboratory and vital sign assessment, the last available assessment before first 
intake will be considered as the baseline for randomized treated patients, and the last available 
assessment before randomization if patients were non-treated. 
When CTC, 
 and/or QoL evaluations were not done before randomization, baseline might 
be considered as the last assessment performed before first treatment intake. 
All baseline safety and efficacy parameters are presented along with the on-treatment summary 
statistics in the efficacy and safety sections (Section 2.4.4 and Section 2.4.5). 
Demographic characteristics 
Demographic variable is: 
 Age in years at screening (quantitative and qualitative: <65, [65-70[, [70-75[ and 
≥75 years). 
 Age (years) at prostate cancer diagnosis (quantitative). 
 Age (years) at diagnosis of metastatic disease.  
 Age (years) at diagnosis of mCRPC (Section 2.5.3 handling of mCRPC missing/partial 
dates). 
Medical or surgical history 
Medical or surgical history includes significant prior and concurrent illnesses other than primary 
prostate tumor cancer surgery. 
This information will be coded using the last version available at the time of database lock of 
Medical Dictionary for Regulatory Activities (MedDRA). 
Prior anticancer therapies 
 Prior surgery for prostatic carcinoma excluding androgen ablation: 
- 
Radical prostatectomy, 
- 
Pelvic lymphadenectomy, 
- 
Extended lymphadenectomy,  
- 
Transurethral resection of prostate (TURP),  
- 
Cryosurgery, 
- 
High Intensity Focused Ultrasound (HIFU), 
- 
Other. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 14 
 Prior surgery for androgen ablation: 
- 
Bilateral orchiectomy, 
- 
Bilateral adrenalectomy, 
- 
Hypophysectomy, 
- 
Other. 
 Radiation therapy prior treatment except radiopharmaceutical therapies: 
- 
Location (according to a code list), 
- 
Intent by location (palliative/curative), 
- 
Radiation type (internal/external). 
 Prior radical prostatectomy or prior radiotherapy of prostate for localized disease 
(ie, before date of metastatic disease). 
 Prior anticancer therapy - Docetaxel: 
- 
Number of lines (quantitative and by class 1 line, 2 lines, 3 lines and >3 lines), 
- 
Initial dosage, schedule, cumulative dose, daily Prednisone/Prednisolone, prophylactic 
G-CSF by therapy type for all docetaxel lines, 
Listings summarizing docetaxel initial dosages other than 75 mg/m² and schedules 
other than 3-weekly/bi-weekly/weekly will be provided. 
- 
Reason for discontinuation: AE, patient lost to follow-up, patient’s request, disease 
progression, completed treatment, other reason,  
- 
Best response: complete response (CR), partial response (PR), progressive disease 
(PD), stable disease (SD), not applicable/not assessed, not evaluable, unknown, 
- 
Treatment duration (months) (calculated as end date - start date + 1)/30.4375, 
- 
Time to disease progression from start date of therapy to date of radiological and/or 
symptomatic progression (months), 
- 
For last docetaxel therapy line: progression-free interval since last cycle (time from 
last cycle to radiological and/or symptomatic progression, whichever comes first):  
Progression during docetaxel treatment, 
Progression <6 months after last docetaxel cycle, 
Progression ≥6 months after last docetaxel cycle, based on end date of last line, 
- 
Number of patients treated with docetaxel for newly diagnosed metastatic 
hormone-naive prostate cancer (first cycle of docetaxel given within three months after 
starting first ADT in patients with M1 disease at diagnosis), 
- 
Number of patients treated with docetaxel for metastatic castration-resistant prostate 
cancer (first cycle of docetaxel given at the date of mCRPC diagnosis or after). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 15 
 Prior anticancer therapy - new AR-targeted agents and regimens containing Docetaxel 
excepted: 
- 
Number of prior hormonal therapies regimen (quantitative if relevant and by class 
0 line, 1 line, 2 lines, 3 lines and >3 lines), 
- 
Number of prior chemotherapy regimens other than docetaxel (by class 0 line, 1 line, 
2 lines, 3 lines and >3 lines), 
- 
Number of prior chemotherapy (docetaxel or not) (quantitative if relevant and by 
classes 0 line, 1 line, 2 lines, 3 lines and >3 lines), 
- 
Therapy type: 
Chemotherapy other than docetaxel, 
Hormonotherapy type: orchiectomy, LHRH agonist, LHRH antagonist, anti-androgen, 
oestrogens, ketoconazole, prednisone for prostate cancer (see Appendix G), 
Immunotherapy, 
Radium 223 (radium RA 223 Dichloride, radium), 
Systemic radiation,  
Other (Gene therapy, Cryotherapy, Biologicals, etc). 
 Prior anticancer therapy: novel AR targeted agents (Abiraterone or Enzalutamide) 
- 
Number of patients with Abiraterone or Enzalutamide, 
- 
Daily Prednisone/Prednisolone, 
- 
Reason for discontinuation: AE, patient lost to follow-up, patient’s request, disease 
progression, completed treatment, other reason, 
- 
Best response: CR, PR, PD, SD, not applicable/not assessed, not evaluable, unknown, 
- 
Total duration of therapy with novel AR targeted agent (months) calculated as 
end date - start date + 1)/30.4375, 
- 
Time from start date of therapy to first relapse/progression date (radiological or 
symptomatic) (months), 
- 
Time from last dose of Abiraterone or Enzalutamide to randomization (months),  
- 
Duration of first ADT (<12 months vs ≥12 months) (ie, time from first intake of ADT 
to subsequent ADT for which the duration is greater than 3months). All prior 
anti-cancer therapy, id est orchiectomy, LHRH, another hormonotherapy, or docetaxel, 
or abiraterone or enzalutamide or radium 223 will be considered to assess this 
parameter, 
If end date of ADT is missing or ADT is ongoing at time of the randomization 
(see Section 2.5.3), 
- 
Total Duration of prior ADT (months) (time from first intake of ADT to screening 
visit). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 16 
Disease characteristics at baseline 
 Initial cancer diagnosis: 
- 
Time between histological diagnosis and screening (months), 
- 
Time between metastatic disease and mCRPC (months), 
- 
Time between mCRPC and screening (months), 
- 
Presence of neuroendocrine component (Yes/No/unknown), 
- 
Total Gleason Score, in continuous and in classes (≤6, 7 and ≥8), 
- 
Staging at initial diagnostic (T, N, M), 
TNM staging according to the following 4 categories, from the best to the worst: 
Localized (T1/T2 & N0), 
Locally advanced (T3/T4 & N0), 
Node-positive (N+ & M0), 
Distant Metastases (M1), 
Unknown. 
 Disease status at study entry: 
- 
Overall criteria on which progression before study entry was diagnosed 
Rising PSA (Yes/No), 
Progression of measurable lesions (Yes/No) [1], 
Progression of non-measurable lesions (except bone) (Yes/No) [2], 
Appearance of new lesions on bone scan (Yes/No) [3], 
Total radiological progression ([1] and/or [2] and/or [3]), 
Total radiological progression and rising PSA, 
Total radiological progression without rising PSA, 
- 
BPI-SF Item 3 (0-1, 2-3, ≥4), 
- 
Consumption of analgesics at study entry (ongoing at randomization or within one 
week prior to randomization) (Section 2.5.3): 
0 (No analgesic), 
1 (mild pain = non-opioid analgesics), 
2 (mild to moderate pain = opioids for moderate pain), 
3 (severe pain = opioids for severe pain).  
 Type of progression at randomization: 
- 
Pain status at study entry (Yes, No): 
No: if BPI-SF in (0, 1) and analgesics level in (0, 1), 
Yes: if BPI-SF >1 and/or analgesics level in (2, 3), 
- 
Rising PSA only (no radiological progression and no pain) (Yes/No),   


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 17 
- 
Radiological progression (± rising PSA) and no pain (Yes/No), 
Radiological progression (with rising PSA) and no pain (Yes/No), 
Radiological progression (without rising PSA) and no pain (Yes/No). 
 Tumor assessment of target and non-target lesions at baseline: 
- 
Number of organ involved, continuous and  by classes (0, 1, 2, 3, ≥4), 
- 
Location (from tumor work-up eCFR form), 
- 
Location category see Table 5 (7). 
Any measurable disease (yes if presence of a target lesion at baseline tumor 
assessment). 
If any, a listing will be provided for other locations.  
“Visceral disease patients were, in turn, placed in one of the following three 
categories: any patient with liver metastases was categorized as having liver 
metastases even if they had other metastatic sites; patients with lung metastases were 
denoted as having lung metastases, unless they also had liver metastases; and all other 
patients with visceral disease were categorized as having nonhepatic, nonpulmonary 
visceral metastases (such as adrenal, kidney, and others). In the nonvisceral disease 
group, patients were classified as either having LN-only disease or bone metastases 
with or without nodal involvement.” (7). 
Table 5 - Classification of site of Metastases by mutually exclusive categories 
Sites of Metastases 
Presence of LNa 
Metastasesb 
Presence of Bone 
Metastasesc 
Presence of Visceral 
Metastasesd 
Category 
LN only 
Yes 
No 
No 
LN 
Bone only 
No 
Yes 
No 
Bone 
Bone with LN involvement 
Yes 
Yes 
No 
Bone 
Lung 
No/Yes 
No 
Yes 
Lung 
Lung 
No/Yes 
Yes 
Yes 
Lung 
Liver 
No/Yes 
No 
Yes 
Liver 
Liver 
No/Yes 
Yes 
Yes 
Liver 
a Abbreviation: LN, Lymph node. 
b Presence of LN Metastases defined as Yes for lesion location is Lymph nodes (target and non-target at baseline). 
c Presence of Bone Metastases defined as Yes for Lesion Location Bone. 
d Presence of Visceral Metastases defined as Yes for all lesions location except LN and Bone (target and non-target at baseline). 
 Tumor markers 
- 
Inclusion PSA (ug/L) value (ie, the last value measured within eight days prior to 
randomization if collected, or last PSA value prior first IMP administration if not 
collected prior randomization), 
- 
Baseline Testosterone (quantitative and <median, ≥median),  
- 
Baseline hemoglobin (quantitative and <median, ≥median), 
- 
Baseline LDH (quantitative and >ULN, and <median, ≥median), 
- 
Baseline Alkaline phosphatase (quantitative, >ULN, and <median, ≥median), 
- 
Baseline Neutrophil to lymphocyte ratio (quantitative and <median, ≥median), 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 18 
- 
Neutrophils (quantitative and <median , ≥median), 
- 
Lymphocytes count (quantitative and <median , ≥median), 
- 
Grade ≥3 neutropenia, n(%). 
 Symptomatic Skeletal Event (SSE) evaluation at baseline 
- 
Total number of patients with SSE, 
- 
Number of patients with an occurrence of new symptomatic pathological fracture,  
- 
Number of patients with use of external beam radiation to relieve bone pain,  
- 
Number of patients with an occurrence of spinal cord compression,  
- 
Number of patients with tumor -related orthopaedic surgical intervention.  
The SSE is given in the SSE evaluation CRF page. 
 Brief Pain Inventory-Short Form (BPI-SF) (questionnaire): 
- 
Pain intensity = worst pain intensity in the last 24 hours (ie, Item 3 of the 
questionnaire: “pain at its worst”, quantitative) (8), 
- 
Item “pain at its least” (Item 4), 
- 
Item “pain at its average” (Item 5), 
- 
Item “pain at its current” (Item 6), 
- 
Mean severity score = mean of the four item above if at least two of them are not 
missing, 
- 
Pain interference = mean of the seven answers of the ninth item of questionnaire if at 
least four answers among seven are not missing. 
 EQ-5D-5L: 
- 
5 Dimensions (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression), 
- 
Global utility index score, 
- 
The EQ Visual Analogue Scale (VAS). 
 Functional Assessment of Cancer Therapy-Prostate (FACT-P): 
- 
5 Subscales of the FACT-P:  
Physical well-being (PWB), social/family well-being (SWB), emotional well-being 
(EWB), functional well-being (FWB), prostate-specific concerns (PSC),  
- 
HRQL assessed using the FACT-P Total score which combines the PWB (7 items), 
SWB (7 items), EWB (6 items), FWB (7 items), and prostate cancer scale/prostate 
specific concerns (12 items),  
- 
Additional HRQL summary scores include the FACT-G Total 
(PWB + SWB + EWB + FWB), the FACT-P Trial Outcome Index (TOI) 
(PWB + FWB + PSC) and the Pain PCS (4 items, P1-P3, GP4). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 19 
Vital signs  
Vital signs at baseline (before first study product intake, or before randomization for non-treated 
patients) are: 
 Weight (kg).  
 Height (cm). 
 BMI (kg/m2) and OMS classes (Underweight <18.5; Normal weight [18.5 to 25[; 
Pre-obesity [25.0 to 30[; Obesity class I [30.0 to 35[; Obesity class II [35.0 to 40[; 
Obesity class III >=40). 
 Body surface area (BSA) (m2). 
 Blood pressure (systolic and diastolic in mmHg). 
 Heart rate (bpm). 
 ECOG PS (0, 1, 2, 3, 4). 
Technical details related to computation, dates and imputation for missing dates are described in 
Section 2.5. 
2.1.2 Prior or concomitant medications (other than anticancer therapies) 
All medications taken within 28 days before randomization or at any time during the study and up 
to 30 days after the end of study treatment are to be reported in the CRF pages. 
All medications will be coded using the last version available at the time of database lock of 
World Health Organization-Drug Dictionary (WHO-DD).  
 Prior medications are those the patient used prior to first investigational medicinal product 
(IMP) administration. Prior medications can be discontinued before first administration or 
can be ongoing during treatment period. 
 Concomitant medications are any treatments received by the patient concomitantly to the 
IMP from randomization to the EOT + 30 days. A given medication can be classified both 
as a prior medication and as a concomitant medication. Concomitant medications do not 
include medications started during the post-treatment period (as defined in the observation 
period in Section 2.1.4). 
 Post-treatment medications are those taken by the patient in the period running from the 
day after last IMP administration up to the end of the study. 
Technical details related to computation, dates or imputation for missing dates are described in 
Section 2.5. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 20 
2.1.3 Efficacy endpoints 
2.1.3.1 Primary efficacy endpoint(s) 
The primary efficacy variable will be the rPFS defined as the time in months from randomization 
to the occurrence of one of the following events: 
 Radiological tumor progression using RECIST 1.1 (see Appendix B) except for lymph 
nodes: if lymph node metastasis is the only evidence of metastasis at baseline, it must be 
≥20 mm in diameter when measured by spiral CT or MRI (as defined by PCWG2). 
 Progression of bone lesions according to  PCWG2 criteria: 
- 
The first bone scan with ≥2 new lesions compared to baseline is observed <12 weeks 
from randomization and is confirmed by a second bone scan performed ≥6 weeks later 
and showing ≥2 additional new lesions compared to previous  bone scan (a total of 
≥4 new lesions compared to baseline), 
- 
The first bone scan with ≥2 new lesions compared to baseline is observed ≥12 weeks 
from randomization and the new lesions are verified on the next bone scan ≥6 weeks 
later (a total of ≥2 new lesions compared to baseline).  
 Death due to any cause from death CRF page. 
2.1.3.2 Secondary efficacy endpoint(s) 
2.1.3.2.1 Primary secondary efficacy endpoint(s) 
Primary secondary efficacy variables will be: 
 OS defined as the time interval from the date of randomization to the date of death due to 
any cause in months. In the absence of confirmation of death, survival time will be 
censored at the last date patient is known to be alive or at the cut-off date, whichever 
comes first. 
In case of incomplete date of death, the following rules will be applied to derive time-to 
death in OS: 
- 
If the day of death date is missing, it will be imputed to the first day of the month, 
except if the date of patient’s last contact is the same month as death date. In this case, 
the death date will be imputed to the date of last contact + 1 day, 
- 
If the day and month of death date are missing, no imputation will be performed. 
Patient’s last contact date will be defined as the latest date corresponding to a 
follow-up update with survival status “alive” or the latest date of any of the following 
panels: investigational product administration, laboratory data, PSA assessment, tumor 
assessment, AE (use New AE start date), and vital signs, whichever comes last, 
- 
If date of last contact is not available after randomization, then the patient will be 
censored for OS to the day of randomization (Day 1). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 21 
 PFS defined as the time interval between the date of randomization and the date of the first 
documentation of any of the following events in months:  
- 
Radiological tumor progression by RECIST 1.1 (see Section 2.1.3.1) except for lymph 
nodes: if lymph node metastasis is the only evidence of metastasis at baseline, it must 
be ≥20 mm in diameter when measured by spiral CT or MRI (as defined by PCWG2), 
- 
Progression of bone lesions using PCWG2 criteria (see Section 2.1.3.1), 
- 
Symptomatic progression defined as:  
Occurrence of urinary or bowel symptoms related to prostate cancer,  
Need to change anticancer therapy (most commonly need to administer radiation 
therapy for palliation of an osseous or epidural lesion), 
- 
Pain intensity progression defined as an increase ≥30% from baseline in the BPI-SF 
(8) pain intensity score (Item 3) observed at two consecutive evaluations ≥3 weeks 
apart without decrease in analgesic usage score (defined as a ≥1 point decrease on the 
WHO analgesic scale), 
World health organization (WHO) analgesic ladder step calculated using the collected 
analgesic medication (see Section 2.5.1, and the Appendix E).  
Either criterion has to be maintained for two consecutive evaluations at least 
three weeks apart.  
Early rise in pain (within the first 12 weeks) only indicates progression if it is 
associated with another sign of disease progression or if it continues beyond 12 weeks. 
Progression will only be dated prior to 12 weeks if there is continued increase in PSA 
beyond that time point or if it was associated with another sign of disease progression. 
- 
Death due to any cause from the death CRF page. 
Patient’s last contact date is the latest date corresponding to a follow-up update with 
survival status “alive” or the latest date of any of the following panels: investigational 
product administration, laboratory data, PSA assessment, tumor assessment, AE (use 
New AE start date), and vital signs, whichever comes last. 
If death or progression is not observed, the patient will be censored at the date of last 
valid tumor assessment (TA) without evidence of progression (meaning with OR equal 
to CR/PR/SD but not NE) or the study cut-off date whichever comes first, regardless 
of other antitumor therapies. 
 Objective tumor response, in patients with measurable disease, defined as either PR or CR 
according to the RECIST 1.1 criteria (see Section 2.1.3.1).  
 PSA endpoints: For each patient, PSA will be assessed at baseline, every 3 weeks during 
study treatment, and in case of study treatment discontinuation without PSA progression 
every 12 weeks until the end of the first further anticancer therapy if any or study cut-off, 
whichever comes first:  
- 
PSA response is defined as a reduction from baseline PSA level of at least 50%, 
confirmed at least three weeks later. It will be calculated among patients with a 
baseline PSA ≥2 ng/mL. Increases (of any magnitude) in PSA during the first 
12 weeks should be ignored in determining PSA response. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 22 
2.1.3.2.2 Other secondary efficacy endpoint(s) 
Other secondary efficacy variables will be: 
 Time to PSA progression defined as the time interval between the date of randomization 
and the date of first documented PSA progression in months.  
PSA progression is defined as follows (9):  
- 
If any decline from baseline: record time from start of therapy to first PSA increase 
that is ≥25% and ≥2 ng/mL above the nadir, and which is confirmed by a second value 
3 or more weeks later (ie, a confirmed rising trend),  
- 
If no decline from baseline: PCWG2 defines PSA progression as PSA progression 
≥25% and 2 ng/mL after 12 weeks.  
Early increase in PSA within 12 weeks, when followed by subsequent decline, is 
ignored in determining this endpoint. Early rise in PSA only indicates progression if it 
is associated with another sign of disease progression or if it continues beyond 
12 weeks. Progression will only be dated prior to 12 weeks if there is continued 
increase in PSA beyond that time point or if it is associated with another sign of 
disease progression. 
 Duration of tumor response, defined as the time between the first evaluation at which 
the tumor response criteria are met (PR or CR as per RECIST 1.1 criteria) and the 
first documentation of tumor progression or death in months. 
 Pain intensity and pain interference endpoints 
Pain scores will be assessed in all patients at baseline, before each cycle, at the EOT and 
then every 12 weeks until disease progression, start of another anticancer therapy or study 
cut-off, whichever comes first. 
- 
Pain response (ie, pain intensity palliation evaluable for i/ patients with pain intensity 
not nul at baseline and analgesic not missing, ii/ patients with pain intensity nul and 
analgesic not missing nor nul) defined as a decrease by at least 30% from baseline in 
the average of BPI-SF pain intensity score observed at two consecutive evaluations 
≥3 weeks apart without increase in analgesic usage score (defined as an increase 
≥1 point on the WHO analgesic score) (10),  
Number of patients evaluable and not evaluable (no pain at baseline and no analgesic 
used), will be summarized by treatment group.  
Increases in pain during the first 12 weeks should be ignored in determining pain 
response. 
- 
Pain intensity progression (see definition in PFS endpoint), 
- 
Pain interference palliation: mean pain interference score (ie, the mean of the scores 
for the pain interference items) decreased by 1.25 points or more compared with 
baseline at two consecutive follow-up visits, 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 23 
- 
Pain interference progression: increase of 1.25 points or more in the mean pain 
interference score at two consecutive follow-up visits, 
Either criterion has to be maintained for two consecutive evaluations at least 3 weeks 
apart.  
For all analyses, we will judge non-consecutive visits to be consecutive when scores 
for intervening visits are missing. All patients will be assessed for pain intensity and 
pain interference progression, but only patients with clinically significant pain at 
baseline and at least one post-baseline pain score will be assessed for palliation. For 
the purpose of the pain intensity analyses, we will define clinically significant baseline 
pain as a score of 4 or more on pain intensity scale and, for the pain interference 
analyses, as a mean score of 4 or more on the pain interference scale. 
 Time to pain progression defined as the time interval between the date of randomization 
and the date of the first documented pain progression in months.  
Pain progression, in patients with no pain or stable pain at baseline, is defined as: 
- 
An increase by ≥30% from baseline in the BPI-SF pain intensity score observed at 
2 consecutive evaluations ≥3 weeks apart without decrease in analgesic usage score 
OR increase in analgesic usage score defined as an increase ≥1 point on the WHO 
analgesic score (see Section 2.5.1, and the Appendix E): 
Either criterion has to be maintained for two consecutive evaluations at least 3 weeks 
apart.  
Early rise in pain (within the first 12 weeks) only indicates progression if it is 
associated with another sign of disease progression or if it continues beyond 12 weeks. 
Progression will only be dated prior to 12 weeks if there is continued increase in pain 
beyond that time point or if it was associated with another sign of disease progression.  
In the absence of pain progression at the time of analysis patients will be censored on 
the last known date the patient was known to have not progressed or at the cut-off date, 
whichever comes first. Subjects with no on-study assessment or no baseline 
assessment will be censored at date of randomization. 
 Symptomatic Skeletal Event (SSE) endpoints (see Section 2.1.1): 
- 
Time to first SSE defined as the time interval between the date of randomization and 
the date of the occurrence of the first event defining a SSE in months. For each patient, 
SSE will be assessed at baseline, every three weeks during study treatment, at the 
EOT Visit and every 12 weeks during follow-up until occurrence of first SSE or study 
cut-off, whichever comes first.  
 Evaluation of the correlation of a signature of resistance to AR targeted agents with 
clinical outcomes, via the analysis of CTCs counts and phenotypes as well as expression 
and localization of proteins including AR isoforms in CTCs.  


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 24 
2.1.4 Safety endpoints 
The safety analysis will be based on the reported AEs including death and other safety 
information, such as clinical laboratory data, vital signs and Electrocardiogram (ECG). 
Observation period  
The observation period will be divided into three epochs: 
 The screening epoch is defined as the time from the signed informed consent date up to 
first administration of the IMP. 
 The treatment-emergent adverse event (TEAE) epoch is defined as the time from the 
date of first administration of the IMP to the date of last administration of the 
IMP + 30 days. 
 The post-treatment epoch is defined as the period of time starting the day after the end of 
the TEAE period up to the end of the study (defined as last protocol-planned visit, or death 
or the resolution/stabilization of all serious adverse events (SAE), related AEs and AEs 
with overdose). 
The on-study observation period is defined as the time from the first study treatment 
administration until the end of the study (defined as last protocol-planned visit or the 
resolution/stabilization of all SAEs, related AEs and AEs with overdose. 
2.1.4.1 Adverse events variables 
Adverse event observation period  
 Pre-treatment AEs are any AE reported from the signed informed consent date up to the 
day before the first administration of IMP. 
 Treatment-emergent AEs (TEAEs) are defined as any AE that is new, gets worse, or 
becomes serious during the treatment period. 
 Post-treatment AEs are AEs reported during the post-treatment period. 
All AEs (including SAEs and AEs with overdose) will be coded to a lower-level term (LLT), 
preferred term (PT), high-level term (HLT), high-level group term (HLGT) and associated 
primary system organ class (SOC) using the last version of MedDRA at the time of database lock. 
Record the occurrence of AEs from the time of signed informed consent until the end of the study. 
AEs with pre specified monitoring include overdose: 
An overdose with the IP is an event suspected by the Investigator or spontaneously notified by the 
patient (not based on systematic pills count) and defined as increase of at least 30% of the highest 
dose of CBZ (ie, 30% of 25 mg/m²) to be administered. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 25 
2.1.4.2 Deaths 
The deaths observation period are per the observation periods defined above.  
 Death on-study: deaths occurring during the on-study observation period. 
 Death on-treatment: deaths occurring during the TEAE period.  
 Death post-treatment: deaths occurring 30 days after the last dose of treatment.  
2.1.4.3 Laboratory safety variables 
Clinical laboratory data consists of blood analysis, including hematology, clinical chemistry, 
endocrinological, tumor markers and dipstick urinalysis. Clinical laboratory values after 
conversion will be analyzed into standard international units and international units will be used in 
all listings and tables. 
Blood samples for clinical laboratories will be taken within eight days prior Day 1 Cycle 1, 
weekly (D8 and D15) during the first three cycles (±1 day window is allowed for hematology) and 
then within further cycles in case of fever or infection. 
The laboratory parameters will be classified as follows:  
 Hematology  
- 
Red blood cells (RBC) and platelets and coagulation: hemoglobin (g/dL), platelet 
count (109/L), international normalized ratio (INR),  
- 
White blood cells (WBC): leucocytes (109/L), neutrophils (109/L), lymphocytes 
(109/L), monocytes (109/L), basophils (109/L), eosinophils (109/L). 
 When expressed in %, all parameters derived from WBC will be converted in Giga/l 
(see Section 2.5.1). Clinical chemistry:  
- 
Metabolism: glucose (mmol/L), total protein (g/L), albumin (g/L), 
- 
Electrolytes: sodium (mmol/L), potassium (mmol/L), calcium (mmol/L), phosphorus 
(mmol/L), magnesium (mmol/L),  
- 
Renal function: creatinine (µmol/L), urea (mmol/L, mg/dl, umol/L, other) or blood 
urea nitrogen (BUN) (mmol/L), CrCl categories (mL/min/1.73m²) (Section 2.4.5.5), 
- 
Liver function: alanine aminotransferase (ALT) (IU/L), aspartate aminotransferase 
(AST) (IU/L), alkaline phosphatase (ALP) (IU/L), lactate dehydrogenase (LDH) 
(IU/L), total bilirubin (µmol/L). 
 Endocrinological: Chromogranin A (g/L), testosterone (ng/mL) at baseline. 
 Tumor markers: 
- 
NLR Neutrophils Lymphocyte Ratio (NLR), evaluation of the influence of NLR 
(<median, ≥median), neutrophilia (neutrophil count ≥median)  and 
grade ≥3 neutropenia on outcome and evaluation of NLR, 
- 
Changes during treatment period, 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 26 
- 
Hb <median, ≥median at baseline, 
- 
LDH>ULN at baseline, 
- 
Alkaline phosphatase >ULN at baseline. 
Technical formulas are described in Section 2.5.1. 
2.1.4.4 Vital signs variables 
Vital signs include: heart rate (bpm), systolic and diastolic blood pressure (mmHg), weight (kg), 
BMI (kg/m²), BSA (m²) and ECOG PS when post baseline assessments are available. 
2.1.4.5 Electrocardiogram variables 
ECGs will be recorded automatically by the device at the investigator site. ECG results (normal, 
abnormal and if abnormal clinically significant or not) will be collected within eight days before 
randomization and at the EOT Visit only if clinically indicated or cardiac event during the 
treatment period. 
2.1.4.6 Other safety endpoints 
Not applicable. 
2.1.5 Pharmacokinetic variables  
Not applicable. 
2.1.6 Pharmacodynamic/genomics endpoints 
Not applicable. 
2.1.7 Quality-of-life endpoints  
 Health-related quality of life (HRQL) evaluation will be performed using the FACT-P 
questionnaire (Version 4), a disease-specific instrument that measures the concerns of 
patients with prostate cancer. 
The FACT-P will be assessed 3 days prior to the first study treatment, on the first day of 
each cycle prior to treatment administration, at the EOT and every 12 weeks during the 
follow-up period until disease progression, the start of another anticancer therapy or study 
cut off, whichever comes first. 
The FACT-P consists of the FACT-G 4 general/core domains/subscales (11) plus 
1 prostate specific domain/subscale (12). 
Each item is rated on a 0 to 4 Likert type scale (0 = Not at all, 1 = A little bit, 
2 = Somewhat, 3 = Quite a bit, 4 = Very much). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 27 
The FACT-P is summed from 39 items to give a total score in the range of 0-156, where 
higher values represent better HRQL. To achieve this, the FACT-P scoring guide 
(Appendix C) identifies those items which must be reversed before being added to obtain 
subscale totals. Negatively stated items are reversed by subtracting the response from “4” 
(ie, 4 - item score). After reversing proper items, all subscale items are summed to a total, 
which is the subscale score. 
The MCID has been proposed as the ‘smallest difference in score in the domain of interest 
which patients perceive as beneficial and which would mandate, in the absence of 
troublesome side effects and excessive cost, a change in the patient’s management’ (13). 
 The 5 subscales of the FACT-P with their corresponding MCID’s are as follows (11): 
- 
physical well-being: 7 questions (Items GP1 to GP7);  range 0-28, MCID = 3, 
- 
social/family well-being: 7 questions (Items GS1 to GS7): range = 0-28;  MCID = 3,  
- 
emotional well-being: 6 questions (Items GE1 to GE6): range = 0-24;  MCID = 3,  
- 
functional well-being: 7 questions (Items GF1 to GF7): range = 0-28;  MCID = 3,  
- 
prostate-specific concerns: 12 questions (Items C2, C6, P1, P2, P3, P4, P5, P6, P7, 
BL2, P8 and BL5): range = 0-48;  MCID = 3. 
Scoring details on the FACT-P can be found in Section 2.4.7.  
HRQL will be assessed using the FACT-P Total score which combines the PWB (7 items), 
SWB (7 items), EWB (6 items), FWB (7 items), and prostate cancer scale/prostate specific 
concerns (12 items). 
Additional HRQL summary scores include the FACT-G Total 
(PWB + SWB + EWB + FWB), the FACT-P TOI (PWB + FWB + PSC) and the Pain PCS 
(4 items, P1-P3, GP4). 
 Health status will be evaluate using EuroQol Group 5-Dimension, 5-Level (EQ-5D-5L) 
questionnaire.  
The EQ-5D-5L is a standardized HRQL questionnaire that provides a simple, generic 
measure of health for clinical and economic appraisal (EuroQol 1990).  
The EQ-5D-5L will be evaluated within 3 days before Randomization, on the first day of 
each cycle prior to treatment administration, at the EOT Visit and every 12 weeks during 
the follow-up period until disease progression, start of another anticancer therapy or study 
cut-off, whichever comes first (see Appendix D). 
The EQ-5D-5L consists of 5 dimensions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) is rated from 1 to 5 likert scale where 
1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 
5 = extreme problems (14). A global utility index score will be calculated per EQ-5D 
utility index scoring in Section 2.4.7. 
The EQ VAS will record the respondent’s self-rated health on a 20 cm vertical, VAS with 
endpoints labelled ‘the best health you can imagine’ and ‘the worst health you can 
imagine’. This information can be used as a quantitative measure of health as judged by 
the individual respondents 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 28 
2.1.8 Health economic endpoints  
Not applicable. 
2.1.9 Further therapy after discontinuation of investigational medicinal product 
administration during the study 
Further therapies after discontinuation of IMP include chemotherapy, hormonotherapy, gene 
therapy, immunotherapy, cryotherapy, biologicals, systemic radiation, surgery for prostate cancer 
etc. (see Section 2.4.8). 
2.1.10 Other endpoints 
Additional exploratory collaborative endpoints will be detailed in a dedicated separate SAP. 
2.2 
DISPOSITION OF PATIENTS 
This section describes patient disposition for both patient study status and the patient analysis 
populations. 
Screened patients are defined as patients with a date of screening visit and a signed informed 
consent.  
Randomized patients consist of all patients with a signed informed consent form who have had a 
treatment kit number allocated and recorded in the IVRS/IWRS database, regardless of whether 
the treatment kit was used. 
For patient study status, the total number of patients in each one of the following categories will 
be presented in the clinical study report using a summary table: 
 Screened patients. 
 Nonrandomized but treated patients. 
 Randomized patients before protocol amendment.  
 Randomized patients after protocol amendment. 
 Randomized patients by stratification factors distribution: 
- 
ECOG PS (0-1 versus 2), 
- 
Time from AR targeted agent initiation to progression ([0; 6 months] versus 
]6; 12 months],  
- 
Timing of AR targeted agent (before versus after docetaxel).  
 Distribution of randomized patients across the 8 level of strata combinations. 
 Randomized but not treated patients. 
 Randomized and treated patients. 
 Patients still on treatment (ie, patients who did not discontinue study treatment). 
 Patients who discontinued study treatment by main reason for permanent treatment 
discontinuation. 
 Status at last study contact. 
 Main Reason for Stopping Study.  


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 29 
For all categories of patients (except for the screened and nonrandomized categories) percentages 
will be calculated using the number of randomized patients as denominator. Reasons for treatment 
discontinuation will be supplied in tables giving numbers and percentages by treatment group. In 
addition, all categories of randomized patients will be split by stratification factors. 
Number of screened patients, randomized patients, treated patients and patients who discontinued 
study treatment will be displayed by country and by site. 
A listing of other reason for permanent study treatment discontinuation will also be provided. 
All critical or major deviations potentially impacting efficacy analyses, randomization and 
drug-dispensing irregularities and other major or critical deviations will be summarized in tables 
giving numbers and percentages of deviations by treatment group. Listings for critical or major 
deviations will be provided. 
Additionally, the analyzed populations for safety and efficacy will be summarized in a table by 
number of patients on the randomized population. 
Efficacy population: intent-to-treat (ITT) population and evaluable populations (see Section 2.3.1) 
and health related quality of life population and health status population (see Section 2.3.3). 
Safety population: see Section 2.3.2.  
2.2.1 Randomization and drug dispensing irregularities 
Randomization and drug-dispensing irregularities occur whenever: 
 A randomization is not in accordance with the protocol-defined randomization method, 
such as a) an ineligible patient is randomized, b) a patient is randomized based on an 
incorrect stratum, c) a patient is randomized twice. 
OR 
 A patient is dispensed an IMP kit not allocated by the protocol-defined randomization, 
such as a) a patient at any time in the study is dispensed a different treatment kit than as 
randomized (which may or may not contain the correct-as-randomized IMP), or b) a 
non-randomized patient is treated with IMP reserved for randomized patients. 
Randomization and drug-dispensing irregularities will be monitored throughout the study and 
reviewed on an ongoing basis. 
All randomization and drug-dispensing irregularities will be documented in the clinical study 
report. If the number of irregularities is large enough to make a tabular summary useful, the 
irregularities will be categorized and summarized among randomized patients (number and 
percentages). Non randomized and treated patients will be described separately. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 30 
Randomization and drug-dispensing irregularities to be prospectively identified include but are 
not limited to: 
 
Randomization and drug allocation irregularities 
Kit dispensation without IVRS transaction 
Erroneous kit dispensation 
Kit not available 
Randomization by error 
Patient randomized twice 
Stratification error 
Patient switched to another site 
2.3 
ANALYSIS POPULATIONS 
Patients treated without being randomized will not be considered randomized and will not be 
included in any efficacy population.   
Patients allocated outside the IVRS/IWRS, who are dispensed at the first call study drug without 
calling the IRT or before calling the IRT, are considered nonrandomized patients.  They are 
excluded from any population for analysis, including safety.  However, if these patients 
experienced any significant safety event, they should be documented separately in the clinical 
study report. 
The randomized population includes any patient who has been allocated to a randomized 
treatment regardless of whether the treatment kit was used. 
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population. The safety experience associated with any later 
randomization will be assessed separately. 
The safety experience of patients treated and not randomized will be reported separately and these 
patients will not be in the safety population. 
2.3.1 Efficacy populations 
2.3.1.1 Intent–to-treat population 
The primary efficacy analysis population will be the ITT population, as defined in the protocol. 
The ITT population is the randomized population analyzed according to the treatment group 
allocated by randomization. 
2.3.1.2 Per-protocol population 
Not applicable. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 31 
2.3.1.3 Other efficacy population 
The following evaluable patient populations are defined for some selected efficacy endpoints. 
 Tumor response will be evaluated in patients with measurable disease at baseline (defined 
by the presence of at least one measurable target lesion at baseline), with at least one 
post baseline assessment.  
 PSA response will be evaluated in patients with PSA level of at least 2 ng/mL at baseline, 
with at least two post-baseline assessments separated by at least 3 weeks.  
 PSA response on first subsequent therapy (FST) will be evaluated in patients with 
PSA level of at least 2 ng/mL before the first further therapy intake, with at least 
one assessment during the first subsequent therapy administration (15). 
 Duration of first subsequent therapy will be evaluated in patients with a FST. 
 Pain response will be evaluated in patients using BPI-SF score and WHO Analgesic 
Ladder at baseline, with at least one post baseline assessment.  
Those populations are subsets of the ITT population and patients are considered in the group “as 
randomized”. 
2.3.2 Safety population 
This population includes all randomized patients who received at least one of the study drugs 
(CBZ, or Abiraterone or Enzalutamide). This population is for all safety analyses. All analyses 
using this population will be based on the treatment actually received (ie, “as treated”).  
In addition: 
 Non randomized but treated patients will not be part of the safety population; however, 
their safety data will be presented separately. 
 Randomized patients for whom it is unclear whether they took the IMP will be included in 
the safety population as randomized. 
 For patients receiving more than one study treatment during the trial, patients will belong 
to the first treatment group and observation of AEs will be followed till 30 days of last 
dose of that treatment or start date of second treatment, whichever starts earlier. 
2.3.3 Other analysis population (Health related Quality of Life and Health status 
population) 
The health related quality of life population based on the ITT population, taking into account 
patients who have at least one evaluable subscale of FACT-P questionnaire at baseline and at least 
one post baseline evaluable FACT-P.  
The health status population is based on the ITT population, taking into account patients who have 
at least one evaluable utility index of EQ-5D-5L at baseline and with at least one post-baseline 
evaluable EQ-5D-5L. 
Those populations are a subset of the ITT population, and patients are considered in the group “as 
randomized”. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 32 
2.4 
STATISTICAL METHODS 
2.4.1 Demographics and baseline characteristics 
Standard demographic and baseline characteristics (including age), medical history, disease 
characteristics at baseline and prior anticancer therapy will be collected at baseline. Baseline 
efficacy variables, eg, tumor assessment, pain, PSA, and other prognostic variables will be 
assessed as well. Baseline value defined see Section 2.1.1. 
Continuous data will be summarized using the number of available data, mean, standard 
deviation, median, Q1, Q3, minimum, maximum and missing data for each treatment group. 
Categorical and ordinal data will be summarized using the number and percentage of patients in 
each treatment group.  
Parameters will be summarized on the ITT. Analyses for the safety population will be included in 
the appendices if the size of the safety population is different (>10%) from the size of that in the 
ITT population for any treatment group. 
Parameters described in Section 2.1.1 will be summarized by treatment group and overall 
treatment groups using descriptive statistics. 
Medical and surgical history at baseline will be presented by descriptive statistics on patients of 
the safety population (number and percentage of patients having a given medical or surgical 
history). 
2.4.2 Prior or concomitant medications (other than anticancer therapies) 
The prior and concomitant medications will be presented for the ITT population.  
Medications will be summarized by treatment group according to the WHO-DD dictionary, 
considering the first digit of the Anatomical Therapeutic Chemical (ATC) (anatomic category) 
and the first three digits of the ATC class (therapeutic category). All ATC codes corresponding to 
a medication will be summarized and patients will be counted once in each ATC category 
(anatomic or therapeutic) linked to the medication. Therefore patients may be counted several 
times for the same medication.  
The table for prior, concomitant and post-treatment medications will be sorted by decreasing 
frequency of ATC followed by all other therapeutic classes based on the overall incidence across 
treatment groups. In case of equal frequencies regarding ATCs (anatomic or therapeutic 
categories), alphabetical order will be used. 
2.4.3 Extent of investigational medicinal product exposure and compliance  
The extent of IMP exposure and dose information will be assessed and summarized by actual 
treatment within the safety population (see Section 2.3.2). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 33 
2.4.3.1 Extent of investigational medicinal product exposure 
The extent of exposure will be assessed by the duration of exposure within the safety population. 
The number of patients treated, number of cycles administered, duration of dosing (weeks), 
cumulative dose (mg/m²), dose intensity (mg/m²/week) and relative dose intensity (%) will be 
presented by treatment group.  
Duration of exposure is defined as: 
 Last dose date - first dose date + 21 days for cabazitaxel. 
 Last dose date - first dose date + 1 day for abiraterone or enzalutamide.  
Regardless of unplanned intermittent discontinuations (see Section 2.5.3 for calculation in 
case of missing or incomplete data). The first and the last study administration is any dose 
of first and last administration of CBZ or AR-target agent (abiraterone or enzalutamide). 
The overall extent of exposure will be assessed for each patient as by using Total number of 
cycles (K), determined by the longest duration of each individual drug. 
The duration of treatment exposure (weeks) and number of cycles will also be provided for the 
two subsets of patients below:  
 Patients without any first subsequent therapy, OR with a first subsequent therapy and 
without any PSA assessment during the first subsequent therapy. 
 Patients with any first subsequent therapy and with evaluable PSA during the first 
subsequent therapy. 
The average (%) of cycles with G-CSF prophylaxis during the whole treatment exposure and the 
number of patients receiving G-CSF as curative intent during treatment exposure n(%) will be 
summarized by treatment group. 
If any G-CSF used as curative intent, number of patients with G-CSF used as curative for 
neutropenia (and/or neutrophil blood decrease) and number of patients with G-CSF used as 
curative for Febrile neutropenia or neutropenic infection will be summarized by treatment group if 
at least 10% of safety population, otherwise a listing will be provided. 
For CBZ arm: 
Dose information will be assessed by the following variables: 
 The actual dose received (mg/m²) by cycle is defined as (actual dose [mg] collected in the 
CRF/BSA [m²]). 
 Cumulative dose (mg/m²): the cumulative dose for a time period (a given cycle or during 
the study) is the sum of all “actual” doses received during this time period. 
 Overall duration of dosing (weeks) is defined as (last IMP administration - first IMP 
administration + 21)/7.  
 The actual dose intensity (ADI) (mg/m²/3 weeks) is defined as the cumulative dose during 
the study divided by overall duration of dosing multiplied by 3. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 34 
 The relative dose intensity (RDI) (%) is defined as the ratio of the ADI to the planned dose 
intensity. The planned dose intensity (mg/m²/3 weeks) is defined as (theoretical dose of 
25 mg/m² x number of cycles x 3 / overall duration of dosing). 
 Dose reduction: a patient with dose reduction is defined as a patient received less than 
about 80% of the original planned study drug dose level at any administration of any 
cycle. Dose reduction event at a cycle will be derived by using the definition provided in 
Table 6. The original planned study drug dose level is taken from the planned dose level at 
Cycle 1 and will be compared with actual received dose for dose reduction event at 
Cycle 1. For the second and subsequent cycles, a dose is deemed to have been reduced if 
the dose level a patient receives is lower than the previous actual dose level. 
There are two reductions allowed for CBZ. 
Table 6 - Cabazitaxel dose reduction levels 
Actual dose level 
Corresponding dose 
level (mg/m²) 
Dose limits 
Over dose 
>32.5 
>32.5 
Upper dose 
NA 
NA 
Planned dose 
25 
≥21.25 to <32.5 
Reduced dose Level 1 
20 
≥16 to <21.25 
Reduced dose Level 2 
15 
≥12.75 to <16 
Reduced dose Level 3 
12 
≥9.6 to <12.75 
Low dose 
<12 
>0 to <9.6 
No dose administered 
0 
0 
 Dose delays: A cycle is deemed to have been delayed if (start date of the current 
cycle - start date of previous cycle) - 21>3 days. 
 Dose interruption: if dose is interrupted for IP at a given cycle, multiple start time and end 
time will be reported in the case report form. 
Number of patients receiving G-CSF as prophylaxis during the 3 first cycles and at all cycles 
[n(%)] will be summarized. The actual dose received, the cumulative dose, the overall duration of 
dosing, the actual dose intensity and the relative dose intensity will be summarized descriptively 
(number, mean, standard deviation, median, Q1, Q3, minimum, maximum and missing data) 
while the dose reduction (respectively delay) will be described by occurrences’ number and the 
number of patients with at least one dose reduction (respectively delay) during the study. 
For comparator arm: 
Dose information will be assessed for each treatment Abiraterone and Enzalutamide and the pool 
both by the following variables: 
 Total intended dose is the sum of intended daily dose during the treatment intake period. 
 Average actual dose received (mg) per cycle during the whole treatment period. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 35 
 Total number of patients with at least one dose reduction, a patient with dose reduction is 
defined as a patient received less than about 80% of the original planned study drug dose 
level at any administration of any cycle. Dose reduction event at a cycle will be derived by 
using the definition provided in Table 7. The original planned study drug dose level is 
taken from the planned dose level at Cycle 1 and will be compared with actual received 
dose for dose reduction event at Cycle 1. For the second and subsequent cycles, a dose is 
deemed to have been reduced if the dose level a patient receives is lower than the previous 
actual dose level.  
Quantitative parameters will be summarized descriptively (number, mean, standard 
deviation, median, Q1, Q3, minimum, maximum and missing data). 
Table 7 - Abiraterone / Enzalutamide dose reduction levels 
AR-target 
therapy  
Initial daily dose  
mg 
(tablets/capsules) 
Initial dose per cycle 
mg 
(tablets/capsules) 
Dose reduction 
1 mg 
(tablets/capsules) 
Dose reduction 
2 mg 
(tablets/capsules) 
Abiraterone 
1000 (4 tablets - 250 mg) 
21000 (84) 
<16750 (<67 tablets) 
<13250 (<53 tablets) 
(or) Abiraterone 
1000 (2 tablets -500 mg) 
21000 (42) 
<16500 (33 tablets) 
<13000 (<26 tablets) 
Enzalutamide 
160 (4 capsules) 
3360 (84) 
<2680 (<67 capsules) 
<2120 (<53 capsules) 
 Total number of dose reduction. 
 Summary of Prednisone/prednisolone will also be given. Details on the average per cycle, 
of number of days taken and number of days not taken. 
2.4.3.2 Compliance  
Dose information will be assessed for AR-targeted agent and specifically within AR-targeted 
agent (ie, AR-targeted agent [abiraterone or enzalutamide], abiraterone and enzalutamide) by the 
following variables: 
 Compliance is defined as the total actual dose divided by the total intended dose.  
The summaries will consist of the number and percentage of patients in each class of 
compliance, starting at ≤75% to a maximum of 100% in increments of 5%, and 
summarized as quantitative as well. 
2.4.4 Analyses of efficacy endpoints 
2.4.4.1 Analysis of primary efficacy endpoint(s) 
Analyses of the primary efficacy endpoint will be performed on the ITT population. 
2.4.4.1.1 Primary analysis 
The primary analysis will consist of rPFS comparison between Abiraterone acetate or 
Enzalutamide group and CBZ group through a 2-sided 5% log rank test procedure stratified by the 
stratification factors recorded at randomization:   
Eastern Cooperative Oncology Group performance status (0-1 versus 2), time from AR targeted 
agent initiation to progression ([0; 6 months] versus [6; 12 months]), timing of AR targeted agent 
(before versus after docetaxel).  


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 36 
When applicable, for all efficacy endpoints, if some strata event rates are too low, we might have 
to consider to pool some strata with others strata in a blinded way depending rPFS events 
distribution within strata, this will be determined before database lock. 
If radiological progression or death is not observed during the study, data on rPFS will be 
censored at the last valid tumor assessment or at the cut-off date (see Section 1.1), whichever 
comes first. 
The survival curves will be estimated using Kaplan-Meier estimates. Median survival times and 
associated 95% CIs will also be provided by treatment arm.  
Reasons for censoring will be summarized by treatment arm, if any lost to follow up, Time from 
last contact to cutoff date (months) will be summarized. 
Date of last valid tumor assessment: 
If several scans are performed at different dates for a given tumor evaluation reported on the 
eCRF, the date of the last valid tumor assessment is the date of latest scan. A patient without event 
(death or progression) and without any valid post baseline tumor assessment will be censored for 
PFS on the day of randomization (Day 1).  
Non evaluable cases:  
Missing scans: if one lesion is not evaluated/missing for a given tumor assessment, the OR should 
generally be NE unless there is clear evidence of progression (independently of the missing 
lesion). For the primary analysis of rPFS, progression or death occurring after a tumor evaluation 
with an OR equal to NE will be considered as an event in the analysis. 
2.4.4.1.2 Secondary analyses 
The primary efficacy endpoint will also be analyzed as follows:  
The survival curves will be estimated using Kaplan-Meier estimates and Median survival times 
and associated 95% CIs will also be provided by treatment arm for the following analyses: 
 Further anticancer treatments after stop of investigational product are very common. 
Patients on the CBZ group are likely to receive AR-targeted agent treatment that could be 
confounded with the treatment effect of CBZ. Patients on the AR-targeted agent group are 
also likely to receive CBZ treatment that could be confounded with the treatment effect of 
AR-targeted agent. A time-dependent variable (time-to the first post-study treatment 
anticancer therapy from randomization) will be added in the Cox hazard proportional 
model stratified by the stratification factor at randomization to check its impact on rPFS. 
Moreover if radiological progression or death is not observed during the study, data on 
rPFS will be censored at the last valid tumor assessment or the start date of another 
anti-cancer therapy, or at the cut-off date (see Section 1.1), whichever comes first. 
 Within each stratification factor level, the treatment effect hazard ratio (HR) and its 
(1-α)% confidence intervals (CI) will be estimated using a Cox Proportional Hazard model 
stratified by the same stratification factors as those used for primary analyses, 
PH assumption will be checked. For each stratification factor level and for the overall 
population, HRs and (1-α)% CI will be displayed using forest plots. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 37 
If radiological progression or death is not observed during the study, data on rPFS will be 
censored at the last valid tumor assessment or the start date of another anti-cancer therapy, or at 
the cut-off date (see Section 1.1), whichever comes first. 
 Subgroup analyses of rPFS: 
The consistency of the treatment effect on rPFS will be evaluated with respect to 
stratification and prognostic factors as defined in Table 8. 
For each parameter, a Cox Proportional Hazard Model will be used for the overall 
population, including the parameter and all or others stratification factors (if subgroup 
analyses made by stratification factor subgroups), treatment effect and the treatment by 
parameter interaction (only pvalue for the interaction term will be provided for descriptive 
purpose only). 
In addition, Kaplan-Meier curves of rPFS and summary statistics showing number of 
patients, number (%) of rPFS, median rPFS and (1-)% confidence limits may be 
provided for each treatment arm in previously selected subgroups defined by the 
stratification /prognostic factors. 
Within each selected subgroup, the treatment effect hazard ratio and its (1-)% confidence 
intervals will be estimated using a Cox Proportional Hazard model on patients of this 
subgroup. For each subgroup and for the overall population, hazard ratios and (1-)% will 
be displayed using forest plots for the following stratification and prognostic factors 
defined in the Table 8. 
Table 8 - Potential Stratification/Prognostic factors 
Stratification factor 
Description (coding) 
ECOG performance status 
0, 1 (ref) vs 2 
Time to progression with AR targeted agent 
[0 ; 6 months] (ref) vs ]6 ; 12 months] 
Timing of AR targeted agent 
Before (ref) vs after docetaxel 
Prognostic factor 
Description (coding) 
Duration of first ADT 
<12 months (ref) vs ≥12 months  
Neutrophils to Lymphocyte Ratio (NLR)a 
<median (ref) vs ≥median 
Neutrophil count 
<median (ref) vs ≥median 
Age (years) 
<70 (ref) vs ≥70 years 
Visceral metsa (see Table 5)  
Yes vs No (ref) 
Gleason 8-10 at diagnosis 
Yes vs No (ref) 
Prior therapy with curative intent (radical prostatectomy or radiation therapy of 
prostate) for localized disease (TNM staging Localized, Locally advanced or Node-
positive) 
Yes (ref) vs No 
M1 disease at diagnosis   
Yes vs No (ref) 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 38 
Stratification factor 
Description (coding) 
Type of progression at randomization 
PSA only (no radiological, no pain) (ref) vs   
Radiological (± rising PSA), no pain 
AND Pain (± radiological, ± rising PSA) vs 
PSA only (no radiological, no pain) (ref) 
Hemoglobina at randomization 
<median (ref) vs ≥median 
Alkaline phosphatasea at randomization 
<median (ref) vs ≥median 
LDHa  at randomization 
<median (ref) vs ≥median 
Testosterone at randomization 
<median (ref) vs ≥median 
PSA value (log 10) at randomizationa 
<median (ref) vs ≥median 
a Last available measure before randomization 
2.4.4.1.3 Sensitivity analysis 
Finally, the two arms will also be compared using a 2-sided 5% stratified log-rank test when 
considering the non-compliance tumor assessment evaluation below. 
Data on rPFS will be censored:  
 At the last valid tumor assessment if documented radiological progression or death occurs 
more than 18* weeks after the last valid tumor assessment without progression. 
And  
 At the start of further anticancer therapy if patients do not have a PD documented before 
start of further anticancer therapies.  
 Or at the cut-off date (see Section 1.1), whichever comes first. 
*The 18-week threshold corresponds to 1.5 the time interval between two tumor 
assessments (every 12 weeks), as defined in the protocol. 
2.4.4.2 Analyses of secondary efficacy endpoints 
Unless otherwise stated, secondary efficacy endpoints defined in Section 2.1.3.2 will be analyzed 
on the ITT population. 
2.4.4.2.1 Primary analyses for secondary endpoints 
Time to event endpoints (OS, PFS) will be compared between treatment arms a 2-sided 5% log 
rank test procedure stratified by the stratification factors recorded at randomization. 
The survival curves will be estimated using Kaplan-Meier estimates.  
The estimates of the HR and corresponding 95% CI will be provided using a Cox proportional 
hazard model stratified by the same stratification factors as those used for the log-rank test 
described above, PH assumption will be checked. Median times and associated 95% CIs will also 
be provided by treatment arm using a forest plot.  


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 39 
For both OS and PFS, reasons for censoring will be summarized by treatment arm. 
Categorical data (Objective tumor and PSA responses rates) will be summarized using number 
and percentage of patients by treatment with their 95% CI estimated by Normal approximation 
(patients with missing data will not be included in the percentage calculation). The two arms will 
be compared using Cochran-Mantel-Haenszel chi-square test stratified by stratification factors at 
the randomization. Objective tumor response and PSA will be analyzed on their respective 
evaluable population, taking into account assessments made during the on-treatment period, 
ie, until starts of first subsequent therapy. 
A waterfall plot of PSA response at Cycle 2 Day 1, at 12 weeks and best PSA response at any 
time during treatment exposure will be provided. 
2.4.4.2.2 Others analysis for others secondary endpoints 
Time to event endpoints (TTPP, duration of tumor response, times to pain progression, time to 
occurrence of SSE) will be summarized by treatment arms.  
Median times and associated 95% CIs will also be provided by treatment.  
If no event for TTPP is observed, patients will be censored at the last valid tumor assessment 
(meaning with OR equal to CR/PR/SD but not NE) date (whatever the start or not another 
anti-cancer therapy) or the study cutoff date, whichever is first.  
In the absence of skeletal-related events, events will be censored at the last assessment (physical 
exam) in the study. Patients with no such assessment on-study will be censored at randomization. 
If no pain palliation/progression is observed during the study, data on pain palliation/progression 
will be censored at the last pain evaluation date. 
If no symptomatic deterioration is observed during the study, data on decision of the clinical 
progression will be censored at the last assessment (physical exam) in the study or the study cutoff 
date, whichever is first.  
For all, reasons for censoring will be summarized by treatment arm. 
Continuous data will be summarized using the number of available data, mean, standard 
deviation, median, Q1, Q3, minimum, maximum and missing data for each treatment group. 
Categorical and ordinal data will be summarized using the number and percentage of patients in 
each treatment group (patients with missing data will not be included in the percentage 
calculation).  
Time to PSA Progression (PSA), tumor response, pain and SSE endpoints will be analyzed on 
their respective evaluable population. 
2.4.4.3 Multiplicity issues 
2.4.4.3.1 Primary endpoint 
Not applicable for primary endpoint (16). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 40 
2.4.4.3.2 Main secondary endpoints 
To control the type I error, a hierarchical step-down testing procedure (17) is applied. 
Only if a significant difference in the rPFS of Abiraterone acetate or Enzalutamide group and 
CBZ has been demonstrated for the primary endpoint, the testing procedure is performed 
confirmatory to test the following main secondary efficacy endpoints by prioritized order (OS, 
PFS, PSA responses rates and Objective tumor response). The tests will stop as soon as an 
endpoint is found not statistically significant at two-sided α=0.05 level. 
2.4.4.3.3 Other secondary endpoint 
No multiplicity adjustment is made on other secondary and exploratory efficacy variables than 
those mentioned above. 
2.4.4.4 Additional efficacy analysis(es) 
Not applicable. 
2.4.5 Analyses of safety data 
The summary of safety results will be presented by treatment group and specifically within 
AR-targeted agent (ie, CBZ, AR-targeted agent [Abiraterone or Enzalutamide], Abiraterone and 
Enzalutamide). 
General common rules 
All safety analyses will be performed on the safety population as defined in Section 2.3.2, unless 
otherwise specified, using the following common rules: 
 Safety data in patients who do not belong to the safety population (eg, exposed but not 
randomized) will be listed separately. 
 The baseline value is defined as the last value or measurement taken up to the first dose in 
the study. 
 The analysis of the safety variables will be essentially descriptive and no systematic 
testing is planned.  
 Selected safety analyses will be summarized by age or any pertinent subgroups (Age at 
inclusion (<65, [65-75 [or ≥75), ECOG at inclusion ([0; 1], ≥2), Number of prior 
chemotherapy lines ([0, 1]; >1 lines). 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 41 
2.4.5.1 Analyses of adverse events 
Generalities 
The primary focus of AE reporting will be on TEAEs. Pretreatment and post-treatment AEs will 
be described separately.  
If an AE date/time of onset (occurrence, worsening or becoming serious) is incomplete, an 
imputation algorithm will be used to classify the AE as pretreatment, treatment-emergent or 
post-treatment. The algorithm for imputing date/time of onset will be conservative and will 
classify an AE as treatment emergent unless there is definitive information to determine it is 
pretreatment or post-treatment. Details on classification of AEs with missing or partial onset dates 
are provided in Section 2.5.3. 
The grade and cycle will be taken into account in the summary. For patients with multiple 
occurrences of the same event, the maximum grade is used. The denominator used for the 
summary by cycle is the total number of cycles administered in a treatment group. For a given 
event, a patient contributes one to the numerator for each cycle in which an episode occurred. An 
episode occurs during a cycle if the date of onset is on or after the first day of the cycle but prior 
to the first day of the next cycle. 
Sorting within tables ensures the same presentation for the set of all AEs within the observation 
period (pretreatment, treatment-emergent and post-treatment). For that purpose, the table of all 
TEAEs will present the number (n) and percentage (%) of patients experiencing an AE by SOC 
(sorted by internationally agreed order), HLGT, HLT and PT (sorted in alphabetical order) for 
each treatment group. 
All tables below are applicable by adding worst NCI grade in the selection. 
Analysis of all treatment-emergent adverse events 
The following TEAE summaries will be generated for the safety population. 
 Overview of TEAEs, summarizing number (%) of patients with any 
- 
TEAE, 
- 
Grade 3-4 TEAE, 
- 
Grade 3-4 related TEAE, 
- 
Serious TEAE, 
- 
Serious related TEAE, 
- 
TEAE leading to death (fatal outcome), 
- 
TEAE leading to permanent treatment discontinuation. 
The same overview will be provided by patient/cycle (except fatal outcome and permanent 
treatment discontinuation). 
 All TEAEs by primary SOC, HLGT, HLT and PT, showing number (%) of patients with at 
least one TEAE sorted by the SOC internationally agreed order. The other levels (HLGT, 
HLT and PT) will be presented in alphabetical order. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 42 
 All TEAEs by primary SOC and PT, showing the number (%) of patients with at least one 
TEAE, sorted by the internationally agreed SOC order and by decreasing incidence of PTs 
within each SOC. 
 Summary of common TEAEs will also be provided by demographic factors including: age 
categories (<65, [65-75 [or ≥75) and subgroups of interest if appropriate. 
 All TEAEs regardless of relationship and related to IMP, by primary SOC, HLGT, HLT 
and PT.  
 All TEAEs related to IMP, by primary SOC, HLGT, HLT and PT.  
Analysis of all treatment emergent serious adverse event(s) 
 All serious TEAEs by primary SOC, HLGT, HLT and PT, showing the number (%) of 
patients with at least one serious TEAE, sorted by the internationally agreed SOC order. 
The other levels (HLGT, HLT and PT) will be presented in alphabetical order. 
 All serious TEAEs regardless of relationship and related to IMP, by primary SOC, HLGT, 
HLT and PT, showing the number (%) of patients with at least one serious TEAE, sorted 
by the internationally agreed SOC order.  The other levels (HLGT, HLT and PT) will be 
presented in alphabetical order. 
Analysis of all treatment emergent non-serious adverse event(s) 
 All non-serious TEAEs by primary SOC, HLGT, HLT and PT, using the threshold of 
≥5%, showing the number (%) of patients with at least one serious TEAE, sorted by the 
internationally agreed SOC order. The other levels (HLGT, HLT and PT) will be 
presented in alphabetical order. 
Analysis of all treatment-emergent adverse event(s) leading to treatment discontinuation 
 All TEAEs leading to treatment discontinuation, by primary SOC, HLGT, HLT and PT, 
showing the number (%) of patients sorted by the internationally agreed SOC order. The 
other levels (HLGT, HLT and PT) will be presented in alphabetical order. 
Analysis of all treatment-emergent adverse event(s) leading to dose modification  
 All TEAEs leading to dose modification, by primary SOC and PT (worst grade by patient), 
showing the number (%) of patients, sorted by the sorting order defined above. 
 All TEAEs leading to dose reduction, by primary SOC and PT (worst grade by patient), 
showing the number (%) of patients, sorted by the sorting order defined above. 
 All TEAEs leading to dose interruption, by primary SOC and PT (worst grade by patient), 
showing the number (%) of patients, sorted by the sorting order defined above. 
 All TEAEs leading to dose delay , by primary SOC and PT (worst grade by patient), 
showing the number (%) of patients, sorted by the sorting order defined above. 
Analysis of adverse events with pre-specified monitoring AEs (overdose): 
 All treatment emergent of pre-specified monitoring AEs, by PT, showing number (%) of 
patients, sorted by decreasing incidence of PT will be presented. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 43 
Analysis of pretreatment and post-treatment adverse events  
 All pre-treatment AEs by primary SOC and PT (worst grade by patient), showing the 
number (%) of patients with at least one pretreatment AE, sorted by the internationally 
agreed SOC order and decreasing incidence of PTs within each SOC. 
 All pre-treatment AEs leading to study discontinuation by primary SOC and PT (worst 
grade by patient), showing the number (%) of patients, sorted by the internationally agreed 
SOC order and decreasing incidence of PTs within each SOC. 
 All post-treatment AEs by primary SOC and PT (worst grade by patient), showing the 
number (%) of patients with at least one post-treatment AE, sorted by the internationally 
agreed SOC order and decreasing incidence of PTs within each SOC. 
 All post-treatment SAEs by primary SOC and PT (worst grade by patient), showing the 
number (%) of patients with at least one post-treatment SAE, sorted by the internationally 
agreed SOC order and decreasing incidence of PTs within each SOC. 
2.4.5.2 Deaths 
The following summaries of deaths will be generated for the safety population: 
 Number (%) of patients who died by study period (on-study, on-treatment, post-study) and 
cause of death. 
 TEAEs leading to death by primary SOC, HLGT, HLT and PT showing number (%) of 
patients sorted by internationally agreed SOC order, with HLGT, HLT and PT presented 
in alphabetical order within each SOC. 
 All TEAEs leading to death and related TEAEs leading to death will be also summarized 
in one table. This table will include a tabular summary of all TEAEs leading to death with 
a column for the related TEAEs leading to death.  
 All pre-treatment AEs leading to death by primary SOC and PT, showing number (%) of 
patients, sorted by SOC internationally agreed order and decreasing incidence of PTs 
within SOC. 
 All post-treatment AEs leading to death by primary SOC and PT, showing number (%) of 
patients, sorted by SOC internationally agreed order and decreasing incidence of PTs 
within SOC. 
Furthermore a listing of deaths in non-randomized patients or randomized but not treated 
patients. 
2.4.5.3 Analyses of vital sign variables 
The summary statistics (including number, mean, median, Q1, Q3, standard deviation, minimum, 
maximum and missing data) of vital signs variables (raw values and changes from baseline) will 
be calculated for each cycle by treatment group for weight,  systolic and diastolic blood pressure 
and heart rate. For ECOG PS, a shift table will be provided for the last and worst evaluations 
respectively relative to baseline. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 44 
2.4.5.4 Analyses of electrocardiogram variables 
Interpretation of ECG will be described at the screening and EoT (if available) visits by treatment 
group. The frequency will be presented on ECG parameter: Normal vs Abnormal using a shift 
table that will be provided for the EoT evaluation respectively relative to baseline. 
2.4.5.5 Analyses of other safety endpoints (laboratory variables) 
All laboratory toxicities will be summarized by treatment group and specifically within 
AR-targeted agent (ie, CBZ, AR-targeted agent [abiraterone or enzalutamide], abiraterone and 
enzalutamide).  
Hematological and clinical biochemistry toxicities will be assessed from laboratory test 
parameters. Each test result will be graded by NCI CTCAE (Version 4.0) using the standards 
lower and upper ranges defined by the sponsor when exist (see Appendix H) whatever they have 
been collected or not in the eCRF. For AST, ALT, Bilirubin, Alkaline phosphatase, LDH and 
creatinine the lower and/or upper ranges when collected in the eCRF will be used.  
In addition to creatinine levels, estimations of the renal function will be made by calculating the 
glomerular filtration rate (GFR) using the abbreviated Modification of Diet in Renal Disease 
(aMDRD) formula if the creatinine at baseline is 1.0-1.5 x ULN: 
GFR(mL/min/1.73m2) = k x 186 x [SCR]-1.154 x [age]-0.203 
with k=1 (men) and SCR=Serum creatinine 
CrCl categories (≥90, [60 to 90[, [45 to 60[, [30 to 45[and, [15 to 30[, <15 mL/min/1.73m²) and 
number of patients with renal function abnormalities on Creatinine clearance will be splitted and 
provided for both, when creatinine ≤1 x ULN and when creatinine >1 x ULN. 
Hematological and biochemistry toxicities will be assessed from laboratory parameters. Worst 
NCI CTCAE grades, whenever applicable will be calculated according to the NCI common 
terminology criteria. 
The number of patients with abnormal laboratory tests at baseline (all grades, Grade 1, Grade 2, 
Grade 3 and Grade 4) will be presented by grade. The frequency of patients in each grade (all 
grades, Grade 1, Grade 2, Grade 3 and Grade 4) of laboratory tests during treatment will be 
summarized. For patients with multiple occurrences of the same laboratory variable during the 
treatment, the maximum grade (worst) per patient will be used. When appropriate, the summary 
table will present the frequency of patients with any grade of abnormal laboratory tests and with 
Grade 3-4 abnormal laboratory tests.  
2.4.6 Analyses of pharmacokinetic and pharmacodynamic variables 
Not applicable. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 45 
2.4.7 Analyses of quality of life/health economics variables 
2.4.7.1 Health-Related Quality of Life 
HRQL analysis will be performed on the HRQL population.  
The FACT-P is summed to give a FACT-P total score in the range of 0-156, where higher values 
represent better HRQL (18). 
To achieve this, the FACT-P scoring guide (see Appendix C) identifies those items which must be 
reversed before being added to obtain subscale totals. Negatively stated items are reversed by 
subtracting the response from “4” (ie, 4 - Item score). After reversing proper items, all subscale 
items are summed to a total, which is the subscale score (18). 
Handling missing items is detailed in Section 2.5.3. 
For all FACT-G see Appendix C - Scoring guide and FACT-P subscale scores and symptom 
indices, the higher the score the better the HRQL. 
The FACT-P total score is calculated as the sum of the un-weighted subscale scores and is 
evaluable when more than 80% of the items are answered (eg, at least 22 of 27 FACT-G items 
completed, at least 21 of 26 TOI items completed). This is not to be confused with individual 
subscale item response rates, which allows a subscale score to be prorated for missing items if 
greater than 50% of items are answered. Additionally a subscale score should be completed if the 
component subscales have valid scores. 
Analyses by cycles will be done up to the cycle (or follow-up visit) for which at least 20% of 
HRQL population will be reached in each treatment group, end-of treatment summary will be 
provided anyway. 
Descriptive summary of the FACT-P evaluable scores (each subscale score from a domain, 
FACT-G, TOI, Pain PCS and total FACT-P scores will be calculated)  for each visit and change 
from baseline at each visit will be provided. 
The comparison of change from baseline on health-related quality-of-life scores (FACT-P total 
scores, subscale scores, summary measure scores: TOI and FACT-G total score and Pain PCS) 
between treatment arms will be performed by using MIXED linear repeated measures model 
where treatment is a fixed effect variable and subject is a random effect variable. The baseline 
stratification variables will be included in the model as covariates as well as the interaction 
treatment*visit. The least square means by treatment group with their 95% CIs obtained from 
mixed model will be presented graphically. These analyses will be conduct up to the cycle (or 
follow-up visit) for which at least 20% of HRQL population will be reached in each treatment 
group, and will include the end-of treatment visit. 
The “robust” empirical estimator will be used to estimate the covariance structure for the 
estimator of model parameters. Compound symmetry will be the assumed covariance structure 
based on periods for the error terms. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 46 
The HRQL secondary analysis will include 4 main FACT-P responder analyses:   
For those who improve and for those who deteriorate across 5 categories of FACT-P 
scales/summary scores (1. FACT-P total; 2. FACT-P subscales summary scale; 3. Pain PCS and 
4. FACT-G and FACT TOI).  These analyses are based on the MIDs for the FACT-P. The MIDS 
for each scale and summary score of the FACT-P can be found in Appendix C.  
The first responder analysis is for the FACT-P total score responders.  
 Improvement in FACT-P total scores is defined as an increase of ≥10-points in 
FACT-P total scores from baseline on 2 consecutive evaluations ≥3 weeks apart during 
on-treatment period.  
 Deterioration in FACT-P total scores is defined as a decrease of ≥10-points in 
FACT-P total scores from baseline on 2 consecutive evaluations ≥3 weeks apart during 
on-treatment period.  
The 2nd responder analysis is for the physical, social, emotional, and functional well-being (PWB, 
SWB, EWB and FWB) scales responders.  
 Improvement in PWB, SWB, EWB and FWB scales is defined as an increase of ≥3 points 
in FACT-P PWB, SWB, EWB, FWB subscale scores from baseline on 2 consecutive 
evaluations ≥3 weeks apart. 
 Deterioration in PWB, SWB, EWB and FWB scales scores is defined as a decrease of 
≥3 points in FACT-P PWB, SWB, EWB, FWB subscales scores from baseline on 
2 consecutive evaluations ≥3 weeks apart. 
The 3rd responder analysis is for Pain PCS summary score responders.  
 Improvement in Pain PCS summary score is defined as an increase ≥2 points from 
baseline in Pain PCS scores observed at 2 consecutive evaluations ≥3 weeks apart. 
 Deterioration Pain PCS summary score is defined as a decrease of at least 2 points from 
baseline Pain PCS scores observed at 2 consecutive evaluations ≥3 weeks apart.  
The fourth and final responder analysis is for the FACT-G Total and FACT-P TOI responders. 
 Improvement in FACT-G Total and FACT-P TOI scores is defined as an increase of 
≥9 points from baseline in the FACT-G Total and the FACT-P TOI summary scores 
observed at 2 consecutive evaluations ≥3 weeks apart. 
 Deterioration in FACT-G Total and FACT-P TOI  summary scores is defined as a 
decrease of ≥9 points from baseline in the FACT-G Total and the FACT-P TOI summary 
scores observed at 2 consecutive evaluations  ≥3 weeks apart.  
For all four types of responder analyses the response rate during on-treatment will be descriptively 
summarized up to the cycle (or follow-up visit) for which at least 20% of HRQL population will 
be reached in each treatment group, end-of treatment summary will be provided anyway.  
The time to definitive deterioration (in months), will be analyzed by using a Cox proportional 
hazard model adjusted for the stratification factors. HRs and corresponding 95% confidence 
intervals will be provided. Kaplan-Meier estimates and the log-rank test will be performed if 
appropriate. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 47 
Deterioration was considered to be definitive if there was no subsequent improvement above the 
defined threshold before further anticancer therapy was administered. If a definitive deterioration 
was observed after a scheduled visit with a missing value, it was assumed that the deterioration 
occurred at the time of the missing value. 
Death was considered an event in the absence of definitive deterioration if it occurred within 
30 days of the last assessment. Otherwise, the patient was considered lost to follow-up and 
censored at the date of last assessment. Patients receiving further antitumor therapy before 
definitive deterioration were censored at the date of their last assessment before therapy. 
2.4.7.2 Health status 
EQ-5D analysis will be performed on the health status population. Analyses by cycles will be 
done up to the cycle (or follow-up visit) for which at least 20% of health status population will be 
reached in each treatment group, end-of treatment summary will be provided anyway. 
Each dimension of EQ-5D-5L will be summarized at each visit using number and percentage of 
patients by treatment (patients with missing data will not be included in the percentage 
calculation).  
The comparison of change from baseline on health-related quality-of-life scores EQ-5D-5L utility 
index scores and EQ-5D-5L VAS between treatment arms will be performed by using MIXED 
linear repeated measures model where treatment is a fixed effect variable and subject is a random 
effect variable. The baseline stratification variables will be included in the model as covariates. 
The least square means by treatment group with their 95% CIs obtained from mixed model will be 
presented graphically. These analyses will be conduct up to the cycle (or follow-up visit) for 
which at least 20% of health status population will be reached in each treatment group, and will 
include the end-of treatment visit. 
Change from baseline to each visit will also be provided. For qualitative parameters (each 
dimension of EQ-5D-5L) change will be assessed in terms of number of patient with worsening, 
no change and improvement.   
EQ-5D-5L VAS and utility index score will be summarized using the number of available data, 
mean, standard deviation, median, Q1, Q3, minimum, maximum and missing data by treatment at 
each visit as well as change from baseline to each visit.  
EQ VAS score at each time points will be described graphically by treatment groups. Mean value 
of Index utility score and corresponding 95% CIs will also be described graphically by treatment 
groups for each time points. Those graphical approach will be done up to the cycle (or follow-up 
visit) for which at least 20% of health status population will be reached in each treatment group, 
and will include the end-of treatment visit. 
The utility index will be derived according to Euroqol specific country algorithms provided to the 
Sponsor. In case a specific country algorithm is missing the value sets based on the UK 
population will be used to generate health utility scores. 
The MID which will be used for the EQ-5D-5L utility index is .14 while the MID which will be 
used for the VAS is 11 (19).  


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 48 
2.4.8 Further anti-cancer therapy after discontinuation of investigational medicinal 
product administration during the study 
A summary table will be provided for further therapies based on WHO-DD coding. Similar 
analysis will be performed for further RT and further surgery.  
Time to subsequent therapy for prostate cancer defined as time interval from the date of 
randomization to the date of initiation of subsequent therapy for prostate cancer. Patients who 
have no subsequent therapy at the time of the analysis will be censored at the last known alive 
date 
The type of post-study treatment will be described by treatment group.  
All analyses below will be performed by type of subsequent therapy. 
Descriptive statistics (or listing if relevant) for reason for discontinuation and best response will 
be provided based on population of patients with further anticancer therapy.  
The PSA response during the first subsequent therapy will be calculated using the last PSA 
assessment before the start of the further therapy as baseline value (if enough patients to be 
considered). 
A waterfall plot will be provided for best PSA change by treatment group and type of subsequent 
therapy. 
Duration of subsequent therapy will be summarized on the ITT population with any first 
subsequent therapy. 
2.5 
DATA HANDLING CONVENTIONS 
2.5.1 General conventions 
The following formulas will be used for computations of parameters. 
Demographic formulas 
Age (years) = Integer [(Date of screening visit - Date of birth)/365.25] 
In case of missing data apply these rules: 
 Missing Day: assume = 15. 
 Missing Month: assume = 6. 
 Missing Year: calculations cannot be done. 
In case of incomplete dates, see Section 2.5.3. 
BSA (m2) = 0.007184 x Height (cm) 0.725 x Weight (kg) 0.425  
(the variation of DuBois and DuBois formula), 
Time between diagnosis and screening (months) = [(Date of screening visit - Date of initial 
diagnosis to be confirmed)/30.4375], 
Time to event (months) = [(Date of event or censure - Date of randomization)/30.4375]. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 49 
Tumor markers 
Nadir value of PSA is defined as the lowest value of PSA from baseline. 
Laboratory data 
Conversion of laboratory data from used units to international units will be done, if necessary 
(see Appendix F) containing conversion factors for all parameters mentioned in this SAP. 
The NCI CTCAE grade of laboratory data will be calculated using the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.0 and upper limit of normal (ULN) and lower 
limit of normal (LLN) (20). The standards lower and upper ranges defined by the sponsor when 
exist (see Appendix H) whatever they have been collected or not in the eCRF will be used. 
For AST, ALT, Bilirubin, Alkaline phosphatase, LDH and creatinine the lower and upper ranges 
collected in the eCRF will be used. 
For all WBC laboratory parameters, when expressed in %, and when possible (ie, if WBC is not 
missing and expressed in Giga/l) then laboratory parameters expressed in % will be derived and 
expressed in Giga/l as well using the formula below:  
Laboratory parameter(Giga/L)= Laboratory parameters (%)*WBC (Giga/l). 
Tumor response 
See Appendix B. 
WHO analgesic score 
The WHO analgesic score will be derived from the pre-treatment and the on-treatment 
medications mentioned in the CRF using the WHO scale (0 for no medication, 1 for non-opioid 
pain medication, 2 for opioids for moderate pain and 3 for opioids for severe pain). 
The correspondence between the medications and the scale will be classified appropriately 
according to the Appendix E (21). 
2.5.2 Data handling conventions for secondary efficacy variables 
Not applicable. 
2.5.3 Missing data 
For categorical variables, patients with missing data are not included in calculations of 
percentages unless otherwise specified. When relevant, the number of patients with missing data 
is presented. 
Handling of computation of treatment duration if investigational medicinal product end of 
treatment date is missing  
For the calculation of the treatment duration, the date of the last dose of IMP is equal to the date 
of last administration reported on the last cycle performed. If this date is missing, the exposure 
duration should be left as missing.  


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 50 
The last dose administration should be clearly identified in the CRF and should not be 
approximated by the last returned package date. 
Handling of CRPC and/or mCRPC missing/partial dates 
For Age at prostate cancer diagnosis,  age at metastatic disease and age at mCRPC diagnosis, 
when date of birth is missing, the age at randomization will be used for the derivation. 
If dates are partially missing, the missing day will be imputed to 15 and the missing month will be 
imputed to June if imputed date are still consistent (mCRPC is after date of metastatic disease, 
except if there was a date for CRPC , and both prior histological diagnosis).  
Handling of medication missing/partial dates 
No imputation of medication start/end dates or times will be performed. If a medication date or 
time is missing or partially missing and it cannot be determined whether it was taken prior or 
concomitantly, it will be considered as a prior, concomitant and post-treatment medication. 
When prior-therapy duration needed, if start date is partially missing then date should be imputed 
to the 15th day of the month, except if the end date is completed and the month and year are the 
same as the start date (then the day of the start date should be imputed to the 1st day of the month). 
If end date is partially missing then date should be imputed to the 1st day of the month, except if 
the month and year are the same as the start date in which case end date will be imputed to start 
date. 
For the first ADT duration calculation [in month and <12 months vs ≥12 months)], when 
applicable if patient has an hormonotherapy ongoing at time of randomization, the end date of the 
first hormonotherapy will be the start date of the next therapy (another hormonotherapy or 
docetaxel or abiraterone or enzalutamide or radium 223). 
For the consumption of analgesics at study entry, if not ongoing at randomization, and end date 
partially missing, if the end is the same month and year than randomization data then the 
treatment intake is considered to be taken within one week prior to randomization.  
Handling of adverse events with missing or partial date of onset 
Missing or partial AE onset dates will be imputed so that if the partial AE onset date information 
does not indicate that the AE started prior to treatment or after the TEAE period, the AE will be 
classified as treatment-emergent. No imputation of AE end dates will be performed. These data 
imputations are for categorization purpose only and will not be used in listings. No imputation is 
planned for date of AE resolution. 
Handling of adverse events when date and time of first investigational medicinal product 
administration is missing 
When the date and time of the first IMP administration is missing, all AEs that occurred on or 
after the day of randomization should be considered as TEAEs. The exposure duration should be 
kept as missing. 
The last dose administration should be clearly identified in the case report form and should not be 
approximated by the last returned package date. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 51 
Handling of missing assessment of relationship of adverse events to investigational medicinal 
product  
If the assessment of the relationship to IMP is missing, then the relationship to IMP has to be 
assumed and the AE considered as such in the frequency tables of possibly related AEs, but no 
imputation should be done at the data level. 
Handling of missing severity/grades of adverse events 
If the severity/grade is missing for one of the treatment-emergent occurrences of an AE, the 
maximal severity on the remaining occurrences will be considered. If the severity is missing for 
all the occurrences, a “missing” category will be added in the summary table. 
Handling of missing dates for times calculations 
Not applicable. 
Handling of missing data for FACT-P 
If there are missing items, subscale scores can be prorated.  This is done by multiplying the sum of the 
subscale by the number of items in the subscale, then dividing by the number of items actually answered. 
When there are missing data, prorating by subscale is acceptable as long as more than 50% of the 
items in a domain were answered (eg, a minimum of 4 of 7 items, 4 of 6 items, 7 of 12 items, 
etc) (18). 
This can be done by using the formula below: 
Prorated subscale score = [Sum of item scores] x [N of items in subscale] ÷ [N of items answered]. 
2.5.4 Windows for time points 
Summaries by cycle focusing on AEs, exposure and tumor assessments will be tabulated based on 
cycles as recorded in the CRF. 
No time windows will be defined except for blood chemistry performed at D8 and D15 during the 
3 first cycles for which 1 day window is allowed. 
2.5.5 Unscheduled visits 
Unscheduled visit measurements of laboratory data, vital signs and ECG will be used for 
computation of baseline and worst values and/or grades. 
2.5.6 Pooling of centers for statistical analyses 
Each parameter will be described globally pooling all centers of all countries. 
2.5.7 Statistical technical issues 
Not applicable. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 52 
3 
INTERIM ANALYSIS 
No interim analysis is planned. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 53 
4 
DATABASE LOCK 
The study is event driven and the cut-off date will be when 196 rPFS events have occurred. The 
end of clinical trial will be last patient last visit. 
So the main database lock will be driven by the cutoff date and the final DBL driven by the 
LPLV, likely to occur in Q3-2019. 
The final database is planned to be locked at 30 days after last patient last visit. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 54 
5 
SOFTWARE DOCUMENTATION 
All summaries and statistical analyses will be generated using SAS Version 9.2. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 55 
6 
 REFERENCES 
1. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for 
treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of 
the COU-AA-301 randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 
2012;13(10):983-92. 
2. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with 
enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97. 
3. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in 
Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. 2013;368:138-48. 
4. Beer TM, Armstrong AJ, Stenberg CN. Enzalutamide in men with chemotherapy-naïve 
metastatic prostate cancer (mCRPC): Results of phase 3 PREVAIL study. Poster of ASCO 
2014 Annual Meeting; 2014 Jan 30-Feb 1; San Francisco, CA. 
5. Sandhu GS, Parikh RA, Appleman LJ, Friedland D. Enzalutamide after abiraterone in patients 
with metastatic castrate-resistant prostate cancer (mCRPC). Abstract 240 Poster ASCO GU 
2014 Annual Meeting, 2014 Jan 30-Feb 1; San Francisco, CA. J Clin Oncol 2014;32(Suppl 
4):240. 
6. Smith MR. Response to androgen signaling (AS)-directed therapy after treatment with 
abiraterone acetate (AA) in patients with metastatic castrate-resistant prostate cancer 
(mCRPC): Post hoc analysis of study COU-AA-302 Abstract 21. Poster of ASCO GU 2014 
Annual Meeting; 2014 Jan 30-Feb 1; San Francisco, CA. 
7. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-Analysis Evaluating 
the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant 
Prostate Cancer. J Clin Oncol. 2016;34:1652-9. 
8. Cleeland CS. The Brief Pain Inventory user guide [Internet]. 2009. Available from: 
https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=350835. 
9. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and End 
Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of 
Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin 
Oncol. 2008;26:1148-59. 
10. Logothetis CL. Effect of abiraterone acetate and prednisone compared with placebo and 
prednisone on pain control and skeletal-related events in patients with metastatic castration-
resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. 
Lancet Oncol. 2012;13:1210-7. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 56 
11. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes 
for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of 
patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;(12):124-9. 
12. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men 
with prostate cancer using the functional assessment of cancer therapy-prostate instrument. 
Urology. 1997;50(6):920-8. 
13. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal 
clinically important difference. Control Clin Trials. 1989;10:407-15. 
14. Oemar M, Janssen B. EuroQol: EQ-5D-5L User’s Guide Basic information on how to use the 
EQ-5D-5L instrument Version 2.10. 2014 and Oct 2013. 
15. De Bono J, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, et al. Subsequent 
Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic 
Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. [Internet]. 
2016 [cited 2016 Jul 9];71(4):[about 1 p]. Available from 
http://dx.doi.org/10.1016/j.eururo.2016.06.033. 
16. EMEA. CPMP Committee for proprietary medicinal products. Points to consider on 
multiplicity issues in clinical trials. 2002 Sep. CPMP/EWP/908/99. 
17. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York: John Wiley & Sons, 
Inc; 2008. 
18. Functional Assessment of Chronic Illness Therapy (FACIT.org). Questionnaires, Cancer 
Specific Measures, Scoring and Interpretation Materials, FACIT Administration and Scoring 
Guidelines, Scoring the FACT-G [Internet]. 2015 [cited 2015 Nov 24]:[1-3]. Available from: 
http://www.facit.org/FACITOrg/Questionnaires. 
19. Loriot Y,  Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al. Effect of 
enzalutamide on health-related quality of life, pain, and skeletal-related events in 
asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic 
castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. 
Lancet Oncol. 2015;16:509-21. 
20. US Department of Health and Human Services. National Institutes of Health, National Cancer 
Institute. Common Terminology Criteriafor Adverse Events (CTCAE) Version 4.0 [Internet]. 
2009 [2009 May 28]. Available from: 
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-
29_QuickReference_8.5x11.pdf. 
21. Borgsteede SD, Deliens L, Zuurmond WW, Schellevis FG, Willems DL, Van der Wal G, et al. 
Prescribing of pain medication in palliative care. A survey in general practice. 
Pharmacoepidemiol Drug Saf. 2009;18(1):16-23. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 57 
7 
LIST OF APPENDICES 
 
Appendix A 
Summary of statistical analyses  
Appendix B 
Tumor response evaluation 
Appendix C 
FACT-P Scoring guideline 
Appendix D 
EQ-5D-5L User Guide 
Appendix E 
WHO analgesic ladder for cancer pain 
Appendix F 
GMA_rfactor file 
Appendix G 
Prior anti-cancer therapy type classification 
Appendix H 
LLN and ULN for laboratory parameters 


Statistical Analysis Plan  
 
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 58 
Appendix A Summary of statistical analyses 
EFFICACY ANALYSIS 
 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
Primary endpoint 
rPFS 
ITT 
A 2-sided 5% log-rank test stratified by the 
stratification factors. 
Survival curves using Kaplan-Meier estimates. 
 
 
 
 
Yes 
HR estimation using Cox proportional hazard 
model stratified by stratification factors and 
its 95% CI with time-dependent variable. 
HR estimation within each stratification factor 
using Cox proportional hazard model by 
each stratification factors and its 95% CI and 
forest plot. 
A 2-sided 5% stratified log-rank test 
considered the start date of another 
anti-cancer therapy. 
Survival curves using Kaplan-Meier 
estimates. 
Sensitivity analysis (Section 2.4.4.1.3)  
A 2-sided 5% stratified log-rank test when 
considering the non-compliance tumor 
assessment. Survival curves using Kaplan-
Meier estimates evaluation. 
Yes 
Subgroups analyses 
(Section 2.4.4.1.2) with 
respect to stratification 
factors, for each 
prognostics factors 
(mentioned in Table 8) that 
would be considered as 
subgroups. Forest plot for 
subgroup analyses. 
  
 
 
 
 
 
 


Statistical Analysis Plan  
 
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 59 
Endpoint 
Analysis 
population 
Primary 
analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
Secondary endpoints 
OS 
ITT 
A 2-sided 5% log-rank test stratified by the 
stratification factors and survival curve. 
Cox proportional hazard model stratified 
by stratification factors and forest plot. 
No  
No  
PFS 
ITT 
A 2-sided 5% log-rank test stratified by the 
stratification factors and survival curve. 
Cox proportional hazard model stratified 
by stratification factors and forest plot. 
No 
No 
PSA response during study 
treatment 
Concerned 
evaluable 
population 
Number and percentage of patients by treatment and 
a CMH chi-square test stratified comparing the 2 
arms. 
Waterfall plots for PSA response at 
Cycle 2 Day 1, at 12 weeks abd best 
PSA response at any time during 
treatment exposure. 
No 
No 
Tumor response 
Concerned 
evaluable 
population 
Number and percentage of patients by treatment and 
a CMH chi-square test stratified comparing the 2 
arms. 
No 
No 
No 
TTPP 
ITT 
Summarized by treatment arm. 
No 
No 
No 
Duration of tumor response 
ITT 
Summarized by treatment arm. 
No 
No 
No 
Time to pain progression 
Concerned 
evaluable 
population 
Summarized by treatment arm. 
 
No 
No 
No 
Number of SSE  
ITT 
Number and percentage of patients with any SSE by 
treatment group (new symptomatic pathological 
fracture, use of external beam radiation to relieve 
bone pain,  spinal cord compression, Tumor-related 
orthopaedic surgical intervention) and a chi-square 
test comparing the 2 arms (at baseline, each cycle, 
EOT and FUP visits) for each cycle and on the on 
treatment period. 
No 
No 
No 
Time to occurrence of SSE 
ITT 
Summarized by treatment arm. 
 
No 
No 
PSA response during the first 
subsequent therapy 
Concerned 
evaluable 
population 
A 2-sided 5% log-rank test and Survival curves using 
Kaplan-Meier estimates. 
A waterfall plot will be provided for best 
PSA change by treatment group and 
type of subsequent therapy. 
No 
No 
Duration of first subsequent 
therapy 
Concerned 
evaluable 
population 
A 2-sided 5% log-rank test and Survival curves using 
Kaplan-Meier estimates. 
No 
No 
No 


Statistical Analysis Plan  
 
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 60 
SAFETY ANALYSES 
Endpoint 
Analysis 
population 
Primary analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
Adverse events 
Safety 
Follow safety guidelines. 
No 
No 
No 
Laboratory Data 
Safety 
Descriptive analysis at baseline 
and each cycle (worst value). 
No 
No 
No 
Vital Signs (except 
PS ECOG) 
PS ECOG 
Safety 
Descriptive analysis at each 
cycle (raw value and change 
from baseline). 
Value at baseline and worst 
post-baseline value during the 
study according to baseline 
value. 
No 
No 
No 
ECG 
Safety 
Descriptive analysis at baseline 
and EOT Visit if available 
according to baseline value. 
No 
No 
No 


Statistical Analysis Plan  
 
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 61 
QUALITY OF LIFE ANALYSES 
Endpoint 
Analysis 
population 
Primary analysis 
Supportive 
analysis 
Subgroup 
analysis 
Other 
analyses 
FACT-P 
Concerned 
evaluable 
population 
Descriptive analyses at baseline, each 
cycle, EOT and follow-up visits and 
change from baseline (at each cycles, 
EOT and F-UP visits) for each 
subscales, TOI and total score. 
Change from baseline analyzed by a 
mixed linear repeated measures model 
with the stratification factors as 
covariates + graphical representation 
of LS means at each timepoints for 
TOI score and FACT-P total score. 
Rate of responders by treatment group for 
deterioration and improvement for all 
5 responders’ classes (see Section 2.4.7). 
 
No 
Responder analyses: time to definitive 
deterioration   of score by 3-points, 
2-points, 9, or 10 (according to the 
sub-domains, sub-scores specific 
MID definition) points will be analyzed 
using Kaplan Meier results and 
Cox model adjusted on stratification 
factors. 
EQ-5D-5L 
Concerned 
evaluable 
population 
Descriptive analyses at baseline, each 
cycle, EOT and follow-up visits for 
each dimension, VAS and Index utility 
index. The comparison of change from 
baseline on health-related 
quality-of-life scores EQ-5D-5L utility 
index scores and EQ-5D-5L VAS 
between treatment arms will be 
performed by using MIXED linear 
repeated measures model where 
treatment is a fixed effect variable and 
subject is a random effect variable. 
The baseline stratification variables will 
be included in the model as covariates. 
The least square means by treatment 
group with their 95% CIs obtained from 
mixed model will be presented 
graphically.   
Change from baseline to each visit will 
also be provided. For qualitative 
parameters (each dimension of EQ-5D-5L) 
change will be assessed in terms of 
number of patient with worsening, no 
change and improvement.   Graphical 
approach (up to the cycle for which at 
least 20% of the concerned evaluable 
population will be reached in the treatment 
group, End of treatment visit included, will 
be used for AQ-VAS and Index utility 
score description.  
No 
No 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 62 
Appendix B 
Tumor response evaluation 
Table 9 - Target lesions and non-target lesions evaluation 
 
Evaluation of target lesions 
Evaluation of non-target lesions 
CR 
Disappearance of all TLs. Any pathological lymph nodes (whether target or 
non-target) must have reduction in short axis to <10 mm. 
Disappearance of all non-target lesions 
and normalization of tumor marker level. 
All lymph nodes must be non-pathological 
in size (<10 mm short axis). 
PR 
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters. 
Non-CR/Non-PD:  
Persistence of one or more non-target 
lesion(s) and/or maintenance of tumor 
marker level above the normal limits. 
SD 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on 
study. 
PD 
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that 
is the smallest on study). In addition to the relative increase of 20%, the 
sum must also demonstrate an absolute increase of at least 5 mm. 
(Note: the appearance of one or more new lesions is also considered 
progression). 
Unequivocal progression of existing 
non-target lesions. (Note: the appearance 
of one or more new lesions is also 
considered progression). 
Although a clear progression of “non-trarget” lesions only is exceptionnal, in such circumstances, 
the opinion of the treating physician should prevail and the progression status should be 
confirmed later on by the review panel (or study chair). 
Table 10 - Time point response: patients with target (± non-target) disease 
Target lesions 
Non-Target lesions 
New lesion(s) 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
NE 
No 
PR 
PR 
Non-PD or not all evaluated 
No 
PR 
SD 
Non-PD or not all evaluated 
No 
SD 
Not all evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
Note: CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and NE = Non evaluable. 
With 35 days as the minimum number of days after study entry to confirm a SD cycle response 
not preceded by an evaluable assessment. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 63 
Table 11 - Best overall response when confirmation of CR and PR required 
Overall response 
First time point 
Overall response 
Subsequent time point 
BEST Overall Response 
CR 
CR 
CR 
CR 
PR 
SD, PD or PRa 
CR 
SD 
SD provided minimum criteria for SD duration 
met, otherwise PD 
CR 
PD 
SD provided minimum criteria for SD duration 
met, otherwise PD 
CR 
NE 
SD provided minimum criteria for SD duration 
met, otherwise NE 
PR 
CR 
PR 
PR 
PR 
PR 
PR 
SD 
SD 
PR 
PD 
SD provided minimum criteria for SD duration 
met, otherwise PD 
PR 
NE 
SD provided minimum criteria for SD duration 
met, otherwise NE 
NE 
NE 
NE 
a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria relative to 
baseline, makes the disease PD at that point (since disease must have reappeared after CR). 
Best response would depend on whether minimum duration for SD was met.  
However, sometimes ‘CR’ may be claimed when subsequent scans suggest small lesions were 
likely still present and in fact the patient had PR, not CR at the first time point. Under these 
circumstances, the original CR should be changed to PR and the best response is PR. 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 64 
Appendix C 
FACT-P Scoring guidelines  
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 65 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 66 
FACT-P Scoring Information and MIDs for each Scale and Summary Score 
 
5 Scales 
5 Summary Scores 
# of items 
Scoring range 
MID 
PWB 
7 
0-28 
3 
SWB 
7 
0-28 
3 
EWB 
6 
0-24 
3 
FWB 
7 
0-28 
3 
PCS 
12 
0-48 
3 
FACT-P Total 
PWB + SWB + EWB + FWB + PCS 
0-156 
10 
FACT-G Total 
PWB + SWB + EWB + FWB 
0-108 
9 
FACT-P TOI 
PWB + FWB + PCS 
0-104 
9 
PCS-Pain 
4 items (P1, P2, P3, GP4) 
0-16 
2 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 67 
Appendix D 
EQ-5D-5L user guide 
https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 68 
Appendix E 
World Health Organization analgesic ladder for cancer pain 
Analgesic medication has been classified as below: 
 0 (No analgesic). 
 1 (mild pain = non-opioid analgesics). 
 2 (mild to moderate pain = opioids for moderate pain). 
 3 (severe pain = opioids for severe pain). 
 
WHO analgesic ladder 
step 
Score on numerical 
rating scale 
Analgesics of choice 
1 (mild pain) 
<3 out of 10 
Paracetamol and NSAIDs 
2 (mild to moderate pain) 
3 to 6 out of 10 
Weak opiods (eg codein or dihydrocoideine) plus paracetamol 
and NSAIDs;  
3 (severe pain) 
>6 out of 10 
Strong opiods (eg, morphine, alfentanil, diamorphine, fentanyl, 
hydromorphone or oxycodone) plus paractemol and NSAIDs. 
 
Table 12 - Analgesic treatment classification 
0 (No analgesic) 
1 (mild pain = 
non-opioid analgesics) 
2 (mild to moderate 
pain = opioids for 
moderate pain) 
3 (severe pain = 
opioids for severe 
pain) 
ACETYLSALICYLIC ACID (if 
indication Other : used as 
anticoagulant) 
ACETYLSALICYLIC ACID (if 
indication Adverse event) 
CAFFEINE;  CODEINE 
PHOSPHATE;  
PARACETAMOL 
BUPRENORPHINE 
AMITRIPTYLINE 
HYDROCHLORIDE 
ACETYLSALICYLIC ACID;  
CAFFEINE;  
ORPHENADRINE CITRATE;  
PHENACETIN 
CODEINE 
BUPRENORPHINE 
HYDROCHLORIDE 
CANNABIS SATIVA 
ANTIINFLAMMATORY 
AGENTS, NON-STEROIDS 
CODEINE PHOSPHATE 
HEMIHYDRATE;  
PARACETAMOL 
FENTANYL 
CAPSAICIN 
ASCORBIC ACID;  
PARACETAMOL 
CODEINE PHOSPHATE;  
DICLOFENAC SODIUM 
FENTANYL CITRATE 
CARBIDOPA;   LEVODOPA 
CAFFEINE;  GUAIFENESIN;  
PARACETAMOL 
CODEINE PHOSPHATE;  
PARACETAMOL 
HYDROMORPHONE 
DEXAMETHASONE 
CAFFEINE;  PAPAVER 
SOMNIFERUM LATEX;  
PARACETAMOL 
CODEINE;  PARACETAMOL 
HYDROMORPHONE 
HYDROCHLORIDE 
DEXAMETHASONE 
SODIUM PHOSPHATE 
CAFFEINE;  
PARACETAMOL 
DEXTROPROPOXYPHENE;  
METAMIZOLE MAGNESIUM 
KETOBEMIDONE 
HYDROCHLORIDE 
DOXEPIN 
CAFFEINE;  
PARACETAMOL;  
PROPYPHENAZONE 
DIHYDROCODEINE 
BITARTRATE 
MORPHINE 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 69 
0 (No analgesic) 
1 (mild pain = 
non-opioid analgesics) 
2 (mild to moderate 
pain = opioids for 
moderate pain) 
3 (severe pain = 
opioids for severe 
pain) 
DRONABINOL 
CELECOXIB 
LEVOMETHADONE 
MORPHINE 
HYDROCHLORIDE 
GABAPENTIN 
DEXAMETHASONE;  
DICLOFENAC 
LEVOMETHADONE 
HYDROCHLORIDE 
MORPHINE SULFATE 
HYOSCINE 
BUTYLBROMIDE 
DEXIBUPROFEN 
METHADONE 
HYDROCHLORIDE 
MORPHINE SULFATE 
PENTAHYDRATE 
LIDOCAINE 
DEXKETOPROFEN 
PARACETAMOL;  
TRAMADOL 
HYDROCHLORIDE 
NALOXONE 
HYDROCHLORIDE;  
OXYCODONE 
HYDROCHLORIDE 
MAGNESIUM SALICYLATE 
DEXKETOPROFEN 
TROMETAMOL 
TRAMADOL 
NALOXONE 
HYDROCHLORIDE;  
TILIDINE HYDROCHLORIDE 
MIDAZOLAM 
DICLOFENAC 
TRAMADOL 
HYDROCHLORIDE 
OXYCODONE 
NALOXONE 
DICLOFENAC DIETHYLAMINE 
OXYCODONE 
HYDROCHLORIDE 
NALOXONE 
HYDROCHLORIDE 
DICLOFENAC POTASSIUM 
OXYCODONE 
HYDROCHLORIDE;  
PARACETAMOL 
PREDNISOLONE 
DICLOFENAC SODIUM 
PIRITRAMIDE 
PREDNISONE 
DICLOFENAC SODIUM;  ORPHENADRINE CITRATE 
TAPENTADOL 
PREGABALIN 
ETORICOXIB 
TAPENTADOL 
HYDROCHLORIDE 
PROCHLORPERAZINE 
IBUPROFEN 
 
TIZANIDINE 
HYDROCHLORIDE 
KETOPROFEN 
 
 
KETOPROFEN LYSINE 
 
 
KETOROLAC 
 
 
MEFENAMIC ACID 
 
 
METAMIZOLE 
 
 
METAMIZOLE MAGNESIUM 
 
 
METAMIZOLE SODIUM 
 
 
NAPROXEN 
 
 
 
NEFOPAM 
 
 
 
NEFOPAM HYDROCHLORIDE 
 
 
NIMESULIDE 
 
 
 
OXACEPROL 
 
 
 
PARACETAMOL 
 
 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 70 
Appendix F 
GMA rfactor file 
 
LBTESTCD LBTEST 
LBSPEC 
CDISCID 
LBORRESU SI_FLAG LBSTRESU LBCONV USSTRESU USCONV LBCAT 
ALT 
Alanine 
Aminotransferase 
 
C64433 
IU/L 
X 
IU/L 
1 
U/L 
1 
CHEMISTRY 
ALB 
Albumin 
CEREBROSPINAL FLUID 
C64431 
g/L 
mg/L 
1000 
g/dL 
0,1 
CHEMISTRY 
ALP 
Alkaline Phosphatase 
C64432 
IU/L 
X 
IU/L 
1 
U/L 
1 
CHEMISTRY 
AST 
Aspartate 
Aminotransferase 
 
C64467 
IU/L 
X 
IU/L 
1 
U/L 
1 
CHEMISTRY 
BILI 
Bilirubin 
URINE 
C38037 
umol/L 
mg/dL 
0,0585 
mg/dL 
0,05847 
BUN 
Blood Urea Nitrogen 
C61019 
mmol/L 
X 
mmol/L 
1 
mg/dL 
2,8011205 
CHEMISTRY 
CA 
Calcium 
C64488 
mmol/L 
X 
mmol/L 
1 
mg/dL 
4 
CGA 
Chromogranin A 
C122108 
nmol/L 
ug/L 
48,918 
ng/mL 
48,918 
CGA 
Chromogranin A 
C122108 
ug/L 
X 
ug/L 
1 
ng/mL 
1 
CREAT 
Creatinine 
C64547 
umol/L 
umol/L 
1 
mg/dL 
0,0113122 
CHEMISTRY 
GLU 
Glucose 
PLASMA 
C105585 
mmol/L 
X 
mmol/L 
1 
mg/dL 
18,014772 
CHEMISTRY 
HB 
Hemoglobin 
C64848 
g/L 
X 
g/L 
1 
g/dL 
0,1 
HEMATOLOGY 
LDH 
Lactate Dehydrogenase 
C64855 
IU/L 
X 
IU/L 
1 
U/L 
1 
CHEMISTRY 
MG 
Magnesium 
C64840 
mmol/L 
X 
mmol/L 
1 
mg/dL 
2,4307244 
PLAT 
Platelets 
C51951 
10^9/L 
X 
10^9/L 
1 
10^3/uL 
1 
HEMATOLOGY 
K 
Potassium 
C64853 
mmol/L 
X 
mmol/L 
1 
mEq/L 
1 
CHEMISTRY 
PROT 
Protein 
SERUM 
C64858 
g/L 
X 
g/L 
1 
g/dL 
0,1 
NAUR 
Sodium 
C64809 
mmol/L 
X 
mmol/L 
1 
mEq/L 
1 
CHEMISTRY 
TESTO 
Testosterone 
C74793 
ng/l 
nmol/L 
3,467 
ng/dL 
100 
UREA 
Urea 
C64815 
mg/dL 
mmol/L 
0,1665 
mg/dL 
1 
CHEMISTRY 
VV-CLIN-0064492 2.0


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 71 
LBTESTCD LBTEST 
LBSPEC 
CDISCID 
LBORRESU SI_FLAG LBSTRESU LBCONV USSTRESU USCONV LBCAT 
UREA 
Urea 
C64815 
umol/L 
mmol/L 
0,001 
mg/dL 
0,006006 
CHEMISTRY 
UREA 
Urea 
C64815 
mmol/L 
X 
mmol/L 
1 
mg/dL 
6,006006 
CHEMISTRY 
BASOLE 
Basophils/Leukocytes 
C64471 
% 
X 
% 
1 
% 
1 
EOSLE 
Eosinophils/Leukocytes 
C64604 
% 
X 
% 
1 
% 
1 
LYMLE 
Lymphocytes/Leukocytes 
C64820 
% 
X 
% 
1 
% 
1 
MONOLE 
Monocytes/Leukocytes 
C64824 
% 
X 
% 
1 
% 
1 
NEUTLE 
Neutrophils/Leukocytes 
C64827 
% 
X 
% 
1 
% 
1 
VV-CLIN-0064492 2.0


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 72 
Appendix G 
Prior anti-cancer therapy type classification  
 
LH-RH ANTAGONISTS 
cdgname 
termcd 
termlbl 
CDG00005 
014536 
CETRORELIX 
CDG00005 
014536 
CETRORELIX ACETATE 
CDG00005 
014536 
CETRORELIX PAMOATE 
CDG00005 
014537 
GANIRELIX 
CDG00005 
014537 
GANIRELIX ACETATE 
CDG00005 
014795 
ITURELIX 
CDG00005 
014812 
ABARELIX 
CDG00005 
017648 
DEGARELIX 
CDG00005 
017648 
DEGARELIX ACETATE 
CDG00005 
022345 
FOLLISTIM/ANTAGON 
CDG00005 
062979 
ELAGOLIX 
CDG00005 
105696 
FOLLITROPIN BETA; GANIRELIX 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 73 
LH-RH AGONISTS 
cdgname 
termcd 
termlbl 
CDG00006 
901147 
GONADOTROPIN RELEASING HORMONES AND ANALOGUES 
CDG00006 
901157 
GONADOTROPIN RELEASING HORMONE ANALOGUES 
CDG00006 
004865 
GONADORELIN 
CDG00006 
004865 
GONADORELIN HYDROCHLORIDE 
CDG00006 
004865 
GONADORELIN DIACETATE 
CDG00006 
004865 
GONADORELIN DIACETATE TETRAHYDRATE 
CDG00006 
007269 
LEUPRORELIN 
CDG00006 
007269 
LEUPRORELIN ACETATE 
CDG00006 
007321 
GOSERELIN 
CDG00006 
007321 
GOSERELIN ACETATE 
CDG00006 
007716 
BUSERELIN 
CDG00006 
007716 
BUSERELIN ACETATE 
CDG00006 
009759 
TRIPTORELIN 
CDG00006 
009759 
TRIPTORELIN ACETATE 
CDG00006 
009759 
TRIPTORELIN EMBONATE 
CDG00006 
009852 
NAFARELIN 
CDG00006 
009852 
NAFARELIN ACETATE 
CDG00006 
012465 
HISTRELIN 
CDG00006 
012465 
HISTRELIN ACETATE 
CDG00006 
017025 
CASODEX W/ZOLADEX 
CDG00006 
018521 
RELEFACT LH/RH/TRH 
CDG00006 
063648 
ZOLACOS CP 
CDG00006 
067603 
DESLORELIN 
CDG00006 
067603 
DESLORELIN ACETATE 
CDG00006 
086980 
LEUPRORELIN ACETATE W/NORETHISTERONE ACETATE 
CDG00006 
126257 
LEUPRORELIN; NORETHISTERONE 
 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 74 
 
ANTI-ANDROGEN HORMONAL 
RECNO 
SEQ1 
SEQ2 
ENGLISH_DR 
000054 
01 
001 
ACONCEN 
002372 
01 
001 
CYPROTERONE 
002372 
02 
001 
CYPROTERONE ACETATE 
005419 
01 
001 
DIANE 
011161 
01 
001 
CLIMEN /01116101/ 
012608 
01 
001 
FEMILAR 
071240 
01 
001 
CYPROTERONE W/ETHINYLESTRADIOL 
076934 
01 
001 
CYPROTERONE W/ESTROGEN NOS 
084315 
01 
001 
CYPROTERONE W/ESTRADIOL VALERATE 
900249 
01 
001 
ANTIANDROGENS 
900250 
01 
001 
ANTIANDROGENS AND ESTROGENS 
900879 
01 
001 
ANTIANDROGENS, PLAIN 
006529 
01 
001 
FLUTAMIDE 
008517 
01 
001 
NILUTAMIDE 
012711 
01 
001 
BICALUTAMIDE 
064485 
01 
001 
ABIRATERONE ACETATE W/PREDNISOLONE 
073193 
01 
001 
GALETERONE 
078429 
01 
001 
ENZALUTAMIDE 
089166 
01 
001 
APALUTAMIDE 
089563 
01 
001 
TAS 3681 
093046 
01 
001 
DAROLUTAMIDE 
110431 
01 
001 
ABIRATERONE; PREDNISOLONE 
143072 
01 
001 
AZD 3514 
143213 
01 
001 
BMS 641988 
145052 
01 
001 
RALANITEN ACETATE 
900554 
01 
001 
ANTI-ANDROGENS 
011300 
01 
001 
FINASTERIDE 
015898 
01 
001 
DUTASTERIDE 
017025 
01 
001 
CASODEX W/ZOLADEX 
035979 
01 
001 
EPRISTERIDE 
062095 
01 
001 
DUTAS-T 
062951 
01 
001 
ABIRATERONE 
062951 
02 
001 
ABIRATERONE ACETATE 


Statistical Analysis Plan  
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 75 
ANTI-ANDROGEN HORMONAL 
RECNO 
SEQ1 
SEQ2 
ENGLISH_DR 
063648 
01 
001 
ZOLACOS CP 
063976 
01 
001 
GESTONORONE 
066493 
01 
001 
PROSTASAX PLUS 
080330 
01 
001 
MINSCALP F 
087221 
01 
001 
ALFUZOSIN HYDROCHLORIDE W/FINASTERIDE 
087346 
01 
001 
DUTASTERIDE W/SILODOSIN 
124910 
01 
001 
DOXAZOSIN; FINASTERIDE 
125031 
01 
001 
FINASTERIDE; TAMSULOSIN 
125064 
01 
001 
DUTASTERIDE; TAMSULOSIN 
126370 
01 
001 
ALFUZOSIN; FINASTERIDE 
 


Statistical Analysis Plan  
 
20-Jun-2019 
XRP6258-LPS14201 - cabazitaxel 
 
Version number: 2 
Property of the Sanofi Group - strictly confidential 
Page 76 
Appendix H 
Sponsor standards LLN and ULN for laboratory parameters  
 
Analyte 
LowValue 
HighValue 
LabUnit 
From Age 
From Age_AGEU 
To Age 
To Age_AGEU 
Sex 
Basophils 
0 
0.15 
10^9/L 
18 
Year 
150 
Year 
 
Eosinophils 
0 
0.4 
10^9/L 
18 
Year 
150 
Year 
 
Hemoglobin 
135 
175 
g/L 
18 
Year 
100 
Year 
Male 
Hemoglobin 
120 
160 
g/L 
18 
Year 
100 
Year 
Female 
Leukocytes 
4.5 
11 
10^9/L 
18 
Year 
150 
Year 
 
Lymphocytes 
1 
2 
10^9/L 
18 
Year 
150 
Year 
 
Monocytes 
0.18 
0.5 
10^9/L 
18 
Year 
150 
Year 
 
Neutrophils 
1.8 
3.15 
10^9/L 
18 
Year 
150 
Year 
 
Platelets 
150 
350 
10^9/L 
18 
Year 
150 
Year 
 
INR 
0.8 
1.2 
Ratio 
18 
Year 
150 
Year 
 
Albumin 
35 
55 
g/L 
18 
Year 
100 
Year 
 
Blood Urea Nitrogen (BUN) 
3.6 
7.1 
mmol/L 
18 
Year 
100 
Year 
 
Calcium 
2.2 
2.6 
mmol/L 
18 
Year 
100 
Year 
 
Glucose 
3.900001 
6.999999 
mmol/L 
18 
Year 
100 
Year 
 
Potassium 
3.5 
5 
mmol/L 
18 
Year 
100 
Year 
 
Magnesium 
0,8 
1,2 
mmol/L 
18 
Year 
100 
Year 
 
Sodium 
136 
145 
mmol/L 
18 
Year 
100 
Year 
 
Phosphate 
1 
1.4 
mmol/L 
18 
Year 
100 
Year 
 
Protein 
55 
80 
g/L 
18 
Year 
100 
Year 
 
Urea 
3.6 
7.1 
mmol/L 
18 
Year 
100 
Year 
 
 
VV-CLIN-0064492 2.0


Signature Page 
lps14201-16-1-9-sap
Approve & eSign
Approve & eSign
Approve & eSign